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ABSTRACT 
Joint injures frequently involve structural damage to articular cartilage and the underlying 
subchondral bone. The outcome of acute joint surface defects (JSD) varies from 
spontaneous healing to the development of post-traumatic osteoarthritis (PTOA). The 
cellular and molecular mechanisms regulating joint surface repair are still unknown and 
failure of these reparative mechanisms could be a contributing factor for PTOA 
development. The absence of animal models suitable for molecular functional studies in 
cartilage regeneration has so far represented a bottleneck for the research in this field.   
In this study we have generated a mouse model of joint surface injury which, in a strain- 
and age-dependent manner results either in spontaneous healing in the DBA/1 strain or in 
PTOA in C57BL/6 strain. The healing outcome in DBA/1 mice was associated with 
progressive decline of chondrocyte apoptosis, cell proliferation within the repair tissue, 
persistent type II collagen neo-deposition, less type II collagen degradation, and aggrecan 
degradation predominantly driven by metalloproteinases, with minor aggrecanase activity. 
Furthermore, we have demonstrated that mechanical injury to articular cartilage in vitro 
and in vivo results in activation of a signalling response with reactivation of 
morphogenetic pathways such as BMP and Wnt.  Notably, we have observed a striking 
up-regulation of Wnt16 following cartilage injury and in osteoarthritis and showed that 
this molecule might have a chondro-protective role in murine osteoarthritis. The in vivo 
model of JSD, being amenable to genetic manipulation, offers the opportunity to 
investigate the function of different candidate molecules modulated in response to injury 
which is an essential prerequisite to develop novel molecular therapeutics to support joint 
surface healing and to prevent possible evolution of PTOA.  
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1.1 Synovial joints 
The synovial joint (Figure 1.1) is a complex organ that allows frictionless motion of the 
skeletal elements. The joint is composed of several tissues of mesenchymal origin 
including the fibrous capsule, the synovial membrane, bone, ligaments and the articular 
cartilage. The capsule, which surrounds the joint and seals the articular cavity, is lined 
with synovial membrane which is composed mainly of macrophage-like synoviocytes 
(type B synoviocytes) and fibroblast-like cells (type A synoviocytes) responsible for 
synovial fluid secretion. The synovial fluid has a high concentration of hyaluronic acid 
and lubricin providing nutrients to the avascular articular cartilage and lubricating the 
joint. The articulating ends of the bones are covered with smooth hyaline articular 
cartilage that functions as a weight-bearing and gliding surface. The articular cartilage is 
supported by a plate of subchondral bone that transmits the load from the cartilage to the 
underlying trabecular bone. The joint is further stabilized by the surrounding tendons, 
ligaments and muscles (1). 
Figure 1.1: Diagrammatic view of the synovial joint structure 
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1.1.1. Structure and Function of articular cartilage 
The articular cartilage is an avascular, aneural and alymphatic tissue covering the 
articulating surfaces of synovial joints. It plays a vital role in the function of the 
musculoskeletal system by allowing smooth frictionless motion between articular 
surfaces. Furthermore, it acts as shock absorber and distributes mechanical loads over a 
large contact area, thereby minimizing the focal stress on the subchondral bone.  This 
tissue  is composed of highly specialized cells, chondrocytes, embedded within a dense 
extracellular matrix (ECM) that consists of (i) fluid, mostly water (70-80% of the wet 
weight), gases and metabolites (ii) a framework of structural macromolecules that 
include mainly type II collagen, the highly sulfated proteoglycans predominantly 
aggrecan, other fibrillar (IX and XI) and non-fibrillar (type VI and X) collagens and 
additional non-collagenous protein molecules such as fibronectin and cartilage 
oligomeric protein (2).  
Articular cartilage, however, is not a homogeneous
 
tissue
 
with morphological and 
biochemical differences existing from
 
the surface zone to the deeper layers (Figure 1.2) 
(3). The superficial zone is characterized by the presence of flattened cells
 
that secrete 
lubricin (4) and a layer of tightly packed collagen fibers parallel to articular surface 
called lamina splendens. This structure maintains the tensile properties of cartilage and 
enables it to resist shear forces during normal joint function and loading. The middle or 
transitional zone contains randomly distributed spherical chondrocytes, proteoglycans 
and arcade like collagen fibers (5). In the deep zone, chondrocytes are spheroidal in 
shape and arranged in columns perpendicular to the surface. This zone has the highest 
concentration of proteoglycans and the largest diameter of collagen fibrils that are 
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perpendicular to the surface. Below the deep zone, is the calcified
 
zone where 
chondrocytes express alkaline phosphatase
 
and type X collagen (6) and therefore their 
phenotype resemble that of the hypertrophic chondrocytes in the epiphyseal cartilage. 
Collagen fibers originating within the deep zone cross the tide mark to be inserted into 
the underlying layers providing a strong anchoring system for the tissue on the 
subchondral bone (3).  
Figure 1.2: A schematic diagram of the cellular and fibrillar organization in the different zones 
of articular cartilage (Figure from (3)). 
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Articular chondrocytes 
Chondrocytes are highly specialized cells that form 1-5% of the cartilage volume. They 
are responsible for the synthesis and the maintenance of the ECM. Because cartilage is 
avascular, chondrocytes receive nutrients through diffusion and therefore survive on low 
oxygen tension and depend on anaerobic metabolism (7).  In the normal articular 
cartilage, tracks interconnecting chondrocytes’ lacunae and cytoplasmic projections 
were observed and proposed to be involved in tissue signaling and nutrition (8-10). The 
ability of chondrocytes to synthesize and maintain ECM gradually decreases with aging 
due to cell senescence and decreased responsiveness to anabolic growth factors (11).  
Extracellular matrix 
The ECM provides the cartilage with its characteristic biomechanical properties and 
plays a vital role in regulating the transmission of different chemical and physical 
signals to the chondrocytes thereby acting as a signal transducer for these cells (12).  
According to the distance from the chondrocytes, the cartilage ECM is organized into 
three different regions (3):  
1) Pericellular matrix: It is a thin (2μm) rim of matrix surrounding chondrocytes together 
forming the chondron. This region is rich in the heparan sulphate proteoglycan perlecan 
(13), type VI collagen and cell membrane associated molecules such as fibronectin and 
chondronectin.  
2) Territorial matrix:  This region of the matrix encloses cluster of chondrocytes 
including their pericellular matrix. The ECM in this area is rich in chondroitin sulfate 
and the collagen fibrils are arranged in criss-cross manner forming a fibril basket that 
surround clustered chondrocytes and protect them from mechanical impacts (2).  
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 3) Inter-territorial matrix: It accounts for most of the matrix volume in cartilage. The 
composition and the orientation of the fibers in that region are different depending on 
the functional requirement and cellular organization of each zone as descried earlier. 
Collagens 
Collagens account for 15-20% of cartilage tissue. Type II collagen is the most abundant 
component (90-95%) in the fibrillar framework that gives the articular cartilage its 
tensile strength. Cartilage also contains other types of collagens such as type VI collagen 
which is mainly located in the pericellular matrix to help in the attachment of the 
chondrocytes to the surrounding matrix, type IX collagen and type XI collagen 
(fibril-associated collagens) that are cross-linked to Type II collagen reinforcing the 
inter-fibrillar connections. Type X collagen is only expressed by the hypertrophied 
chondrocytes in the calcified layer (14).  
The basic molecular unit of collagen is tropocollagen which is a fibrillar molecule 
forming rod-like structures measuring 280nm in length and 1.5nm in diameter. 
Tropocollagen consists of three α-polypeptide chain subunits arranged in a tripe helix 
configuration. A distinctive feature of collagen is the regular arrangement of amino acids 
in each of the three α chains. The amino acid sequence often follows the pattern 
Glycine-proline-Y or Glycine-X-hydroxyproline.  Therefore, glycine accounts for 33.5% 
of the amino acid sequence while proline and hydroxyl-proline form 12% and 10% 
respectively. Differences in the chemical structure of the α-polypeptide chains are 
responsible for the various types of collagen. For example, type II collagen has three 
identical α1 chains while type VI collagen is formed of three different α chains (α1, α2, 
α3). During collagen biosynthesis, each α chain is synthesized intracellulary with an 
additional peptide (telopeptide) on both the amino- and carboxyl-terminal ends to form 
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the procollagen molecule. This peptide prevents premature intra-cellular precipitation 
and assembly of the procollagen molecule. When procollagen is transported out of the 
cell, the procollagen peptidase enzyme removes the telopeptides and thus allows the 
resulting protein (tropocollagen) to assemble into polymeric collagen fibrils (15).  
Proteoglycans    
This family of macromolecules consists of a core protein attached covalently to one or 
more glycosaminoglycans (GAG). GAGs are long linear chains of repeated 
disaccharides that are negatively charged due to the presence of sulfate and carboxyl 
groups. The negative charge attracts cations such as Na2 that in turn increases osmolarity 
of the articular cartilage and thus contributes to the compressive strength and resilience 
to that tissue (5). Mechanical compression forces associated with joint motion expel the 
water out of the cartilage ECM and when pressure is released water is attracted back by 
GAG negative charge. Such water movement is essential for the nutrition of cartilage 
facilitating the interchange of O2, CO2 and other molecules between the synovial fluid 
and articular cartilage (2).  
The most abundant proteoglycan in cartilage is aggrecan. The protein core of aggrecan 
(Figure 1.3) consists of three globular structural domains (G1 & G2 at the N-terminal 
end and G3 at the C-terminal end) separated by two extended inter-globular domains (E1 
&E2).  The G1 domain is linked to hyaluronic acid thus forming larger aggregates 
containing up to 100 aggrecan molecules. GAGs (Chondroitin sulfate and keratin 
sulfate) are attached to the E2 inter-globular domain (Figure 1.3) (16).  
Less abundant small proteoglycans are also present in cartilage including decorin, 
biglycan, fibromodulin and perlecan. Such small proteoglycans bind to other matrix 
macromolecules and thus play a role in stabilizing the matrix (17). In addition, small 
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cartilage proteoglycans also bind several growth factors including TGFβ (18) and FGFs 
(13) thereby on one hand regulating their actions and contributing to the formation of 
gradients, and on the other hand acting as storage for signaling molecules.  
Other non-collagenous proteins  
Several non-collagenous proteins and glycoproteins have been found in cartilage ECM 
and have been proposed to play a role in cell/matrix interaction and in binding different 
components of ECM. Cartilage oligomeric matrix protein (COMP), a pentameric 
glycoprotein, can bind to collagen through zinc-dependent interactions and therefore 
facilitate collagen cross-linking (19). Chondronectin is a glycoprotein macromolecule 
that binds to chondroitin sulfate, hyaluronic acid and type II collagen mediating the 
adherence of the chondrocytes to the surrounding ECM. Fibronectin, a large dimer 
localized in pericellular matrix, is composed of 2 similar polypeptide subunits attached 
together by disulfide bonds. Each arm of this V shaped macromolecule has binding sites 
for various extra-cellular matrix components and integrins at the cell membrane (3).  
Matrix turnover 
Throughout life, articular cartilage undergoes continuous remodeling as chondrocytes 
can detect changes in ECM compositions and respond accordingly to maintain the 
integrity of the matrix. Normally, there is a balance between anabolic and catabolic 
activities as chondrocytes replace matrix macromolecules lost through degradation. This 
remodeling is accelerated in pathological conditions such as osteoarthritis (OA) (20) and 
during cartilage repair, for instance following autologous chondrocyte implantation 
(ACI) (21).  The main proteinases responsible for cartilage matrix degradation are 
matrix metalloproteinases (MMPs) and the A disintegrin and metalloproteinase with 
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thrombospondin motifs (ADAMTSs). The catalytic action of these enzymes is inhibited  
by the tissue inhibitors of metalloproteinases (TIMPs) (22). 
MMPs are a family of 23 zinc-containing proteinases that are capable of degrading 
ECM proteins. They share a conserved domain structure that consists of a pro-peptide 
domain with Cysteine switch that interact with the zinc-dependent active site to prevent 
binding and cleavage of the substrate and keeping the enzyme in an inactive form, a 
catalytic domain with the Zinc binding motif and a haemopexin-like C-terminal domain 
that is responsible for protein-protein interaction and therefore determine the substrate 
specificity. The hinge (linker) region connects the catalytic and C-terminal domains. 
MMPs are traditionally classified according to their substrates into collagenases 
(MMP-1, 8 and 13), gelatinases (MMP-2 & MMP-9), stromelysins (MMP-3, 10 and 11) 
and membrane-type MT-MMPs (MMP-14, 15, 16, 17, 24 and 25). Some members of 
MMPs such as MMP-7, 12 and 19, however, do not easily fit into any of these classes as 
they are capable of degrading many substrates (reviewed in (22). In addition to their role 
in the continuous matrix remodeling, the degradation of ECM by MMPs has been 
postulated to create space for cells to migrate, regulate tissue architecture, release 
growth factors bound to ECM molecules and activate or inactivate signaling molecules. 
Thus they have important roles in morphogenesis, remodeling, angiogenesis and wound 
healing (23).  Dysregulated or excessive MMP activity has been proposed as a 
pathogenic mechanism associated with different diseases including the destruction of 
cartilage in arthritis. In OA cartilage, elevated levels of several MMPs were observed 
(24;25). Mice expressing constitutively active MMP13 under the control of the 
cartilage-specific type II collagen promoter showed increased OA lesions compared to 
their wild-type (WT) littermates when challenged in an OA model induced by 
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destabilization of the medial meniscus (DMM) (26) and significant protection against 
OA was achieved when treating STR/Ort mice with Ro-32-3555 (collagenase selective 
inhibitor of MMP-1, 8and 13) (27). When evaluating the MMP-3 KO mice in the DMM 
model, no difference was seen in comparison to their WT mice. MMP-9 null mutant 
mice, however, developed three fold higher OA score than WT mice when challenged in 
the same model (26). These data, together with the failure of clinical trials of compounds 
inhibiting MMP activity due to occurrence of musculoskeletal side effect, suggest that 
MMP activity may be required for remodeling and homeostatic responses in joint tissue.   
ADAMTSs are 19 members that comprise a related family to MMPs as they also 
contain a zinc atom at their catalytic domain.  ADAMTSs have been shown to cleave 
aggrecan specifically at four different sites in the chondroitin sulfate CS -2 domain at the 
C terminus and at the TEGE
373↓374ALGS inter-globular domain (IGD) near the N 
terminus (Figure 1.3).  The aggrecan fragment (TEGE
373
) resulting from the cleavage at 
the TEGE
373↓374ALGS inter-globular domain was identified in the synovial fluid of 
patients with osteoarthritis and inflammatory joint disease (28;29) and was used to raise 
antibodies that specifically detect aggrecanase-cleaved aggrecan. The first ADAMTS to 
be identified was ADAMTS-4 (aggrecanase-1) (30) followed by ADAMTS-5 
(aggrecanase-2) (31). Recently, ADAMTS-5 has been shown as the main aggrecanase in 
mouse and human cartilage (32;33). Indeed, deletion of ADAMTS-5, but not 
ADAMTS-4, resulted in cartilage protection from degradation after surgical induction of 
joint instability leading to OA (32;34). Although MMPs can also cleave aggrecan in the 
inter-globular domain at the DIPEN
341↓342FFGVG site, it is believed that ADAMTS-
mediated activity is crucial for aggrecan breakdown during OA as mice resistant to 
aggrecanase cleavage in the IGD (Jaffa mice) were protected from cartilage erosion in 
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experimental arthritis whereas mice resistant to IGD cleavage at the MMP cleavage site 
(Chloe mice) developed severe OA like features (16).  
 
Figure 1.3:  The aggrecan core protein is composed of two N-terminal (G1 and G2) and one C-
terminal (G3) globular domains that are connected by the inter-globular domain E1&E2. The E2 
domain between G2 and G3 is loaded with CS chains (wavy lines). Arrows indicate the 
aggrecanase and MMP cleavage site sequences in the mouse IGD and CS-2 domains and the 
amino acids that are different in human aggrecan are shown above. Numbering corresponds with 
the mouse sequence (Figure from (16)) 
   
TIMPs are natural inhibitors of MMPs. In humans, there are four TIMPs that limit the 
degrading activity of MMPs with different effectiveness. TIMP activity was higher than 
MMP activity in normal non-arthritic human cartilage but the balance between MMP 
and TIMP was shifted towards MMPs in OA cartilage (35). In addition, TIMP-3 KO 
mice developed spontaneous OA at 6 months of age whereas their WT controls did not, 
thereby supporting the protective role of TIMP-3 against OA development (36). 
Interestingly, TIMP-3 was reported as an inhibitor for both ADAMTS-4 and 
ADAMTS-5 (37). 
Different cytokines released into cartilage matrix in response to various stimuli can 
modify chondrocyte anabolic and catabolic activities. For example, inflammatory 
molecules such as interleukin1 (IL1) and tumor necrosis factors (TNFα) can induce 
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matrix degradation  through the production and activation of MMPs and ADAMTSs 
(38;39). On the other hand, anabolic effects can be induced by other signaling molecules 
such as fibroblast growth factor (FGF), insulin growth factor (IGF) and transforming 
growth factor-β (TGF-β) superfamily including BMPs that can stimulate ECM synthesis 
and oppose catabolic activities (40) by down-regulating MMPs and inducing TIMP-1&3 
expression in chondrocyte (41). These mechanisms ensure a lifelong balanced 
remodeling of the cartilage ECM.   
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1.1.2. Embryonic development of the skeleton and synovial joints 
During embryonic limb development, mesenchymal cells within the limb bud 
condensate into uninterrupted elements that prefigure the future skeleton. Mesenchymal 
condensations are initiated and patterned by a coordinated morphogenetic signaling 
involving FGF, hedgehog, BMP and Wnt signaling that regulate the distribution and the 
proliferation of mesenchymal cells (42).  The cells located in the periphery of these 
condensations give rise to perichondrial cells which subsequently differentiate into 
osteoblasts forming the bone collar whereas, the cells in the center differentiate under 
the control of Sox9 into chondrocytes expressing proteoglycans and collagen type II 
(43). The skeletal elements then ossify through endochondral bone formation. In this 
process, chondrocytes further differentiate to become post-mitotic, prehypertrophic and 
then hypertrophic chondrocytes which express type X collagen and alkaline 
phosphatase. Hypertrophic chondrocytes calcify their surrounding ECM and eventually 
die through apoptosis. Following vascular invasion of the calcified cartilage, several cell 
types populate the cartilage anlagen including osteoclasts, which degrade the matrix, and 
osteoblasts, which form bone at the expense of cartilage (Figure 1.4). These events are 
controlled by several signaling pathways including BMP, Wnt, FGF and Indian 
hedgehog (reviewed in (44)).  
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Figure 1.4: Diagrammatic representation for endochondral bone formation: a) cartilaginous 
model for future bone develops. b) Chondrocytes become hypertrophic and peripheral cells 
differentiate into osteoblast to form the bone collar. c) Hypertrophic chondrocytes induce ECM 
mineralization and cells die through apoptosis, the calcified matrix is then invaded by blood 
vessels that deliver osteoblasts and osteoclast precursors initiating endochondral ossification and 
forming the primary ossification center d) The medullary cavity is then formed and secondary 
ossification center appear in the epiphysis. e) Longitudinal growth continues from growth plate. 
 
Joint formation 
The synovial joints form through segmentation of the pre-existing continuous 
mesenchymal anlagen (Figure 1.5). This process begins at the site of future articulation 
with the appearance of a high cell density region, called interzone, formed of flattened 
cells interconnected with gap junctions and expressing joint specific markers such as 
Gdf5/CDMP1 (45), Wnt-4, -9a,-16 (46;47), Noggin (48), Gli3 (49), CD44 (50) and Erg 
(51). The interzone cells differentiate into three layers. The cells of the central layer of 
the interzone (the central intermediate lamina) will eventually disappear to form the joint 
cavity. Cavitation takes place through a combined action of programmed cell death, 
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embryonic limb movements and Hyaluronan synthesis (52). Hyaluronan binds to 
specific cell surface receptors (CD44) inhibiting their aggregation and facilitating the 
formation of a fluid filled cavity separating  the skeletal elements (53). Meanwhile, cells 
on either side of the central intermediate lamina will give rise to articular chondrocytes, 
synovial lining and inner joint ligaments (54). In contrast to the epiphyseal 
chondrocytes, the articular cartilage is resistant to vascular invasion, mineralization and 
endochondral bone formation (reviewed in (55)).  
 
Figure 1.5: Diagrammatic representation for synovial joint formation. A: uninterrupted 
Mesenchymal condensations appear in the early limb bud. B: Unknown upstream patterning 
mechanisms determine the exact location for  joint initiation. C: The interzone forms at the joint 
site by further gathering and condensation of mesenchymal cells. The rest of the mesenchymal 
cells constituting the condensations differentiate into chondrocytes to establish the cartilaginous 
skeleton. D: The cavitation process starts to form the synovial cavity separating the adjacent 
skeletal anlagen. E: Morphogenesis takes place to shape the opposing sides of the joint F: The 
different tissues within the joint, including the opposing end of the bone, articular cartilage, 
capsule, synovial cavity ligaments, and menisci undergo the final maturation and differentiation 
leading to a mature joint. (Figure from (55)).  
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1.1.3. Signaling pathways involved in embryonic joint development 
The process of joint formation is regulated by a large number of signaling factors and 
morphogens including members of Wnt family and bone morphogenetic proteins BMPs.  
1.1.3.1. Wnt signaling 
An outline of the Wnt pathway  
Wnt proteins constitute a family of 19 secreted, cysteine-rich glycoproteins. They share 
35%-83% amino-acid sequence identity with a conserved pattern of 23 cysteine residues 
and an N-terminal signal sequence (56).  Wnt proteins are synthesized in the 
endoplasmic reticulum where they undergo a number of post-translational modifications 
including gylcosylation and palmitoylation that are required for secretion and signaling 
activity (57). Once secreted, Wnt proteins associate with Heparan sulphate 
proteoglycans in the ECM and bind to cell surface (58). It has been recently shown that 
glycosaminoglycans not only modulate Wnt signaling by concentrating Wnt proteins at 
the cell surface and presenting wnt ligands to cell surface receptors (59;60) but also can 
maintain the solubility of Wnt proteins, thus stabilizing their signaling activity (61). 
Wnts exert their actions through binding to Frizzled (Fzd) receptors and LDL-receptor-
related-protein (LRP) co-receptors.  Fzd receptors, of which 10 members have been 
identified in humans and mice, have an extracellular amino-terminal cysteine-rich 
domain (CRD) that binds Wnts, seven transmembrane domains and a short cytoplasmic 
tail at the carboxyl terminus. Two members of LRP family (LRP-5 & LRP-6) can bind 
Wnts to form a complex with Wnts and Fzd. Wnt signals can be transduced through the 
Canonical β-catenin-dependent pathway or the non-canonical β-catenin-independent 
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pathways that include the planar cell polarity pathway and the Ca
2+
 dependant pathway 
(62). Different sets of Wnts and Fzd can activate each of these pathways leading to 
unique cellular responses.  
The Canonical Wnt/β-catenin pathway (shown in Figure 1.6) is the most studied and 
the best characterized. Signaling through this pathway depends on the levels of β-catenin 
in the cell. In the absence of Wnt ligands, β-catenin is constitutively phosphorylated by a 
destruction complex that contains adenomatous polyposis coli (APC), Axin, glycogen 
synthase kinase 3β (Gsk3β) and casein kinase 1α (CK1α). Phosphorylated β-catenin is 
recognized by E3 ubiquitin ligase and targeted for proteosomal degradation. The binding 
of Wnt ligands to Fzd/LRP recruits a complex formed of Dishevelled (Dsh), Axin, 
Gsk3β to Fzd receptors at the cell membrane. Gsk3β then phosphorylates LRP5/6 
receptor allowing Axin to dock onto the phosphorylated residues removing it from the 
destruction complex which is thereby inactivated. Non-phosphorylated β-catenin will 
then accumulate in the cytoplasm, translocate into the nucleus and form complexes with 
transcription factors, such as members of T cell factor / lymphoid enhancer factor (TCF-
LEF) modulating the expression of Wnt responsive genes. These target genes include 
OPG, Myc and CyclinD as well as members of the Wnt pathway itself like axin2 which 
provide a feedback control during Wnt signaling (reviewed in (63)).  
Planar cell polarity pathway PCP (shown in Figure 1.6) regulates the polarity of the 
cells through organizing their cytoskeleton. For instance, it is required for the proper 
orientation of cilia in epithelial sheets and for the control of polarized cell movement 
during gastrulation and neurulation. In the non-canonical planer cell polarity pathway, 
Wnt signaling is mediated through Fzd receptors leading to recruitment of Dsh and 
activation of two parallel pathways involving the small GTPases Rho and Rac. For 
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activation of the Rho branch of the signaling, Dsh forms a complex with dishevelled 
associated activator of morphogenesis (Daam1). The activation of Rho GTPase results in 
activation of Rho-associated kinase (ROCK) and myosin leading to actin polymerization 
and cytoskeletal rearrangement. The second branch of the signaling activates Rac 
GTPase independent of Daam1. The activated Rac stimulates c-JUN N-terminal domain 
kinase (JNK) activity and cytoskeletal modulation. The downstream factors for planar 
cell polarity pathway are poorly defined and it is still unclear whether this pathway has 
any role in transcriptional regulation or it functions only through cytoskeletal 
modulation (reviewed in (62). 
Wnt/Ca
2+
 pathway (shown in Figure 1.6) involves activation of G–protein that will lead 
to an increase in intracellular Ca
2+
 release from sarcoplasmic reticulum and the 
subsequent stimulation of Ca
2+ 
sensitive proteins such as Ca
2+
/calmodulin-dependent 
kinase II (CamKII) and protein kinase C (PKC) (64).  
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Figure 1.6: Wnt signaling pathways: Diagram exemplifying the three main signal transduction 
pathways. The canonical Wnt/β-catenin pathway (in blue and red): the degradation complex is 
disassembled resulting in β-catenin accumulation and translocation into the nucleus.  The planar 
cell polarity pathway (green): the signal is transduced through small GTPases Rho and Rac to 
JNK regulating the cytoskeleton. The Wnt/ Ca
2+
 pathway (orange): stimulates the release of 
intra-cellular Ca
2+ 
activating protein kinase C (PKC) and Ca
2+
 /calmodulin-dependent kinase II 
(camKII). Figure from (65) 
.  
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Wnt signaling can be modulated extracellulary by several secreted proteins such as 
Wnt-inhibitory factors (WIF), Cerberus, sclerostin, Dickkopf (DKK) and a family of 5 
secreted Frizzled-related proteins (sFRP) including sFRP3 (Frzb). sFRPs display 
homology to the extracellular cysteine-rich domain (CRD) of Fzd molecules but lack the 
transmembrane segment therefore they can interact directly with Wnt proteins 
antagonizing their functions through preventing their binding to Fzd receptor. DKK 
molecules bind to LRP5/6 with high affinity promoting its internalization through 
Clathrin-mediated endocytosis (66) and thus making it unavailable for Wnt interaction. 
 In the cytoplasm, Nkd protein encoded by the Naked gene can bind directly to Dsh to 
inhibit Wnt signaling (67). Axins, GSK-3 and APC are repressors of Wnt signaling as 
they participate in regulating β-catenin degradation in the cytoplasm (68). The nuclear 
localization of β-catenin upon Wnt stimulation is regulated by Rac1-JNK2 that 
phosphorylates the stabilized β-catenin at Ser191 and Ser605 and directs it to the nucleus 
(69). Recently, Smad7 has been shown to interact with Axin dissociating β-catenin from 
the degradation complex and stabilizing it. However, rather than being translocated to 
the nucleus, Smad7-stabilized- β-catenin binds to E-cadherin complex to promote cell-
cell adhesion (70). The levels of cadherin-bound and signaling pool of β-catenin are 
tightly regulated in the cell to coordinate changes in gene expression with cellular 
adhesions and migration (71).  
Within the nucleus, the transcriptional activation of target genes by β-catenin/TCF 
complex is regulated by a number of transcriptional co-activators and co-repressors. For 
instance, CBP (72) and Brg-1 (73) are co-activators that induce chromatin remodeling 
favoring gene transcription. Further interaction between β-catenin/TCF complex and 
chromatin can be mediated by BCL/Legless and pygopos (74). On the other hand, 
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Wnt-dependent gene expression can be suppressed by a number of transcriptional 
inhibitors such as Groucho that makes DNA refractory to transcriptional activation 
through the interaction with Histone deacetylase (HDAC) (75). The β-catenin binding 
proteins Chibby and ICAT block the interaction between β-catenin and TCF leading to 
the dissociation of β-catenin/TCF complex (76;77). Nemo-like kinase (NLK) 
phosphorylates TCF/LEF factors and thus inhibits the interaction of the beta-catenin-
TCF complex with DNA and negatively regulates the Wnt signaling pathway (78). 
Role of Wnt signaling in embryonic joint development 
Wnt signaling has a crucial role in regulating cell fate determination, proliferation, 
migration and patterning during embryonic developmental. Wnt/β-catenin signaling has 
been shown to be active during early and late stages of joint formation in all joints (54).  
Wnt 4, Wnt9a (known previously as Wnt14) and Wnt16 were found to be expressed in 
the joint interzones (46;47). Expression of these Wnt genes in the prospective joint 
region is one of the earliest markers of joint determination that is followed by induction 
of growth and differentiation factor-5 (Gdf5) expression (46) and the formation of the 
joint interzone (47). Activation of Wnt/β-catenin signaling is required and sufficient for 
joint formation as genetic deletion of β-catenin in early mesenchymal condensations in 
β-catfl/fl; Dermo1-Cre (47) and β-catfl/fl; Prx1-Cre (79) mice resulted in joint 
fusion/ablation whereas, ectopic expression of constitutively active β-catenin induced 
ectopic joint formation and expression of joint markers including GDF5 (47). 
Furthermore, experiments overexpressing Wnt9a signaling in chick and mouse limbs 
resulted in morphological and molecular changes characteristic of the joint interzone 
region including the up-regulation of Gdf5, CD44 and down-regulation of Sox9 and 
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Col2a suggesting that Wnt9a is involved in joint induction (46;47). Wnt signaling is not 
only needed for initiation of joint formation but also required to suppress 
chondrogenesis of cells in presumptive joint region thereby, enabling joint formation 
and maintaining the fate of the joint interzone cells and the integrity of joints at later 
stages (79). The individual loss of either Wnt4  (80) or Wnt 16 (unpublished data) did 
not lead to joint abnormality and deletion of Wnt9a resulted only in partial fusion of 
carpal and tarsal joints that was augmented in Wnt9a/Wnt4 double mutants. This 
indicates that Wnt4, wnt14 and Wnt16 may play partially redundant roles in the process 
of joint formation (79). Conditional mutants deficient in Wnt/β-catenin signaling created 
using Col2-Cre or Gdf5-Cre had anatomically normal joints with some fusion observed 
in the wrist or ankle area only (47;54). Histologically, these grossly normal joints 
displayed a defective flattened superficial cell layer that expressed markedly reduced 
levels of lubricin and Col2a indicating that Wnt/β-catenin signaling plays an important 
role in generation and maintenance of the superficial zone of articular cartilage (54). 
Role of Wnt signaling in joint homeostasis 
Different lines of evidence suggest that molecular pathways involved in embryonic joint 
development including Wnt signaling play a role in postnatal joint homeostasis.  
Differential expression studies have reported regulation of several molecules involved in 
Wnt signaling in OA cartilage, bone, and synovial membrane. These include 
up-regulation of Frzb2 (sFRP4) (81), Wnt7b (82), Fz-6, DKK-3, and Wnt-induced 
signaling protein 1 (WISP-1) (83;84), Wnt5b, Fz3, sFRP5, APC and Axin2 (85), and 
downregulation of frzb (82). 
. 
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More importantly, an association between the development of hip OA and 
polymorphism in the Wnt antagonist Frzb gene substituting Arg324Gly has been 
demonstrated (86). This mutation reduces the antagonistic activity of Frzb without 
affecting its interaction with Wnt ligands (86;87). Furthermore, functional deletion of 
Frzb in different murine models of OA results in exacerbation of the disease. Cartilage 
breakdown in Frzb-/- mice was associated with increased Wnt signaling in the articular 
cartilage and with increased expression levels and activity of MMP3 (88). This study 
also demonstrated an interaction between Frzb and MMP3, probably through Frzb netrin 
domain, leading to dose dependent inhibition of MMP3 activity. Polymorphism in LRP5 
or WISP1 gene were found to be associated with spinal osteoarthritis in postmenopausal 
Japanese women (89;90) strongly indicating the involvement of wnt signaling in OA.    
Wnt/β-catenin pathway was found to be involved in cartilage matrix catabolism by 
activating the expression of MMPs and ADAMTSs (91). It has been reported that Wnt3a 
and Wnt7a can induce articular cartilage de-differentiation through transcriptional 
activation of β-catenin and c-Jun N-terminal kinase (JNK) pathway (92;93).  It has been 
also demonstrated that Wnt/β-catenin signaling inhibits apoptosis in articular 
chondrocytes by activating cell survival signaling such as phosphatidylinositol 
3-kinase/Akt which block apoptotic signaling cascades (92). 
The Wnt pathway was identified as a key regulator of joint remodelling as blocking the 
activity of DKK-1 reversed bone destruction in mouse models of inflammatory arthritis 
(94). In this important paper, it was shown that joint inflammation up-regulates the 
levels of DKK-1 in a TNFα-dependent manner, which in turn inhibited bone formation 
in an OPG-dependent manner. Administration of a blocking antibody to DKK-1 restored 
bone formation, blocked the formation of joint erosions and transformed the rheumatoid 
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arthritis-like phenotype of collagen induced arthritis in mice into an OA like phenotype 
characterized by osteophyte formation. The critical role of Wnt signaling in postnatal 
joint homeostasis was further highlighted by recent studies inhibiting or activating β-
catenin signaling in articular chondrocytes. Both gain and loss of function experiments 
resulted in articular cartilage destruction and development of a spontaneous OA like 
phenotype but through different mechanisms (95;96). Increased cell apoptosis 
contributed to articular cartilage damage in Col2a1-ICAT transgenic mice where Wnt/ β-
catenin signaling was blocked in chondrocytes (96) whereas, premature chondrocyte 
differentiation caused OA development in mice with conditional activation of β-catenin 
in adult articular chondrocytes (95). This indicate that Wnt signaling needs to be tightly 
controlled in articular chondrocytes to maintain a functional, stable phenotype thus 
supporting joint function throughout life. 
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1.1.3.2. BMP signaling 
An outline of the BMP pathway 
Bone morphogenetic proteins (BMPs), originally identified as proteins that induce 
ectopic bone and cartilage formation, are multifunctional growth factors and 
morphogens that belong to the transforming growth factor β superfamily that also 
include TGF-βs, activins/inhibins, nodal and anti-mullerian hormone. More than 20 
proteins have been identified and subdivided into several groups based on their structure 
similarities (97): 
 BMP2/4: BMP-2 and BMP-4 
 BMP-5,-6, -7 (Osteogenic protein-1 OP1),  -8 (OP2)  and BMP-8b (OP3)  
 BMP3: BMP-3 (osteogenin) and BMP-3b (GDF-10) 
 BMP9/10: BMP-9 (GDF-2), BMP-10 
 Growth and differentiation factors GDF: GDF-5 (Cartilage derived 
morphogenetic protein-1 CDMP-1), GDF-6 (CDMP-2, BMP13), GDF-7 
(BMP12) 
 GDF1: GDF1, GDF3 
 GDF8: GDF-8 (myostatin), GDF-11(BMP-11) 
 GDF9: GDF-9, GDF-9b (BMP15), GDF15 
BMPs are synthesized as large precursor molecules that are then cleaved at a consensus 
Arg-X-X-Arg site to generate mature dimers held together by disulfide bonds (98). 
BMPs can bind to three distinct type II serine/ threonine kinase receptors (BMP type II 
receptor BMPR-II, activin type II receptor ActR-II and activin type IIB receptor 
ActR-IIB) which in turn recruit and phosphorylate type I serine/ threonine kinase 
receptors (activin receptor like kinase ALK-2, 3 and 6) at Gly-Ser domains forming 
BMP-receptor II- receptor I complex. On receptor activation, type I receptors 
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phosphorylate receptor regulated Smads (R-Smads) which are Smads 1, 5 and 8. The 
phosphorylated R-Smads form a complex with Co-Smad (Smad-4) and translocate into 
the nucleus where, in complex with several co-activators and co-repressors, they 
participate in the transcriptional regulation of target genes (Figure 1.7) (99)   
 
Figure 1.7: BMP signaling pathway: BMPs bind to type II receptor phosphorylating type I 
receptor which in turn phosphorylates R Smads (Smad1/5/8). The R-Smads form a complex with 
Co-Smad (Smad4) and translocate into the nucleus where they regulate transcription of target 
genes. The signaling is modulated extracellulary by BMP antagonist (including noggin, chordin 
and follistatin), intracellulary by I-Smads and Smurfs and in the nucleus by transcriptional co-
activators and co-repressor. (Figure from (99)) 
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BMP signaling is regulated by different mechanisms on all levels of its pathway (Figure 
1.7). Extracellulary, the activity of BMPs is inhibited by soluble BMP antagonists such 
as Noggin, Chordin, Germilin, Dan, Cerberus and Follistatin which bind to the ligands 
preventing their interaction with the receptors. Intracellulary, Smad signaling is 
antagonized by inhibitory Smads (I-Smad) such as Smad6 and Smad7 which can 
compete with R-Smads for activation by type I receptors and interact with R-Smads to 
prevent the complex formation between R-Smads and Co-Smads. In addition, E3 
ubiquitin-protein ligase Smurf1 and Smurf2 facilitate R-Smads ubiquitination and 
degradation thus regulating their intracellular pool. In the nucleus, transcriptional 
co-activators such p300 and CBP and co-repressors such as c-Ski and SnoN regulate the 
transcription of target genes by controlling the accessibility of the Smad complex to the 
transcription machinery (100). 
Role of BMP signaling in embryonic joint development  
Many members of BMP family have been implicated in skeletal and joint development. 
BMPs including GDF-5/CDMP1 (101), GDF-6 (45), BMP-2 and BMP-4 (102) along 
with BMP antagonists Noggin and Chordin (103) are among the earliest factors to be 
expressed during the process of joint formation.  
At the early stages of limb development, GDF-5 is expressed throughout the 
mesenchymal condensations promoting the recruitment and the differentiation of cells 
into chondrogenesis (45). At later stages, GDF-5 expression is restricted to joint 
interzones where positive cells form distinct progenitor cells responsible for articular 
cartilage and synovial joint formation (54).  Mutations in GDF-5/CDMP1 cause the 
brachypodism phenotype in mice and chondrodyplasia in humans. These phenotypes are 
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mainly characterized by short limbs, loss of proximal inter-phalangeal joints and fusion 
of bones in the wrist and ankle joints (101;104;105). Exogenous GDF-5 protein could 
rescue the abnormalities present in the digits of brachypodism mice. However, in spite 
of its early appearance in joint formation, GDF-5 is not sufficient for joint specification 
as its overexpression in mouse wild type limbs resulted in joint fusions probably by 
causing cartilage overgrowth but did not lead to morphological or molecular changes 
characteristic of the formation of a new joint (106). GDF-6 and GDF-7 are also 
expressed in developing joints and mice lacking GDF-6 displayed fusions between 
bones in the wrist and ankles and compound ablation of GDF-5 and 6 genes caused 
additional widespread joints defects (107).   
BMPs play a key role in mediating inter-digital apoptosis (108) and BMP-7 up-regulates 
HA and CD44 expression in chondrocytes (109). Therefore these molecules might be 
involved in regulating the process of joint cavitation. Over-expression of BMP-2 or 
BMP-4 led to a dramatic increase in the volume of cartilage elements, altered their shape 
and led to joint fusion. This increase in volume appeared to result from an increase in the 
amount of matrix and in the number of precursors recruited to chondrogenic fate (102).  
BMP antagonists (Noggin and chordin) are expressed in the developing skeletal 
elements. Noggin is expressed in the limb mesenchyme and in the cartilage condensation 
including the developing joint (45;48). In noggin knockout mice, the mesenchymal 
condensations and the cartilage anlagens became larger and the joints failed to form 
indicating the importance of noggin in the normal development of both long bones and 
joints (48). In humans, several skeletal phenotypes such as multiple synostoses 
syndrome in which multiple joint fusions is a principal feature (110) and Tarsal-Carpal 
Coalition Syndrome (111) have been reported as a result of different noggin mutations. 
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Chordin is also expressed in developing joints (45) and chordin-null mice develop 
normal joints with minor craniofacial skeletal defects (112). BMP antagonists are thus 
required to regulate the extent of chondrogenesis preventing premature rapid conversion 
of mesenchymal condensation into chondrocytes (55).  
Role of BMP signaling in adult joint homeostasis 
Several studies have linked the regulation of BMP signaling with adult joint 
homeostasis. Different BMP ligands, receptors, intra-cellular mediators and antagonists 
are expressed in normal adult cartilage with some alteration in the expression levels in 
arthritic conditions. For example, BMP-2 was expressed at low levels in normal 
cartilage but highly expressed during osteoarthritis (113;114). BMP-7/OP-1 was found 
in the superficial and middle layers of healthy cartilage but markedly reduced with 
increasing age or progression of OA (115). CDMP-1 and CDMP-2 expression were also 
reported in normal articular cartilage predominantly in the superficial layer but further 
extended to all damaged areas in osteoarthritic cartilage (116). Expression of BMP 
antagonists such as Chordin, Follistatin and Gremlin was upregulated in osteoarthritis 
compared to normal cartilage (117;118).  
In vitro studies demonstrated that different BMPs have anabolic effects on cartilage 
stimulating proteoglycan and collagen type II synthesis (109;119;120) and genetic 
studies in humans showed that polymorphisms in either GDF-5 or BMP-2 genes were 
associated with increased susceptibility to OA development (121;122). 
The role of BMPs in cartilage homeostasis has been extensively studied in vivo.  
Intra-articular injection of BMP-2 in the mouse knee increased proteoglycan and 
collagen type II synthesis in the articular cartilage (123;124) and resulted in osteophyte 
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formation (125). Intra-articular treatment with BMP-7 had a chondroprotective effect in 
different animal models of OA (126;127).  A tissue specific conditional knock-out 
mouse lacking BMPRIa receptor in articular region (GDF5
+/cre
; BMPRIa
-/floxP 
mice) 
showed progressive damage to articular cartilage postnatally compared to their wild type 
littermates (128). Noggin haploinsufficiency provided protection for articular cartilage 
in methylated bovine serum albumin (mBSA) induced arthritis and noggin 
overexpression by adenovirus administration made cartilage more vulnerable to 
destruction in the same model of arthritis (129). Taken together, these data support the 
critical function of BMP signaling and the importance of its critical control in 
maintaining cartilage homeostasis.  
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1.2. Joint surface injury and repair 
1.2.1. Epidemiology and Natural history 
Joint surface defects (JSD) are common lesions involving the loss of articular cartilage 
with or without the underlying subchondral bone. In a retrospective study reviewing 
31,516 knee arthroscopies, chondral lesions were observed in 63% of patients. 74% of 
these patients had a single chondral lesions and 36.6% had no associated ligamentous or 
meniscal pathology (130). In a Prospective study evaluating 1.000 knee arthroscopies; 
Hjelle et al (131) reported the presence of chondral defects in 61% of the patients. The 
patellar articular surface (43.3%) and the medial femoral condyle (39.6%) were the most 
common locations of lesions reported in two recent studies analyzing 5114 and 25,124 
knee arthroscopies (132;133).   
JSD are often symptomatic and disabling (134), associated with progressive cartilage 
loss and may predispose to post-traumatic secondary osteoarthritis (PTOA) which was 
estimated to account for 13% of knee OA and 73% of ankle OA (135). Joint trauma in 
young age was reported to double the risk of developing OA (136) and joint surface 
defects were an independent risk factor for the need of prosthetic joint replacement 
within 4 years if occurring in patients with already established OA (137;138). Cartilage 
breakdown is the inevitable outcome of most rheumatic conditions causing pain and 
disability for millions of people worldwide. Therefore, joint surface restoration is a 
major priority in modern medicine (139).   
It has been long thought that cartilage injuries never heal and lead to progressive joint 
degeneration and OA development (140). However, recent longitudinal studies have 
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showed evidence of spontaneous healing. In a long term (14 years) follow up study of 28 
young athletes with isolated severe chondral damage in the weight-bearing area of the 
knee joint, 22 patients (78%) had excellent or good knee function and were able to 
return to pre-injury sport activities without any initial specific treatment (141). In 
another independent study, 79% of patients with chondral lesions also returned to 
pre-injury sports activities including jumping, twisting, and pivoting in the absence of 
any intervention on the cartilage lesion (142).  
In prospective MRI studies, approximately 50% of asymptomatic individuals have 
chondral defects. Only 18.15% of individuals with a chondral defect had history of knee 
trauma. After 2.3 years follow up, 33% of the subjects had a worsening and 37% of the 
subjects had an improvement in cartilage defect score as graded by MRI and the rest 
remained stable. Worsening in scores was associated with age, female sex and body 
mass index (143). This confirms that functional as well as anatomical restoration can 
happen in a number of cases. In people with already established knee OA, superimposed 
chondral defects tended to progress in 81%, remained stable in 15% and improved only 
in 4% of patients over 2 years (144).  
So far, it is not possible to predict the outcome of JSD as its natural history varies from 
spontaneous healing to secondary post-traumatic OA development
 
(135;143). The 
reasons why some injured joints return to their normal function whereas other 
degenerate can be partially explained by the presence of risk factors related to the patient 
or to the nature of the injury itself that can interfere with joint surface repair.  
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1.2.2. Factors influencing outcome  
Age is a strong risk factor for the development of PTOA (143). Articular cartilage 
undergoes significant age related changes in chondrocyte function, molecular 
composition and organization of the matrix including the production of shorter aggrecan 
molecules, increase in collagen cross-linking and decreased water content (145). With 
age, articular cartilage chondrocytes show a decrease in their mitotic and synthetic 
activity, become less responsive to anabolic growth factors and thus less able to 
maintain and repair cartilage tissue after injury (146). Clinical studies have shown that 
the risk of developing PTOA following articular cartilage injury in the knee joints 
increased 3-4 fold in patients older than 50 years (147). Animal studies in rabbits have 
demonstrated better reparative response in younger animals in comparison to older ones 
(148). However, the exact mechanisms of the age-dependent decline in the repair 
capacity of joint surface are unknown. It was postulated that such phenomenon might be 
due to age-related decrease in proliferative and synthetic activity of chondrocytes, 
unavailability of sufficient stem cell pool, insufficient release of growth factors or 
decreased sensitivity of cells to signaling molecules (149).  
The Size and the depth of the defect are important factors determining the repair 
outcome. Defects exceeding a critical size do not achieve spontaneous repair and more 
likely develop secondary OA. In rabbits and goats, 3 mm diameter defects underwent 
complete repair whereas large (more than 5 mm) diameter defects showed progressive 
degeneration (150). Similarly in horses, large 9mm diameter lesion did not heal but a 
smaller 3mm diameter lesion was fully repaired in three months (151).  
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Cartilage lesions can be classified as either partial or full thickness depending on 
whether they extend or not to the subchondral bone. Partial thickness defects do not heal 
spontaneously. It has been suggested that this repair failure is due to the fact that they do 
not penetrate the subchondral bone and thus had no access to progenitor cells residing in 
bone marrow spaces. However, these lesions are asymptomatic and there is no evidence 
that they may evolve into osteoarthritis. Therefore, they do not represent an indication 
for surgical intervention (143;152). Full thickness cartilage defect extend to the 
underlying subchondral bone causing hemorrhage and fibrin clot formation. 
Experimental data suggest that mesenchymal stem cells (MSCs) from the underlying 
bone marrow migrate into the injury site and subsequently differentiate and assume a 
chondrocyte phenotype and start to synthesize collagen type II and proteoglycans. The 
subchondral bone plate is restored through the process of endochondral bone formation 
with the preservation of the articular cartilage surface (5;153). Although full thickness 
defects heal better than partial thickness lesions, they are clinically relevant because 
sometimes they persist and become symptomatic and disabling and therefore represent 
an indication for chondral surgery (154).  
Associated joint instability and Malalignment is poor prognostic factor as it alters the 
joint biomechanics. Traumatic lesions causing combined joint surface injury and joint 
instability through rupture of ligaments, menisci or joint capsule, increase the 
susceptibility of joints to degenerate and therefore, associated with a higher risk for 
PTOA development (155). Joint instability affects the normal apposition of joint 
surfaces during motion and thus causes excessive focal shear and compressive forces on 
some regions of the articular surface leading to its degeneration (156). Experimental 
models show that mechanical instability induced by anterior cruciate ligament (ACL) 
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transection (157) or menisectomy of the knee joint leads to progressive joint 
degeneration (158). The combination of instability and articular cartilage injury were 
more likely to cause rapid progressive loss of cartilage than either condition alone (159). 
In humans, meniscal lesions and meniscal instability are well known risk factors of OA 
(160) and poor repair of JSD (143) 
1.2.3. Available treatments 
Several surgical therapeutic approaches have been developed in order to relief the 
symptoms, reconstruct joint surface, improve joint functionality and avoid progression 
towards OA.  
1) Bone marrow stimulation procedures 
Microfracture and pridie drilling take advantage of the intrinsic repair response observed 
upon penetration of subchondral bone in full thickness defects. Access to the 
subchondral bone marrow is gained by perforating the bed of the JSD through 
generating micro-holes. This induces the formation of fibrin clot and the recruitment of 
bone marrow-derived MSCs which subsequently undergo chondrogenesis. The resulting 
repair tissue is variable in composition, structure and durability. Biopsy specimens 
obtained from patients 2 years after microfracture showed that 11.4% were 
predominately formed of hyaline cartilage, 17.1% were formed of a mixture of hyaline 
and fibrocartilage and the rest were mainly formed of fibrocartilage (161).  
The durability of the repair tissue is controversial. Although favorable outcome and 
longevity were reported after microfracture for up to 7 years (162), an independent 
longitudinal study of patients treated with microfracture over 36 months showed a 
significant deterioration after 18 month following an initial improvement especially in 
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individuals older than 40 years (163). The rate of failure after microfracture (patient 
needing re-operation due to lack of healing of the treated defect and persistent 
symptoms) increased from 2.5% after 2 year follow up to 23% after 5 years (164).  
2) Cartilage replacement procedure (Mosaicplasty)  
Mosaicplasty is performed by implanting autologous osteochondral graft, obtained from 
non weight-bearing area of the joint, into the full thickness defect. This technique can be 
done either as an open procedure or arthroscopically (165). In a large series of more than 
1.000 mosaicplasties involving different compartments in the knee joint (166), good 
results were reported in 92%, 87% and 74% of patients defects in femoral condyles, 
tibial plateau and patellofemoral joints respectively for up to 10 years post-operatively. 
Survival of the transplanted cartilage and acceptable fibrocartilage covering of the donor 
site were found in 81 of 98 second look arthroscopies (166).  
The main advantage of this technique is that it immediately fills the defect with hyaline 
articular cartilage and thus provides a fast symptomatic relief. Nonetheless, this 
procedure has several disadvantages. For example, harvesting of osteochondral plug 
induces chondrocyte death at the margin of the plug leading to tissue degeneration and 
failure of the graft (167). Lateral integration of the plug with native cartilage is hindered 
by the loss of chondrocyte viability at the margins and the inevitable spaces left between 
the graft and recipient tissue. This raises the concern that synovial fluid may leak into 
the subchondral layer causing cyst formation (154).  Moreover, the translocation of 
tissue from low weight bearing area to a high weight bearing area may lead to 
degeneration of the graft as a consequence of mechanical overloading in the new 
position (168). There are also technical difficulties in restoring smooth joint surface due 
to differences in cartilage thickness between donor site and native tissues (169). Donor 
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site morbidity, associated with osteochondral transfer, must also be considered as it 
always associated with chondrocyte death adjacent to the harvest sites leading to 
degeneration of the tissue overtime (152). Failure of cartilaginous repair tissue to fill the 
void created in the donor site has been reported and associated with increased stiffness 
of the joint (170).  
3) 
 
Autologous chondrocyte implantation (ACI) 
In this procedure, healthy cartilage is harvested from non-weight bearing area of the 
joint at an initial arthroscopy. Autologous chondrocytes are released by enzymatic 
digestion, expanded in vitro for 2-3 weeks and then injected into the chondral defect 
underneath a periosteal flap in a second surgical procedure (171). In 1994, Brittberg et al 
presented clinical results of first 23 patients (14-48 years old) with full thickness 
cartilage defect in the knee treated by ACI. They reported good results in 70% of all 
patients and 88% of cases with femoral condylar transplants 2 years after transplantation 
(171). Long term clinical studies showed satisfactory results in 80% of patients (92% of 
patients with femoral condylar defect) for up to 9 years (172) and good results were 
reported in 51 of 61 patients treated with ACI in a 5-11 years follow up study (173).  
Three potential sources were proposed for the origin of the repair tissue in ACI 
procedure; the transplanted chondrocytes, precursor cells from periosteal flap or 
mesenchymal stem cells derived from the underlying bone marrow (152). Using a goat 
model of ACI and a tracking dye, it has been shown that the implanted chondrocytes 
persisted in the cartilage defect and constituted the majority of the repair cartilage tissue 
after 12 weeks (174). However, it can not be excluded that these cells may play a 
different role including the support of the local repair mechanisms by delivering 
bioactive molecules such as BMPs and FGFs (174).  
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It is known that the in vitro chondrocyte expansion, necessary for obtaining enough 
numbers of cells, cause gradual de-differentiation of chondrocytes (175) and affect their 
phenotypic stability potentially leading to loss of their capacity to form stable cartilage 
in vivo, and to resist vascular invasion and endochondral bone formation (176). This is a 
pivotal issue for successful cell based repair protocol. Molecular markers, such as 
FGFR3, BMP2, COL2A1 and ALK1, can predict the ability of expanded human 
articular chondrocytes to form ectopic stable cartilage in vivo and thus can be used to 
monitor the phenotypic stability of chondrocytes during in vitro expansion (176). 
Importantly, Saris et al have demonstrated that ACI performed using chondrocytes 
optimized by these markers for its biological potency to form stable cartilage tissue in 
vivo results in better structural and clinical outcome than microfracture (177;178). 
Randomized control trials 
Randomized control trials have been performed to identify a superior method for 
cartilage repair. Mosaicplasty has largely been abandoned in recent years due to the 
several problems listed above and to a poorer performance compared to ACI in 
randomized clinical trial (179). Microfracture and ACI have repeatedly shown similar 
efficacy in clinical trials. Knutsen et al., 2004 compared ACI with microfracture two 
years after surgery and there was little difference in favor of microfracture in term of 
clinical scores but there was no significant difference in macroscopic or histological 
results between the two treatment groups (161). In a follow-up study at 5 years in the 
same cohort, both ACI and microfracture had comparably satisfactory results in 77% of 
the patients with no significant difference in the clinical and radiographic outcome 
between the two treatment groups (164). One important finding of this study was that the 
histological quality of the repair tissue correlated with the clinical outcome as none of 
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patients with good quality cartilage (predominantly hyaline) at 2 years had a later failure 
at the 5 years follow up (164).  
A recent randomized control trial comparing a variant of ACI where the chondrocyte are 
quality controlled for their cartilage forming capacity after in vitro expansion (176) 
versus microfracture three year after treatment, reported superior structural and clinical 
outcome in chondral defects treated with characterized chondrocyte implantation 
(178;180) thereby stressing the importance of phenotypic stability of implanted 
chondrocytes in achieving better structural regeneration.  
Despite the presence of many different treatment methods providing symptomatic relief, 
each method has several limitations and no method has yet been able to regenerate a 
neo-cartilage similar in structure and mechanical properties to that of a native normal 
hyaline articular cartilage, and the best treatment for long term durability is still 
unknown. Most importantly, the current therapeutic options involve invasive and 
challenging surgeries and the cell-based technologies are extremely expensive. 
Therefore, intense research is still ongoing to identify novel therapeutic options that 
could circumvent these problems.  
1.2.4. Cartilage tissue engineering 
Tissue engineering is a fast developing area in medicine that combine cells, scaffolding 
biomaterials and signaling molecules to engineer functional replacement tissue for 
clinical use. There are two main approaches for tissue engineering. In the first, repair 
tissue is engineered completely in vitro and then implanted into the defect. The 
advantage of this method is that the manufacturing is well controlled and the tissue will 
be immediately capable of weight bearing. However, there are several problems 
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associated with the implantation of pre-formed mature implant including tissue 
integration, mechanical fixation, immune reactivity and inadequate physical properties. 
In addition, the clinical application of this approach is difficult because of the high costs 
that it implies and the regulatory hurdles that a composite product should pass before it 
can be approved. 
In the second approach, the basic building blocks containing a matrix scaffold, cells and 
signaling molecules will be assembled in vitro. The desired differentiation and 
remodeling processes will take place in vivo following implantation under the control of 
the delivered signaling molecules and physiological mechanical loading. In this case, the 
immature engineered cartilage could be injected in a minimally invasive procedure that 
may reduce morbidity and it is hoped that the repair tissue will integrate with the native 
articular cartilage by taking the shape of the defect that it has been injected into. 
However, the high costs, the complex regulation that cell based product will be 
subjected to and the difficult control over cellular activity on the long term are all 
considered as disadvantages of this technique (152).  
Stem cells 
Although the use of autologous chondrocytes in ACI offers the advantage of using 
differentiated cells that are committed to the appropriate phenotype, several concerns 
have been raised regarding the additional injury affecting the donor site, the need for two 
operations, the in vitro manipulation of the cells that may affect its phenotypic stability 
(176) and finally the high cost associated with the in vitro chondrocyte expansion. 
Therefore, chondrogenic cells that are in more abundant supply and more easily obtained 
have been proposed as an alternative source for cartilage reconstruction. Mesenchymal 
stem cells (MSCs) are multipotent cells that have the capacity to differentiate into a 
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variety of other connective tissue cells, including chondrocytes (181) and can be isolated 
from several tissues such as bone marrow (181), periosteum (182), synovial membrane 
(183), articular cartilage (184), skeletal muscle and adipose tissue (185). These 
properties of MSCs would allow the generation of large quality controlled batches for 
allogeneic transplantation and thus overcome the limitation and variability of autologous 
cell protocols (186).  However, the immunogenicity of MSCs must be taken into 
consideration as conflicting results have been obtained in different experimental 
conditions, tissue/organ systems or animal species (187)  
The implantation of undifferentiated bone marrow MSCs has been tested in a variety of 
animal models with initial encouraging results (188;189;190). However, at later time 
points, cartilage tissue became thinner due to progressive endochondral bone formation 
with the advancement of the bone front at the expenses of overlying articular cartilage 
(191;192). This can be explained by the known characteristic of these cells to terminally 
differentiate into hypertrophic chondrocytes and/or the insufficiency of the in vivo 
environment to promote chondrogenesis (193). Thus, the implantation of a 
pre-committed MSCs towards chondrogenic lineage was proposed to reduce the risk of 
undesired tissue formation. The in vitro chondrogenic differentiation of MSCs can be 
induced through a large variety of different growth factors including TGF-β1, IGF-1, 
BMPs and FGFs (194). However, this acquired phenotype was not stable in vivo in a 
nude mouse assay of ectopic cartilage formation (195). During in vitro chondrogenic 
induction, MSCs not only up-regulate hyaline cartilage specific markers such as 
collagen type II and aggrecan, but also up-regulate markers for hypertrophic 
chondrocytes and osteogenesis such as Collagen type X, MMP13 and increase in 
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alkaline phosphatase activity (196). In contrast, engineered cartilage from mature 
chondrocytes does not express type X collagen or alkaline phosphatase (197).  
At present, there are scattered studies in humans testing the potential of autologous 
culture expanded bone marrow MSCs transplantation to promote the repair of articular 
cartilage defects. One clinical trial compared autologous expanded bone marrow derived 
MSCs cultured on a collagen scaffold versus cell free scaffold controls. The 2-year 
outcome showed significantly better hyaline cartilage formation in the cell-transplanted 
group compared to the cell-free control group (198).  In 3 case reports, cultured MSCs 
were placed into cartilage defects and covered with autologous periosteum. Clinical 
symptoms had improved significantly for up to 2 years however; the histological 
outcome of repair tissue was variable ranging from hyaline like cartilage to 
fibrocartilage (199-201). It is still unclear whether the newly formed tissue consisted of 
the implanted MSCs or the applied cells indirectly promote regeneration via secreted 
bioactive factors.  
Further studies are still needed to better understand the regulatory mechanisms involved 
in enhancing and maintaining chondrogenic differentiation. It is crucial also to 
characterize the difference between MSCs derived from different tissues to determine 
the best source in terms of chondrogenic ability and easy accessibility. Importantly, the 
role and the contribution of transplanted cells to the repair tissue as well as structural and 
functional properties of this tissue over long term must be addressed and compared to 
results obtained from ACI procedure.  
Scaffolds  
Biomaterial science runs in parallel with the advances in tissue engineering in an attempt 
to develop biocompatible, biodegradable, porous, mechanically stable and supportive 
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scaffolds that not only can be used to keep the implanted cells in the site of damage but 
can also  influence cell differentiation and tissue pattering through controlled delivery of 
bioactive molecules (202). Scaffold materials may be either natural or synthetic. Natural 
materials include agarose, hyaluronan, gelatin, fibrin and collagen derivatives. These 
materials can be produced in an injectable form which later can set to gel and fill any 
shape and size of cartilage defect.  The use of agarose, gelatin and fibrin has been 
limited by their mechanical fragility and the possibility of evoking immune reactions.  
Collagens and hyaluronan provide a substrate that would normally be found in articular 
cartilage and thus have better biocompatibility (168). Synthetic scaffolds can be 
manufactured from polyglycolic and polylactic acids in many variants. The mechanical 
and biochemical properties of the synthetic materials can be modified to generate 
products more resistant to the friction of joint motion and easier to be fixed to the 
recipient site. The degradation rate can also be adjusted to be sufficient for scaffold 
purpose without impeding tissue regeneration (203).  The scaffold architecture can be 
designed to mimic the depth-dependent heterogeneity of articular cartilage structure 
(204) or to generate biphasic scaffolds to promote the simultaneous growth of bone and 
cartilage with a stable interface for engineering osteochondral tissue (205). At the same 
time, the immune reaction problems of the natural materials are avoided (206).   
Synthetic self-assembling biomaterials are being developed to generate 3D scaffolds that 
polymerize spontaneously in situ to support implanted cells and act as carriers systems 
for controlled release of bioactive molecules to achieve a coordinated process of cell 
differentiation and tissue repair. One example of such strategy comes from the field of 
neural regeneration, Silva and colleagues (207) described the generation a self-
polymerizing peptide carrying the neurite-promoting laminin epitope IKVAV. This 
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peptide assembled itself into nanofibers encapsulating neuronal progenitor cells and 
presenting them to a bioactive peptide at high density. This induced rapid neuronal 
differentiation of the progenitor cells, while discouraging development of astrocytes. In 
a similar approach in bone regeneration, Lutolf et al (208) have engineered a hydrogel 
that can promote cell adhesion through an integrin-dependent mechanism and deliver 
rhBMP-2 at the site of critical size cranial defects in rats. The hydrogel was infiltrated 
rapidly by fibroblast-like cells and replaced with bone tissue resulting in efficient and 
highly localized bone regeneration.  
Signaling molecules  
 Several growth factors and signaling molecules influence various cell activities such as 
proliferation, migration, differentiation and matrix synthesis and therefore could be used 
to specifically guide the course of differentiation in the desired direction and to maintain 
the chondrocyte phenotype. A number of growth factors such as TGF-β, IGF1, FGF and 
especially BMPs have been shown to induce chondrogenesis and stimulate the anabolic 
activity of chondrocytes (209) and therefore have represented for many years an 
attractive therapeutic target for chondro-protection and cartilage repair. These bioactive 
molecules have been intensively explored in vitro and in animal models 
(210;211;212;213;214). However, their use might result in adverse effects in the joints 
such as osteophyte formation, swelling and synovial hyperplasia (125;215). In addition, 
the delivery of these proteins to the sites of cartilage damage at therapeutic 
concentrations and for sustained periods of time has been difficult due to their limited 
half-lives in vivo (209).   
Thus far, these approaches to cartilage engineering are still at the experimental stage of 
development and several issues must be addressed before the application in clinical 
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practice. These issues include the potency, safety and toxicity of the cellular 
product/proposed molecules, the optimal source, dose and delivery system for 
cells/growth factors to the lesion, anatomical and functional integration of the resulting 
repair tissue with the surrounding cartilage and bone, cost effectiveness, identification of 
proper clinical indications and management of adverse effect (186).   
Another alternative or complementary approach for cartilage tissue regeneration and 
restoration of joint homeostasis could be the controlled delivery of bioactive molecules 
to the site of injury for a defined period of time and at the right dose to trigger/support 
repair response by recruiting joint progenitor cells to the site of damage and controlling 
their fate decisions and differentiation in vivo (molecular therapy). This approach would 
thereby avoid the limitations of the current cell-based therapies that are related to in 
vitro manipulation of cells, high costs, variability, disease transmission and 
immunogenicity.  A key step for the development of such an approach is the 
identification of the appropriate potential molecular signal (s) that can be targeted to 
enhance the biological repair of joint surface defects with phenotypically stable cartilage 
resistant to vascular invasion and endochondral bone formation. 
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1.3. Models of acute cartilage injury 
1.3.1. In vitro models  
Many in vitro models in which cartilage injury can be induced by either explantation, 
re-cutting (216) or impact loading (217) have been developed to investigate the cellular 
and molecular response of adult articular cartilage to acute mechanical injury.  Several 
studies have investigated the effect of cartilage injury on chondrocyte viability and 
demonstrated that mechanical overloading and wounding can induce cell death in 
cartilage tissue (218-220). The extent of chondrocyte apoptosis was positively correlated 
with the amount of load applied (221) and was associated with cartilage damage and 
degeneration suggesting a role of chondrocyte cell death in the pathogenesis of PTOA 
(222). Redman et al studied the cellular response of articular cartilage to sharp and blunt 
trauma and showed extensive cell death in response to trephine (blunt) trauma and 
limited cell death adjacent to lesion edge when cartilage is wounded with scalpel (sharp 
trauma) (223). It is not yet clear how mechanical injury triggers the apoptotic process 
but it was postulated that disruption of cell-matrix interaction during injury might be the 
stimulus for chondrocyte apoptosis (224). Activation of cellular proliferation was also 
reported following a single impact load (225) and in cartilage explants subjected to sharp 
and blunt trauma (223).  
Mechanical cartilage injury has been demonstrated to cause strong up-regulation of 
MMPs and aggrecanases suggesting that these enzymes may be involved in the active 
degradation of proteoglycans after injury (226;227). Chondrocytes respond to 
low/moderate loading by up-regulating their biosynthetic activity to maintain the 
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mechanical properties and function of the tissue (228). However, impact loading was 
found to decrease proteoglycan synthesis correlating with increased load frequency and 
duration (229).  
Intracellular signaling pathways such as extracellulary regulated kinase (ERK), p38, and 
c-jun-terminal kinase (JNK) were strongly activated by mechanical injury and were 
sufficient to induce expression of inflammatory mediators such as IL-1α and β (230).  
The activation of ERK pathway upon cutting or loading articular cartilage was 
dependent on fibroblast growth factor-2 (FGF-2) release from pericellular matrix 
(13;216;231). FGF-2 plays a pivotal role in promoting MSCs migration during the early 
phases of articular cartilage repair (232) and in protecting cartilage from degradation by 
suppressing aggrecanase activity (233). This data indicate a functional role of molecular 
signals activated in response to injury and validate the use of in vitro models to identify 
therapeutic targets to enhance cartilage repair.  
1.3.2. In vivo animal models  
Several animal models have been generated to study the pathophysiology of joint 
surface injury and to develop/evaluate different therapeutic approaches for 
reconstructing the damaged articular cartilage. Although none of these models 
reproduces the human lesions due to the physiological and anatomical differences 
between human joints and those of experimental animals (234), the use of animal 
models has played a significant role in the current advancement of joint resurfacing 
techniques and in our understanding of cartilage response to injury and phenomenology 
of repair process.  
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In these models, partial cartilage defects neither heal spontaneously nor evolve into OA 
(152). This is in line with the human data in which similar defects are asymptomatic 
with no evidence of OA evolution (143). In full thickness joint surface injury, however,  
spontaneous structural repair was reported in several large animal models such as rats 
(235), rabbits (153), dogs (236) and horses (151). Interestingly, this repair phenomenon 
involved a coordinated and polarized morphogenetic process recapitulating 
chondrogenesis and endochondral bone formation during embryonic skeletogenesis 
(153). These data thereby document the presence of cartilage repair mechanisms that 
involve endogenous progenitors in adult animals and suggest that mechanisms similar to 
those involved in skeletal development were reactivated during postnatal repair process. 
This was further supported by a recent study characterizing the early events of repair of 
full thickness defects in rats and demonstrating that morphogenetic and molecular events 
taking place during repair are analogous to those observed during skeletal development 
(237).  
Although the histological features of cartilage repair process has been extensively 
characterized, the molecular and cellular mechanisms governing such events are not yet 
understood. This could be attributed to the unavailability of a suitable animal model 
amenable to genetic manipulation to allow functional testing of molecules involved in 
joint surface repair. Therefore, one of the main aims of the work presented in this thesis 
was to develop a reproducible and consistent adult mammalian animal model of joint 
surface injury/repair that is suitable for biological and biochemical quantification, 
detailed molecular analysis and genetic studies.  
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CHAPTER 2  
HYPOTHESIS AND AIMS OF THE STUDY 
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2.1. Hypothesis: 
This work tests the hypothesis that mechanical injury to adult articular cartilage 
can trigger a specific molecular and cellular response in this tissue leading to joint 
surface repair.  
Previous experiments in animal models and recent clinical evidence demonstrate that the 
joint surface, under favorable circumstances, can heal cartilage defects. So far, the 
molecular and cellular program governing the repair process is unknown. We anticipate 
that some signalling molecules activated upon cartilage injury may regulate joint surface 
regeneration and therefore may represent a molecular tool to enhance/support the 
biological repair processes in patients with chronic joint surface defects. 
2.2. Aims of the study: 
The ultimate goal of this study was to investigate the cellular and molecular mechanisms 
regulating joint surface healing by studying the early response to mechanical articular 
cartilage injury.  
The specific aims for this thesis were to: 
1. Characterize the molecular response of articular cartilage to acute mechanical injury.  
2. Generate and validate an in vivo model of joint surface injury and regeneration in 
adult mice as this species is amenable for genetic manipulation and thus allow functional 
molecular studies. 
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3. Characterize the cellular responses and ECM remodeling following acute mechanical 
injury of the joint surface in vivo 
4. Investigate whether the modulation of signaling pathways in response to cartilage 
injury in vitro also takes place in vivo where cartilage interacts with neighbouring 
tissues in the joint. 
5. Investigate the function of Wnt16, a morphogen expressed specifically by injured 
articular cartilage, in joint surface homeostasis, regeneration, and development of 
experimental OA.  
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CHAPTER 3 
MATERIALS AND METHODS 
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3.1: Generation of the acute mechanical cartilage injury 
To investigate the response of articular cartilage to mechanical injury, we used an in 
vivo and in vitro cartilage injury models. 
3.1.1: In vivo joint surface injury model 
Male C57BL/6, DBA/1 and MRL/Mpj mice strains were purchased from Jackson 
laboratory. BAT-GAL mice in which β-galactosidase is expressed under the 
transcriptional control of TCF/LEF1 responsive elements were obtained as a kind gift 
from Professor Stefano Piccolo (University of Padua, Italy) and Axin2 knock-in mice in 
which a LacZ cassette replace exon 2 of the Axin 2 gene were obtained from Dr. Boris 
Jerchow and Professor Walter Birchmeier (Center for Molecular Medicine, Berlin, 
Germany).  Wnt16 null mutants were obtained through a collaboration with Professor 
Jing Yu and Professor Andrew McMahon (Harvard University, Boston USA).  
All mice were maintained on free diet under pathogen free conditions. Mice were 
anesthetized using Ketamine (40 mg/kg) and Xylazine (5 mg/kg). After lateral skin 
incision, medial Para-patellar arthrotomy was performed under a dissection microscope 
(Leica), by inserting microsurgical scalpel medially and proximally to the insertion of 
the patellar tendon on the tibia and extending it proximally until the attachment of the 
quadriceps muscle. The medial margin of the quadriceps was separated from the muscles 
of the medial compartment (Figure 3.1.A&B). The joint was extended and the patella 
was dislocated laterally (Figure 3.1C). The joint was then fully flexed to expose the 
patellar groove. A longitudinal full thickness injury was made in the patellar groove 
using a custom made device in which a glass bead was placed approximately 200μm to 
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the tip of a 26G needle (Figure 3.1D). The tip of the needle was placed anteriorly to the 
intercondylar notch and gently moved along the entire length of the patellar groove 
(Figure 3.1D). The patellar dislocation was then reduced. The joint capsule and the skin 
were sutured in separate layers. The contra-lateral knee was either left non-operated or 
subjected to arthrotomy and patellar dislocation without cartilage injury (sham-operated 
controls). After recovery, the mice were allowed to walk freely in standard cages and 
then killed at different time points. All procedures were approved by the local Ethics 
committee and the UK Home Office. 
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Figure 3.1: surgical induction of joint surface injury in mice: Lateral skin incision (A) and 
medial Para-patellar arthrotomy was performed (B). The patellar groove is exposed by lateral 
dislocation of the patella (C). The devise is placed with its tip just anteriorly to the intercondylar 
notch (lower end of dotted line) and dragged proximally in the centre of the entire length of 
patellar groove (dotted line) (D). P=Patella; PT=Patellar tendon; Q=quadriceps muscle and 
T=Tibial tuberosity.  
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3.1.2: In vitro cartilage injury model 
Cartilage samples were obtained from patients who underwent either total knee 
replacement for unicompartmental OA (7 patients with a mean ± SD age of 68 ± 7 years) 
or limb amputation because of traffic accident (a 53-years-old man). A rectangular 
cartilage explant was dissected and divided into three equal parts of 6x 6 mm each. One 
part was immediately snap-frozen in liquid nitrogen for total RNA extraction preserving 
a full thickness slice for histological analysis (freshly isolated sample). The remaining 2 
explants were maintained in culture in 4ml of Dulbecco’s modified Eagles’s medium 
(Invitrogen, UK) in the presence or absence of 10% FBS (Invitrogen, UK) and 
antibiotics/ antimycotics (Invitrogen, UK) in individual 33mm bacteriological petri 
dishes (BD Bioscience) to avoid spreading of the cells from the explants. After 6 days, 
the medium was replaced and one of each pair of adjacent samples was cut at 1 mm 
interval using a scalpel (injured sample). The other explant of each pair was left 
uninjured (uninjured sample). After 24 hours, the culture was terminated and explants 
were used for RNA extraction and histological analysis. The peripheral part (1mm) of 
each explant was discarded to eliminate the portion of cartilage that was injured during 
the initial dissection before the culture. The model is summarized in Figure 3.2 
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Figure 3.2: In vitro model of mechanical cartilage injury: Adult human articular cartilage 
explants were obtained, dissected and processed immediately or placed in culture in separate 
bacteriological Petri dishes. After 6 days, one explant was injured and 24 hours later the cultures 
were terminated for gene expression and histological analysis.   
 
3.2: Surgical destabilization of the medial meniscus (DMM) 
DMM was performed according to the previously published procedure (34). Breifly, 
mice were anesthetized using intra-peritoneal injection of Ketamine (40 mg/kg) and 
Xylazine (5 mg/kg).  A longitudinal incision medial to the patellar ligament was made, 
the joint capsule was opened, and the meniscotibial ligament, anchoring the medial 
meniscus to the tibial plateau, was identified and transected, resulting in destabilization 
of the medial meniscus (DMM). In sham operated animals, arthrotomy was performed 
without any further manipulation. In both sham and DMM animals, the joint capsule and 
the skin were sutured separately. After recovery from anesthesia the mice were allowed 
to move freely and were kept under standard conditions. 
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3.3. Tissue processing for Histology and immunohistochemistry   
3.3.1. Fixation and decalcification 
Mouse knee joints were dissected immediately after killing the animals and fixed in 
buffered isotonic solution of 4% PFA (Paraformaldehyde) at 4°C for 24h.  The joints 
were then washed with phosphate buffered saline (PBS) and decalcified in 4% EDTA 
(ethylenediaminetetra-acetic acid) for 2 weeks at room temperature with changing the 
solution every 3 days.  
Human cartilage explants were also fixed in buffered isotonic solution of 4% 
Paraformaldehyde at 4°C over night immediately after the termination of the cultures 
and then processed for embedding  
3.3.2. Embedding 
Paraffin embedding 
Following fixation and, when appropriate, decalcification, the tissues  were washed in 
PBS and fitted into the embedding cassettes and processed in Leica TP 1050 tissue 
processor as follows: 
1) 70% Ethanol, two changes, 1 hour each. 
2) 80% Ethanol, two changes, 1 hour each. 
3) 95% Ethanol, two changes, 1 hour each. 
4) 100% Ethanol, three changes, 1 hour each. 
5) Xylene or xylene substitute, three changes, 1 hour each. 
6) Paraffin wax (56-58 C), two changes, 1 hour and half each. 
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Finally the tissue samples were embedded into paraffin blocks and placed in a cold plate 
to set for at least 2 hours. Cartilage explants were embedded with their lateral side facing 
down so that cutting would result in full thickness sections. Mouse joints were orientated 
in a “kneeling position” with the anterior aspect of the tibia facing down, and the femur 
angles at 90’ with the tibia directed upward. This orientation resulted in sections that 
were frontal in the tibia and coronal in the femur, as shown in figure 5.1A. Paraffin 
embedded samples were stored in boxes at room temperature until use.   
Frozen sample embedding 
Samples were washed in PBS and transferred into 5% sucrose/PBS and incubated for 2 
hours at 4°C on rotating plate. The solution was then replaced with 30% sucrose/PBS for 
an overnight incubation at 4°C. Half of the solution was then replaced with OCT 
(optimal cutting temperature) mounting medium and samples were kept on the rotating 
plate until solution was homogeneous. A drop of OCT was placed in a shallow cylinder 
made of aluminum foil. The sample was embedded in the OCT and then covered 
completely with OCT. A 6 well plate filled with isopentane (2-methyl butane) was 
placed in a box filled with liquid nitrogen, bringing the isopentane at its freezing point (-
160°C). The cylinder with the embedded sample was then placed within the ice-cold 
isopentane, until completely frozen. Blocks were then stored at -80°C in 6 well plate 
until needed. 
3.3.3: Sample sectioning 
Paraffin embedded samples 
Paraffin embedded mouse knee joints and cartilage explants were placed on ice to cool 
down and serially sectioned at 5µm interval using Leica RM 2135 microtome 
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(Knowlhill, UK). The sections were then floated on a warm water bath (45
o
 C), and 
picked up onto Superfrost microscopic slides and allowed to dry on a 70°C hot plate. 
After few hours, the slides were removed from the hot plate and stored in cardboard 
boxes at room temperature until use.  
Frozen samples  
The frozen blocks were equilibrated to the cutting temperature by incubating the blocks 
overnight in a -20°C freezer and then placing them in the cryostat with adjusting the 
temperature between -21 and -24 °C. 5µm-thick sections were cut and collected onto 
Superfrost microscopy slides.  Slides were left overnight at room temperature to dry, 
individually wrapped in aluminum foil, placed in boxes and stored at -80ºC until use. 
Each slide was allowed to adjust to room temperature before being unwrapped and used.  
3.4: Histological and histochemical stainings 
3.4.1: Toluidine blue staining 
To determine the level reached during sample sectioning, rapid and simple Toluidine 
blue staining was performed. Slides were dried on a 70°C hot plate for 1 minute, 
deparaffinized in xylene for 1 minute, dehydrated in 100% ethanol for another minute 
and washed in water. The section was covered with a drop of Toluidine blue (Appendix) 
for few seconds, washed in water and visualized under the microscope. The slides were 
then left to air-dry, cleared in xylene and mounted with DEPEX. 
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3.4.2: Hematoxylin and Eosin (H&E) staining 
To visualize the microscopic structure of the tissues, H&E staining was performed 
according to the standard protocols. Briefly, paraffin embedded sections were 
deparaffinized in xylene (2 changes, 5 minutes each), gradually rehydrated in 
descending grades of ethanol (100%, 70% and 50% ethanol for 5 minutes each) and 
rinsed with water for 5 minutes. Slides were then placed in jars containing filtered 
Mayer’s Hematoxylin (BDH, UK) for 5 minutes, washed in water and placed in 1% 
Acid Alcohol for a few seconds. The slides were then washed again in water and placed 
in Eosin (BDH, UK) for 1 minute. Finally the slides were washed again, dehydrated in 
ascending grades of ethanol (50%, 70% and 100% for 5 minutes each), cleared in xylene 
(2 changes, 5 minutes each) and  mounted in organic solvent soluble mounting medium 
(DEPEX).  
3.4.3: Safranin O/Light green staining 
To stain the highly sulfated, negatively charged glycosaminoglycans in the cartilaginous 
tissue, Safranin O/Fast green staining was performed on mouse knee joints and human 
cartilage explants. Slides were deparaffinized and rehydrated as previously described. 
Sections were then stained in Safranin O (Raymond A. lamb Ltd, UK) for 15 minutes, 
washed in water, incubated with 0.5% Light green (Raymond A. lamb Ltd, UK ) and 
evaluated every 30 sec for the intensity of counterstain. Slides were washed again in 
water, hydrated, cleared and mounted in DEPEX.  
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3.4.4: X-GAL staining 
Whole mount X-GAL staining was performed on samples obtained from BAT-GAL and 
Axin2 KI mice. Tissues were fixed for 1 hours in fixing solution containing 2% 
Paraformaldehyde and 0.02% glutaraldehyde in PBS, washed twice with PBS and 
incubated overnight at 30
o
C in a freshly made staining solution (Appendix) containing 
the β-galactosidase substrate X-Gal (5-bromo-4-chloro-3-indolyl-beta-d-
galactopyranoside). Tissues were then washed with PBS, decalcified, embedded in OCT 
and sectioned as previously described.   
3.5: Histomorphometry 
Histomorphometric analysis was done on sections obtained from animals killed one day 
following the injury.  Non-consecutive sections from levels indicated in figure 5.1A 
were used to evaluate variability within the same animal and between different 
experimental animals. In this analysis, articular cartilage thickness, cross sectional 
depth, cross sectional width and cross sectional area of the injury were measured using 
cell-p software (Olympus, UK). The ratio between the depth of the injury and the 
cartilage thickness was calculated and represented as percentage value. The coefficient 
of variation was calculated by dividing the standard deviation by the mean. All the data 
are expressed as the mean ± standard error of the mean (SEM). 
3.6: Histological scoring 
The structural outcome of the joint surface injury in mice was assessed using well 
validated histological scoring systems. Cartilage repair was scored as previously 
described by Wakitani et al (188). This grading scale is composed of 5 categories with 
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total score ranging from 0 to 14. The cell morphology was graded from 0 (for repair 
tissue that looks normal compared to native adjacent uninjured cartilage) to 4 points 
when cartilaginous tissue was absent. The degree of metachromatic matrix staining was 
graded from 0 when the intensity of the staining was comparable to normal adjacent 
cartilage to 3 when metachromasia was completely absent. The surface regularity was 
scored 0 when more than three-quarter of the surface was smooth to 0 when less than 
one-quarter was smooth. The average thickness of the cartilage in the defect compared 
to that of the surrounding normal cartilage was graded 0 when repair cartilage was more 
than two-third of the surrounding cartilage to 2 when it is less than one-third. The 
integration of the repair tissue with the adjacent cartilage was scored 0 when no gap was 
seen between them to 2 when there was a complete lack of integration (Table 3.1). 
The severity of OA in mouse articular cartilage and in human cartilage explants was 
evaluated using Modified Mankin score (238;239). This score is assessing structure 
giving 0 to normally looking cartilage to 6 when there is completely disorganized 
structure. Cellular appearance was scored 0 when it is normal to 3 when hypo-cellularity 
was seen.   The intensity of matrix staining was scored 0 when normal to 4 when it was 
completely absent. Therefore, 0 points indicate normal cartilage, whereas 13 points 
represents sever cartilage lesions (Table 3.2). 
Cartilage damage induced by destabilization of medial meniscus was scored using 
modified Mankin score and Chambers score (240) in which 0= Normal cartilage 0.5= 
loss of metachromatic staining without structural changes. 1= roughened articular 
surface and small fibrillations. 2= fibrillations down to the layer immediately below the 
superficial layer and some loss of surface lamina. 3= Loss of surface lamina and 
fibrillations extending down to the calcified cartilage. 4= Major fibrillations and 
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cartilage erosion down to the subchondral bone. 5= Major fibrillations and erosion of up 
to 80% of the Cartilage. 6= Severe loss involving more than 80% of cartilage. The 
medial tibial plateau, medial femoral condyle, lateral tibial plateau and lateral femoral 
condyle were scored separately. Scores of the four quadrants were then added to obtain 
the summed score. 
Scoring was performed independently by two observers blinded to the group assignment 
(myself and Dr Dell’Accio).  All the data are expressed as the mean ± standard error of 
the mean (SEM). 
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Table 3.1: Histological repair grading scale  
Category points 
Cell Morphology  
         Hyaline cartilage 0 
         Mostly Hyaline cartilage 1 
         Mostly fibrocartilage 2 
         Mostly non-cartilage 3 
         Non-cartilage only 4 
Matrix staining (Metachromasia)  
         Normal (compared with host adjacent cartilage) 0 
         Slightly reduced  1 
         Markedly reduced  2 
         No metachromatic stain 3 
Surface  regularity   
          Smooth (>3/4) 0 
         Moderate (>1/2-3/4) 1 
          Irregular (1/4- 1/2) 2 
          Severely irregular (<1/4)  3 
Thickness of cartilage   
          >2/3 0 
          1/3 – 2/3 1 
          <1/3 2 
Integration with host adjacent cartilage  
           Both edges integrated  0 
           One edge integrated  1 
            Neither edge integrated  2 
Total Maximum score 14 
                                                                                        Wakitani  et al., JBJS, 1994 
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 Table 3.2: Modified Mankin Score 
Category points 
Structure  
    Normal 0 
    Slight disorganization ( Cellular  row absent, some       
superficial clusters 
1 
     Irregular surface, including fissures into the radial layer 2 
     Pannus  3 
      Superficial cartilage layers absent  4 
      Fissures into the calcified cartilage layer   5 
      Sever disorganization (Chaotic structure) 6 
Cellular abnormalities   
       Normal 0 
       Hypercellularity 1 
       Clusters  2 
       Hypocellularity 3 
Matrix staining (Metachromasia)  
       Normal 0 
       Staining reduced in radial layer 1 
       Staining reduced in inter-territorial matrix 2 
       Only present in pericellular matrix 3 
       Absent 4 
Total Maximum score  13 
                                                        Mankin et al., 1971 & van der Sluijs et al., 1992 
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Table 3.3: Chambers Score  
Category points 
    No damage 0 
    Loss of metachromatic staining without structural changes 0.5 
    Roughened articular surface and small fibrillations 1 
    Fibrillations down to the layer immediately below superficial 
layer  
2 
    Loss of surface lamina and fibrillations extending 
down to the calcified cartilage  
3 
  Major fibrillations and cartilage erosion down to  the 
subchondral bone 
4 
  Major fibrillations and erosion of up to 80% of the 
cartilage 
5 
  More than 80% loss of cartilage 6 
                                                                                                              Chambers et al., 2001 
3.7: immunohistochemistry 
Paraffin sections were de-paraffinized and re-hydrated by incubating the slides in xylene 
(2 changes, 5 minutes each), followed by passages in 100% absolute ethanol (2 changes, 
5 minutes each), 70% ethanol (2 changes, 5 minutes each) and 50% ethanol (2 changes, 
5 minutes each). Slides were then post-fixed with 4% buffered PFA and washed in 
phosphate buffered saline (PBS). For Antigen retrieval, sections were either boiled in 
sodium citrate buffer (PH 6) for 10 minutes and then allowed to cool down for 30 
minutes at room temperature or treated by proteolytic enzymes. For proteolytic induced 
Antigen Retrieval, several enzymes were used depending on the antigen to be 
demonstrated. In pepsin digestion, sections were equilibrated in 0.02% HCL for 15 
minutes at 37 °C and then digested in 0.25 mg/ml of Pepsin (sigma UK) in 0.02% HCL 
for 45 minutes at 37
o
C. In Chondroitinase ABC digestion, sections were equilibrated in 
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0.1M Tris HCL, pH 8.0 for 15 minutes and then digested in Chondroitinase ABC 
(Sigma, UK) in 0.1M Tris HCL, pH 8.0 for one hour at 37ºC. In Proteinase K treatment, 
the solution containing the enzyme was pre-warmed at 37°C for 15 min before use and 
placed on the slides for 5 minutes at 37°C.  
After the antigen retrieval step, slides were post-fixed in 4% buffered PFA for 10 
minutes at room temperature and washed twice in 0.2% Tween-20 in phosphate buffered 
saline (PBST). The endogenous peroxidase activity was quenched by incubating the 
sections with 3% H2O2 for 15 minutes to avoid non specific staining if DAB substrate 
was used for detection. The sections were blocked in 0.5% bovine serum albumin in 
PBST for one hour at room temperature, blotted and incubated overnight in a humid 
chamber at 4 °C with a primary antibody (Table 3.4) diluted in an antibody diluent 
(DakoCytomation, UK). Sections were then washed twice in PBST, incubated for one 
hour with the appropriate secondary antibody (Table 3.4) and washed twice in PBST.  
Pilot titration experiments were run to determine the optimal working dilutions for the 
primary and secondary antibodies. These dilutions were then used in subsequent 
experiments. Negative controls were treated with isotype and species matched 
immunoglobulins or normal serum instead of the primary antibody. The specificity of 
the Wnt16 antibody was further confirmed by pre-absorbing the primary antibody with a 
blocking peptide (697 cell lysate form human pre-B lineage leukemia cell line). The 
antibody was incubated with the blocking peptide at a ratio of 1: 2 for 2 hours at 37°C, 
centrifuged for 15 minutes at full speed and then applied to tissue sections.  
If Avidin-Biotin complex (ABC) was to be used as an amplification system, sections 
were incubated for 30 minutes with StreptABComplex/HRP (DakoCytomation, UK) and 
then washed in PBST. Liquid DAB substrate Chromogen system was used as peroxidase 
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substrate. Slides were washed in PBS and either mounted directly in Mowiol containing 
4, 6-diamindino-2-phenylidole (DAPI) for nuclear staining or counterstained with 
Hematoxylin, and mounted with DPX (BDH, UK). Images were captured using a Nikon 
digital camera linked to an Olympus BX61 microscope. Images were analyzed with 
Cell-P software (Olympus UK Ltd, UK). Adobe Photoshop software was used to 
optimize the images for best rendering. 
A complete list of primary and secondary antibodies for detection of various targets used 
in this study as well as the antigen retrieval methods and colorimetric systems used in 
each immunostaining is reported in Table 3.4.  
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Table 3.4: A summary of the immunostainings performed in this thesis  
Staining Antigen 
Retrieval 
Primary antibody Secondary antibody Colori-
metric 
System 
PHH3 Pepsin 
Digestion 
Rabbit anti human/mouse 
PHH3 (Cell Signaling) 
1:50 
Cy
TM
3 conjugated goat 
anti rabbit antibody 
(Jackson 
immunoResearch 
Laboratories, USA) 1:600 
Florescent 
CPII Pepsin 
Digestion 
Rabbit anti human/mouse 
CP II antibodies (kindly 
provided by Dr Lindsay 
King from IBEX, Canada) 
1:800 
Cy
TM
3 conjugated goat 
anti rabbit antibody 
(Jackson 
immunoResearch 
Laboratories, USA) 1:600 
Florescent 
Col2-
3/4Cshort 
Pepsin 
Digestion 
Rabbit anti human/mouse 
C1,2C (Col2-3/4Cshort)            
(IBEX, Canada) 1:800 
EnVision®+Dual Link 
system-HRP 
(DakoCytomation, UK) 
DAB 
Substrate 
Chromogen 
System 
(DakoCyto
mation, UK) 
 
TEGE
373
 Chondroitinase 
ABC 
Digestion 
anti-TEGE
373
 (kindly 
provided by Professor 
Bruce Caterson and Dr 
Debbie Tudor, Cardiff 
University). 1:10 
EnVision®+Dual Link 
system-HRP 
(DakoCytomation, UK) 
DAB 
Substrate 
Chromogen 
System 
(DakoCyto
mation, UK) 
VDIPEN Chondroitinase 
ABC 
Digestion 
anti-VDIPEN (kindly 
provided by Professor 
Bruce Caterson and Dr 
Debbie Tudor, Cardiff 
University). 1:10 
EnVision®+Dual Link 
system-HRP 
(DakoCytomation, UK) 
DAB 
Substrate 
Chromogen 
System 
(DakoCyto
mation, UK) 
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BMP2 Pepsin 
Digestion 
Rabbit anti human/mouse 
BMP2 (abcam,UK) 1:20 
Biotinlyated sheep anti 
rabbit (Serotec,UK) 1:100 
StreptABCc
omplex/HR
P and DAB 
Substrate 
Chromogen 
System 
(DakoCyto
mation, UK) 
 
 
PSMAD 1, 5, 
8 
Boiling in 
Citrate Buffer 
Rabbit anti human/mouse 
PSMAD 1,5, 8 (Cell 
signaling, USA) 1:100 
Biotinlyated sheep anti 
rabbit (Serotec,UK) 1:100 
StreptABCc
omplex/HR
P and DAB 
Substrate 
Chromogen 
System 
(DakoCyto
mation, UK) 
FRZB Pepsin 
Digestion 
Goat anti human/mouse 
FRZB (R&D, UK) 1:100 
Biotinlyated rabbit anti 
goat (DAKO, UK) 1:300 
StreptABCc
omplex/HR
P and DAB 
Substrate 
Chromogen 
System 
(DakoCyto
mation, UK) 
Wnt16 Pepsin 
Digestion 
Mouse anti human 
WNt16 (BD PharMingen, 
UK) 1:200 
Biotinlyated rabbit anti 
mouse (DAKO, UK) 
1:200 
StreptABCc
omplex/HR
P and DAB 
Substrate 
Chromogen 
System 
(DakoCyto
mation, UK) 
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β- Catenin Pepsin 
Digestion 
Rabbit anti human/mouse          
β-catenin (Cell signaling, 
USA) 1:50 
Biotinlyated sheep anti 
rabbit (Serotec,UK) 1:100 
StreptABCc
omplex/HR
P and DAB 
Substrate 
Chromogen 
System 
(DakoCyto
mation, UK) 
OPG Pepsin 
Digestion 
Goat anti human/mouse 
OPG (Santa cruze, UK) 
1:100 
Biotinlyated rabbit anti 
goat (DAKO, UK) 1:200 
StreptABCc
omplex/HR
P and DAB 
Substrate 
Chromogen 
System 
(DakoCyto
mation, UK) 
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3.8. Apoptosis Detection (TUNEL analysis) 
Detection of apoptotic cells was performed by coupling the TUNEL assay and the 
cytological appearance of the cells. DNA fragments that are generated by the cleavage 
of DNA during apoptosis were detected by the terminal deoxnucleotidyl transferase-
mediated dUTP nick-end labeling (TUNEL) using the TACS in situ apoptosis detection 
kit. In this system, Biotinlyated nucleotides are incorporated into the 3΄-OH ends of the 
DNA fragments by terminal deoxnucleotidyl transferase (TdT). The Biotinlyated 
nucleotides are then detected using a streptavidin-fluorescein conjugate and positive 
cells are subsequently visualized using a fluorescence microscope.  The TUNEL assay 
was performed according to the manufactures protocol (R&D systems, UK). Briefly, 
paraffin sections were de-paraffinized and re-hydrated as described above, washed twice 
in DNase-free water and then incubated in 1% phosphate- buffered saline (PBS) for 10 
minutes. Enzymatic proteolysis was performed by Proteinase K digestion for 10 minutes 
at 37ºC. Next, sections were washed in DNase-free water and incubated for one minute 
in TdT Labeling buffer. DNA fragments in apoptotic cells were labeled by incubating 
the sections in humidity chamber for one hour at 37ºC with labeling reaction mix. The 
enzymatic reaction was then stopped by placing the slides in TdT Stop buffer for 5 
minutes at room temperature. Sections were incubated with Streptavidin-FITC Detection 
Solution in the dark for 20 minutes, washed in PBS and mounted in Mowiol 
(Calbiochem) containing 4, 6-diamindino-2-phenylindole (DAPI) for nuclear staining. 
The fluorescin-stained cells were subsequently visualized using a florescence 
microscope equipped with a digital camera. For positive control, sections were digested 
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with TACS-DNase prior to TUNEL assay. For negative control, TUNEL assay was 
carried using labeling Reaction Mix without TdT Enzyme.   
3.9. Gene expression analysis 
3.9.1. Total RNA extraction 
Adult human cartilage explants and mouse femoral heads were snap-frozen in liquid 
nitrogen immediately after termination of the culture, powdered with a mortar and pestle  
pre-chilled in liquid nitrogen and subsequently homogenized in TRIZOL reagent (a 
mono-phasic solution of phenol and guanidine isothiocyanate) (Invitrogen, UK) using a 
homogenizer. Articular cartilage from mouse knee joints was directly homogenized in     
1ml TRIZOL reagent using a syringe and a 26G needle for 5 minutes. The suspension 
was then incubated on ice for 20 minutes and spun at 10.000g for 10 minutes at 4 ºC to 
remove insoluble debris. Chloroform (200μl/1ml TRIZOL) was added and the tubes 
were shaken for 30 seconds, incubated on ice for 2 minutes and centrifuged at 10.000g 
for 15 minutes at 4 ºC. Following centrifugation, the mixture separates into a lower red 
phenol-chloroform phase containing proteins, an inter-phase containing DNA, and a 
colorless upper aqueous phase containing RNA. The aqueous phase was removed to 
another sterile, RNAse free tube and 5μg RNase-free glycogen was added and tubes 
were incubated on ice for 5 minutes.  RNA was then precipitated from the aqueous 
phase by mixing with an equal amount of ice-cold isopropyl alcohol, incubating on ice 
for 20 minutes and centrifuging at top speed for 60 minutes at 4 ºC. The RNA precipitate 
forms a gel-like pellet on the side and bottom of the tube. The supernatant is then 
removed and the RNA pellets were washed once with 1 ml of 70% ethanol, centrifuged 
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for 5 minutes at 4°C. As much ethanol as possible was removed carefully using a pipette 
without disturbing the pellet. The pellet was then dried for 15 minutes at room 
temperature and re-suspended in RNase-free water.  
For the human cartilage explants, The aqueous phase was removed to clean tube and 
equal volume of phenol solution saturated with 0.1M citrate buffer (pH 4.3) 
(Sigma-Aldrich, UK) was added to each tube, mixed thoroughly, incubated on ice for 30 
minutes. Chloroform-isoamyl alcohol 24:1 (2ml) was added to each tube, mixed 
thoroughly, incubated on ice for 2 minutes and centrifuged at 10.000g for 15 minutes. 
The aqueous phase was then removed to a clean tube and extraction with phenol and 
separation with Chloroform-isoamyl alcohol were repeated as prescribed above for 3 
times. The aqueous phase obtained after the third separation was collected and RNA was 
precipitated with isopropyl alcohol (1 hour at 14.000 at 4°C), washed in 70% ethanol in 
water, dried and suspended in water according to the standard protocol. RNA yield was 
assessed by spectrophotometry using a NanoDrop spectrophotometer (Labtech, UK).  
3.9.2. Reverse transcription PCR 
RNA was reverse transcribed to cDNA using the Thermoscript RT-PCR System for 
First-Strand cDNA Synthesis (Invitrogen, UK).  Briefly, 1µg of purified total RNA from 
each sample was mixed with 1 µl of Oligo(dT)20 Primers (50 µM) and 2 µl of 10 mM 
dNTP mix and brought to a 12 µl volume reaction with DEPC-treated water in a 0.5ml 
PCR tube. After brief spinning down in a microcentrifuge, samples were incubated for 5 
min at 65°C and samples were immediately cooled on ice. For the final reaction, 8 µl of 
a master mix containing 1 µl of ThermoScript™ RT (15 U/µl), 1 µl of 0.1 M DTT, 1 µl 
of RNaseOUT™ Ribonuclease Inhibitor (40 units/µl), 1 µl of DEPC-treated water and 4 
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µl of 5X cDNA synthesis buffer were added. After mixing and a brief spin down of the 
tubes, the reverse transcription to cDNA was run in a PCR machine (Applied 
Biosystems 9700) for 1h at 50°C and the reverse transcriptase was inactivated at 85°C 
for 5 min. In order to remove the original RNA that could interfere with the quantitative 
real-time PCR analysis, RNA digestion was performed using 1µl of E. coli RNase H (2 
units/µl) at 37°C for 20 min. Finally, the completed cDNA strand was stored at -20°C 
until used.  
3.9.3. Quantitative real time PCR 
For quantitative Taqman real-time evaluation of gene expression levels, sequence-
specific primers and probes from Applied Biosystems were used (Table 3.6). When 
using the double-stranded DNA binding dye SYBR green, QuantiTect primer assays 
(Qiagen, UK) or primers designed using Vector NTI (Invitrogen, UK) were ordered 
(Table 3.5& 3.6). Primers were designed in parts of the sequence that were unique to the 
target gene as assessed by running BLAST searches. We aimed at generating amplicons 
between 100 and 300 base pairs, as close as possible to the poly-A sequence with 
primers with a GC content between 45 and 65%, a target Tm of 60
o
C and no more than 
1
o
C of difference between them. 
The real-time PCR were run in triplicate on 384-well PCR plates (Applied Biosystems 
using the 7900HT Taqman Instrument (Applied Biosystems). The thermal cycling 
conditions used comprised a 2 minutes equilibration step at 50ºC, a 95ºC Taq 
polymerase enzyme activation step for 10 min, and 40 cycles including a denaturation 
step at 95 ºC for 15 sec and one step of annealing and extension at 60ºC for 60 sec. 
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Results were then analyzed using the 7900HT Sequence Detection System Version 2.1 
(SDS 2.1). 
Relative quantification was measured using the Comparative Ct (Threshold Cycle) 
method and normalized for the expression of housekeeping gene beta-actin. The ΔCt (Ct 
of the target gene minus CT of the endogenous control) for each of the triplicate and 
then the average ΔCt of the triplicates were calculated. To calculate the ΔΔCt, the ΔCt of 
each sample was subtracted to the chosen reference sample (normal control or untreated 
sample). The relative quantity was then calculated following the equation RQ= 2
-ΔΔCT
. In 
order to assess the efficiency of the real-time PCR for each gene, a standard curve was 
prepared by serial 2^5 dilutions (i.e. 1:1, 1:32 and 1:1024) of the cDNA from a positive 
control sample. Dissociation curve was checked when SYBR green is used to confirm 
specificity.  
 
Table 3.5: List of primers used in human articular cartilage 
Gene mRNA 
Accession 
number  
Primer Amplicon 
size 
source 
hBMP2 NM_001200 F5’CGTCAAGCCAAACACAAACAGCG-3’ 
R 5’CACCCACAACCCTCCACAACCAT-3’ 
341 bp Invitrogen 
hFRZB U24163 F 5’GGGCTATGAAGATGAGGAACGT-3’ 
R 5’-ACCGAGTCGATCCTTCCACTT-3’ 
79 bp Invitrogen 
hWNT16 NM_016087 F 5’- AAAGAAATGTTTCCCTGCCC -3’ 
R 5’-GACATTTTCCATGGGTTTGC -3 
106 bp Invitrogen 
hAxin2 NM_004655 F 5’-TACCGGAGGATGCTGAAGGC-3’ 
R 5’-CCACTGGCCGATTCTTCTT-3’ 
345bp Invitrogen 
hβ-actin BC014861 F 5’-CACGGCTGCTTCCAGCTC-3’ 
R 5’-CACAGGACTCCATGCCCAG-3’ 
134 bp Invitrogen 
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Table 3.6: List of primers used in mouse samples 
Gene mRNA 
Accession 
number 
Assay ID Amplicon size Source 
mAxin 2 NM_015732  Mm01265782_g1 84bp Applied 
Biosystems  
mWNT16 NM_053116                Mm01168147_g1 107bp Applied 
Biosystems 
m β-actin NM_007393 Mm02619580_g1 143bp Applied 
Biosystems 
mWNT4 NM_009523 QT00104622 134bp Qiagen 
mWNT9a NM_139298 QT01062250 139bp Qiagen 
mOPG NM_008764 QT00106757 111bp Qiagen 
mCol2a1 NM_031163 QT01055523 60bp Qiagen 
mCol10a1 NM_009925 QT00144809 148bp Qiagen 
mAggrecan NM_007424 QT00175364 143bp Qiagen 
m β-actin NM_007393 QT01136772 77bp Qiagen 
 
3.10. Tissue culture 
Mouse articular cartilage was dissected from the femoral heads of 8-weeks BAT-GAL 
old male mice by separating the articular cartilage surface from subchondral bone using 
a scalpel. Samples were obtained in sterile condition and washed twice in Dulbecco's 
modified Eagle medium (D-MEM/F-12 1:1, high glucose; Invitrogen) containing 10% 
fetal bovine serum (FBS; Invitrogen), 1mM Sodium Pyruvate (Sigma-Aldrich) and 2× 
antibiotic-antimycotic solution (Gibco, Invitrogen). Articular cartilage samples were 
then incubated in sterile Dulbecco's modified Eagle medium (D-MEM/F-12 Invitrogen) 
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containing 10% fetal bovine serum (FBS; Invitrogen), 1mM Sodium Pyruvate (Sigma-
Aldrich) and 1× antibiotic-antimycotic solution (Gibco, Invitrogen). After 6 days, the 
samples were treated with 100ng/ml of mouse recombinant Wnt3A (R&D, UK) or 
0.1%BSA-PBS for one or two days.  
3.11. Maintaining and Breeding Wnt16 KO colony 
Wnt16 null mice were kindly provided by Prof. Andrew McMahon, Harvard University, 
USA. In these mice, exon 2 of the Wnt16 gene was excised using cre/loxP technology. 
They are fertile and apparently phenotypically normal.  
3.11.1. Genotyping 
Mouse genomic DNA was extracted using Extract-N-Amp
™
 Tissue PCR Kit (Sigma, 
UK) according to the manufacturer instructions. Briefly, tissue samples (obtained from 
ear marking) were incubated in Tissue Preparation Solution and Extraction Solution for 
10 minutes at room temperature. The samples was heated to 95 °C for 3 minutes and 
then mixed with neutralizing solution prior to PCR. An aliquot of the DNA extract is 
then added directly to the PCR mix supplied within the kit in the presence of Forward 
primer: 5’-gcggaacccagggcaactggat-3’ and Reverse primer 5’-gtatgtcctaccatccccgag-3’. 
The amplification reaction was performed using an Applied Biosystems GeneAmp PCR 
System 9700 thermocycler under the following conditions: 
10 min at 95°C followed by 40 cycles of a three step PCR 
- 30 sec at 95°C 
- 30 sec at 55°C 
- 30 sec at 72°C 
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Following amplification, DNA product was separated by 1% agarose gel electrophoresis 
and visualized with ethidium bromide.  To prepare agarose gels, agarose powder was 
suspended  in 1x Tris Acetic Acid EDTA (TAE) buffer (see Appendix), boiled in a 
microwave for 2 minutes, then 5μl of ethidium bromide was added and the solution was 
poured into a gel tray where a comb was inserted. After polymerization, the comb was 
removed and the gel was placed in the electrophoresis tank and covered with 1x TAE 
running buffer. Samples were loaded into the gel wells. DNA ladder (1Kb Ladder, 
Fermentas,UK) was used as a reference for molecular weight. Electrophoresis was 
carried out at 100V (voltage) for 45 minutes. DNA was visualized using a UV light 
trans-illuminator and examined for the size of bands. Wild-type mice will have 500bp 
band, Knock-out mice will have 250bp band and heterozygous mice will have both (Fig. 
3.3). 
 
 
Figure 3.3: Wnt16 mice genotyping: Representative Agarose gel showing different genotypes 
for WNT16 gene in 7 mice. Mice number 1 & 6 are knock-outs, Mice 2, 3 & 7 are wild-types 
and Mice number 4 & 5 are heterozygous.   
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3.11.2. Backcrossing into DBA/1 strain  
We originally obtained 2 female wnt16 deficient mutants on a mixed C57/BL6 / 
129EvSv background. To transfer the Wnt16 null trait into the DBA/1 background, the 
mutant mice were backcrossed into the DBA/1 strain. To this end, the female Wnt16
-/-
 
mutants were mated with wild-type male DBA/1 mice. From each generation 2 
heterozygous females were selected for mating with the wild-type male DBA/1 mouse 
and the rest of the mice were discarded. With each successive backcross, there is an 
increase in the percentage of DBA/1 DNA that constitutes to the genome of the 
offspring as shown in Table 3.7. We aimed at backcrossing 10 times when 99.9% of the 
DNA will be of DBA/1 origin for the final experiments. 
 Table 3.7: The residual percentage of 129 DNA remaining after each backcrossing  
   Generation 129% DBA/1% 
F1 50.00 50.00 
N2 25.00 75.00 
N3 12.50 87.50 
N4 6.25 93.750 
N5 3.13 96.875 
N6 1.58 98.438 
N7 0.78 99..219 
N8 0.39 99..609 
N9 0.20 99..805 
N10 0.098 99..902 
N11 0.049 99..951 
N12 0.024 99..976 
N13 0.012 99..988 
N14 0.0061 99.994 
N15 0.0031 99..997 
N16 0.0015 99.998 
N17 0.00078 99..999 
N18 0.00038 99..99962 
N19 0.00019 99..99981 
N20 0.00010 99..99990 
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3.13. Statistical analysis 
The mean histological scores were compared using the Mann-Whitney U test for 
unpaired non-parametric data. Student’s unpaired t-test was used for the other 
comparisons between the two strains. Differences were considered statistically 
significant when P was < 0.05.  
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CHAPTER 4: RESULTS 
Molecular response of articular cartilage to injury 
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4.1. Genes modulated by mechanical cartilage injury  
To explore the early molecular response of adult human articular cartilage to acute 
mechanical injury at the whole genome level, Dr Dell'Accio, in our Laboratory, 
performed a microarray analysis on freshly isolated, uninjured and injured cartilage 
explants in a well validated in vitro model of cartilage injury (Described in Materials 
and Methods chapter and summarized in Figure 3.2) (241). Using a functional gene 
clustering algorithm on the differentially modulated genes, we revealed statistically 
significant clustering of genes encoding signalling molecules, or known to play a role in 
wound healing, or involved in cell communication, morphogenesis and development 
including skeletal development (Figure 4.1) (241). This finding suggests that the adult 
articular cartilage, following injury, deploys a molecular response that involves the 
release of signalling molecules and morphogens which might have the potential to 
activate the repair process. Therapeutic targeting of these pathways may improve current 
protocols of joint surface repair and/or prevent the evolution of post-traumatic OA. 
Therefore, we further focused on molecular pathways known to play a crucial role in 
embryonic skeletogenesis, joint morphogenesis and post-natal homeostasis as well as 
repair process. 
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Figure 4.1: Representative clusters of genes differentially expressed following injury to human 
articular cartilage. Figure from Dell’accio et al., 2008 (241) 
 
4.2. BMP pathway is activated upon cartilage injury in vitro 
BMPs are secreted molecules that belong to TGF-β superfamily of morphogens. Upon 
binding to their ligands, BMP receptors phosphorylate the carboxy-terminal domain of 
SMAD-1,-5 and -8. Phosphorylated SMADs then translocate into the nucleus where they 
participate in the transcriptional regulation of target genes (99). BMPs have been 
implicated in the regulation of stem cell functions and the induction of cartilage and 
bone formation and therefore have the potential for stimulating cartilage repair (98).   
Statistically significant up regulation of BMP-2 mRNA was detected one day following 
cartilage injury in vitro (Figure 4.2A&C). Several factors can determine the activation of 
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BMP signalling independently of the expression of one ligand. These include the 
secretion and the solubility of the ligand, its binding to matrix molecules, the presence of 
secreted or intracellular inhibitors and receptor regulation.  To test whether the observed 
BMP-2 up-regulation in the explants was associated with downstream activation of the 
signalling pathway, immunohistochemistry was performed using an antibody that 
recognizes the phosphorylated form of SMAD-1/-5/-8 (Figure 4.2B). In the freshly 
dissected explants, 41% of the cells stained positive for Phospho-SMAD-1/5/8 and 
nearly all positive cells localized in the intermediate layer. In the cultured explants, we 
detected phospho-SMAD-1/-5-/-8 positive chondrocytes in all cartilage layers in the 
uninjured as well as the injured explants (83% in the uninjured versus 100% in the 
injured explants) (Figure 4.2B&C). These results demonstrated that BMP-2 
up-regulation following cartilage injury in this explant model is associated with 
activation of the BMP intracellular signal transduction pathway and that cartilage itself 
is a target of BMP signaling. The number of Phospho-SMAD positive cells in the rested 
explants was intermediate between freshly dissected explants and the re-injured explants 
suggesting that the resting period (6 days) might not be sufficient to completely reverse 
the molecular response to wounding during the initial dissection of the explants. 
Consistent with this hypothesis, BMP-2 mRNA levels were lowest in the freshly 
dissected cartilage, intermediate in the uninjured cultured explants and highest in the 
injured explants (Figure 4.2C).   
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Figure 4.2: Activation of bone morphogenetic protein (BMP) pathway in vitro after cartilage 
injury: Real-Time RT-PCR comparing the expression levels of BMP-2 mRNA in injured and 
uninjured cartilage explants (A). Relative gene expression was normalized for the housekeeping 
gene β-actin. B, Immunostaining for phosphorylated SMAD-1/-5/-8 in freshly dissected normal 
cartilage (positive cells were mainly seen in the intermediate layer indicated by the bracket), 
injured and uninjured explants. The top insets are large magnifications of the corresponding 
squared areas. C, Graphic summary of the proportion of Phospho SMAD-1/-5/-8 positive cells 
(closed bars) and the expression of BMP-2 (open bars). Values are expressed as percent of 
positive cells for PSMAD and BMP-2 mRNA. 
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4.3 Activation of the WNT pathway in adult human articular cartilage 
following mechanical injury 
Wnts constitute a large family of morphogens (19 Wnt ligands) that transduce their 
signalling through different intracellular pathways.  The key event in the activation of 
the canonical Wnt pathway is the accumulation and the translocation of β-catenin into 
the nucleus, where it binds to TCF/LEF family of transcription factors, thereby 
activating transcription of target genes. In the absence of Wnt ligands, β-catenin is 
instead phosphorylated by a destruction complex and targeted for ubiquitination and 
subsequent proteolytic destruction through the proteosomal pathway (63).  
The microarray differential gene expression screening revealed a striking up-regulation 
of only one of the 19 known Wnt ligands 24 hours after mechanical injury to human 
adult articular cartilage: Wnt16. All other Wnts were either not expressed or not 
regulated. Wnt16, which is known to signal through the beta catenin dependent pathway 
in a rat chondrocyte cell line RCS (47), was expressed at the lower limit of detection by 
microarray hybridization in control and freshly dissected cartilage explants but was up-
regulated >20 times upon injury. The extracellular Wnt inhibitor FRZB was 
downregulated following injury and known transcriptional target genes of the β-catenin 
dependent Wnt signalling pathway such as osteoprotegerin (OPG), c-Myc, cyclin D and 
axin2 were up-regulated indicating activation of canonical Wnt pathway (Figure 4.3).  
The differential regulation of FRZB, Wnt16, and Axin2 mRNA following mechanical 
injury was further confirmed in 8 pairs of samples by quantitative real time RT-PCR 
(241). 
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Figure 4.3:  Gene modulation within the canonical Wnt pathway in adult human articular 
cartilage following injury. White boxes indicate genes detectable in <20% of all samples. Gray 
boxes indicate genes detectable in ≥20% of all samples but with no significant differences 
between injured and control samples. Red and yellow boxes indicate genes that were 
significantly (p≤0.05) up-regulated in the injured explants ≥ 2-fold or 1-2 folds respectively. 
Dark blue and light blue boxes indicate genes that were significantly (p≤0.05) down-regulated in 
the injured explants ≥ 2-fold or 1-2 folds respectively. The average fold change is shown on the 
right of the boxes. Figure from Dell’accio et al., 2008 (241) 
 
 
The modulation of these molecules at the protein level was then investigated by 
immunohistochemical analysis in 3 independent pairs of explants. FRZB was present in 
both injured and uninjured explants but the proportion of FRZB positive cells was 
significantly lower in the injured explants compared to uninjured samples (Figure 4.4). 
Wnt16 protein was undetectable in freshly dissected as well as uninjured explants but 
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stained intensely in the injured ones. It was also undetectable in preserved areas of the 
joints with OA but highly detectable in areas with moderate to severe OA, with a 
territorial expression pattern suggesting that Wnt16 up-regulation takes place in vivo in 
cartilage pathology (Figure 4.5A).  
 
 
Figure 4.4: immunohistochemical staining for FRZB (red) in uninjured and injured explants 24h 
after injury. Larger magnification of the boxed area and the percentage of the FRZB positive 
cells are shown on the right  
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Wnt16 has been previously shown to signal through the canonical Wnt pathway which is 
dependent on the accumulation and the nuclear localization of β-catenin (47). To further 
investigate whether mechanical injury to adult human articular cartilage results in 
activation of Wnt signalling through the canonical pathway, I performed 
immunostaining for β-catenin. In the preserved (freshly isolated) and uninjured control 
samples, cells were either not stained or weakly stained with predominantly cytoplasmic 
pattern. This pattern is compatible with the known role of β-catenin in cell adhesion, in 
conjunction with E-cadherin (242). In the injured explants and OA samples, cells were 
positively stained with strong cytoplasmic and nuclear pattern suggesting accumulation, 
nuclear translocation and activation of β-catenin dependent Wnt signalling (Figure 
4.5B). To further confirm the nuclear localization of β-catenin, I performed 
immunoflurescence staining for β-catenin and used conofocal microscopy for 
localization at the sub-cellular level. The cytoplasmic and nuclear pattern of β-catenin 
staining was confirmed in injured and OA samples (Figure 4.5C). To obtain quantitative 
comparison, β-catenin positive cells were counted regardless of the intensity of the 
staining. In the control samples, 46% of cells were stained weakly positive. In the 
injured samples, 86% of cells stained strongly positive and in the preserved cartilage 
areas of OA joints, β-catenin was weakly detectable in 23% of the cells and undetectable 
in most cells. In severely damaged areas, 94% of the cells showed strong nuclear and 
cytoplasmic staining (Figure 4.5D).   
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Figure 4.5: WNT signaling in injury and osteoarthritis. A and B, Immunohistochemical analysis 
of Wnt-16 (A) and β-catenin (B) in uninjured and injured explants,  freshly dissected cartilage 
sample from a preserved joint area, and a cartilage sample from a damaged area of a knee with 
OA. The inset in A is the blocking peptide negative control for WNT16 obtained by 
pre-absorbing the primary antibody with Wnt16 before staining. Insets in B are higher 
magnification views. C, immunoflurescence staining for β-catenin in injured (left) and OA 
(right) samples imaged with conofocal microscopy demonstrating the nuclear localization of B 
catenin in OA cartilage. D, the percentage of β-catenin–positive cells in rested controls (rc), 
injured samples (i), freshly dissected samples from preserved joint areas (pr), and samples from 
areas with severe OA (oa). Positive cells were counted, regardless of the intensity of the staining, 
which was very faint in the control and preserved samples, and regardless of the 
nuclear/cytoplasmic pattern, which was strikingly nuclear in the injured and OA samples. Values 
are expressed as mean ± SD. 
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Discussion 
Joint surface defects are commonly regarded as irreversible lesions that never heal 
spontaneously. However, acute full thickness joint surface defects that do not exceed a 
critical size appear to have repair capacity in animals and humans (141;142;153;236). 
The repair of these defects involves a coordinated process of patterning and tissue 
maturation that recapitulates aspects of embryonic skeletal development (153;237), 
thereby requiring morphogenetic signaling. In this chapter, we have demonstrated that 
mechanical injury in vitro can elicit the activation of two of the most important signaling 
pathways involved in embryonic joint development and morphogenesis namely BMP 
and Wnt signaling. Such modulation of morphogenetic pathways following joint surface 
injury might thus play a role in the activation of the repair process and in the 
morphogenesis of the repair tissue. BMPs are known for their anabolic effect on 
cartilage and therefore, have been proposed as potential therapeutic candidates for joint 
surface regeneration. Indeed, BMP-2 has been tested in cartilage tissue engineering 
approaches and although it was capable of promoting repair in an animal model of full 
thickness cartilage defects (243), its use in knee joints resulted in osteophyte formation 
and synovial hyperplasia (125;215). Further studies are still necessary to optimize the 
required dose/delivery system and to ensure their safety for use in cartilage repair. 
Wnts have been involved in supporting the repair process in many systems (244-246) 
through the regulation of stem cell proliferation, migration and fate determination (247). 
It is thus possible that controlled activation of Wnt signaling would play a similar role in 
the repair of JSD. However, other previous studies have suggested that abnormal wnt 
signaling is also implicated in cartilage breakdown and the development of OA 
 108 
(reviewed in (248)). Therefore, functional studies are necessary to evaluate the role of 
these molecular activations in vivo in the context of cartilage repair/damage.  
The in vitro culture conditions used to maintain cartilage explants may influence their 
molecular response to injury, potentially introducing artifacts. In this system, the 
cartilage explants have already been injured upon dissection and therefore the sensitivity 
of the in vitro system to the re-injury response largely depends on the duration of the 
initial injury response and on its capacity to subside during the resting period. A period 
of 6 days was allowed to rest the tissue in culture before being re-injured however; the 
length of the resting period needed for optimal detection of regulation may be different 
for different molecules depending on the duration of their up-regulation following 
injury. For instance, in our experiment, the resting period did not appear to be sufficient 
to completely reverse the response due to the initial dissection of the explants as the 
expression level of BMP2 and the number of phospho-SMAD-1/-5/-8 positive cells was 
intermediate between the freshly dissected explants and the reinjured explants after the 
resting period.  Moreover, the duration of the resting period allowed for the response to 
dissection to subside before re-injury limited the genes that could be detected to those 
regulated transiently after injury. This could be one reason for the poor representation of 
some genes that were expected to be regulated by injury such as those associated with 
cell proliferation or matrix remodeling.  
The finding that Wnt16, which is known to play a redundant role in mouse embryonic 
joint morphogenesis with Wnt4 and Wnt9a (47), is the only Wnt ligand regulated in this 
experimental system raises the important biological issue of the specificity and/or 
redundancy of different Wnt ligands. However, it is possible that in vivo Wnt16 might 
not be the only Wnt ligand modulated by injury as other Wnts can either be produced 
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from other neighboring tissues within the joint (83;249) or their regulation in the 
articular cartilage upon injury is not transient and therefore could not be detected in the 
in vitro system. Wnt16 up-regulation was associated with down-regulation of the Wnt 
inhibitor FRZB, nuclear localization of β-catenin and up-regulation of several Wnt target 
genes. The functional importance of FRZB regulation in joint homeostasis is 
underscored by the observations that a single nucleotide polymorphism causing loss of 
function of the FRZB gene is associated with hip OA in humans (86)  and targeted 
deletion of FRZB gene in mice resulted in an OA like phenotype (88). 
Using microarray differential gene expression screening, we have characterized the early 
molecular events that occur within 24 hours after mechanical injury of adult human 
articular cartilage. However, it is still important to study the temporal sequence of these 
events, the hierarchy of different signaling molecules triggered by damage and their role 
in cartilage homeostasis and repair. The explant culture system relies on isolated 
articular cartilage and thereby focuses specifically on the cartilage-borne responses to 
mechanical injury and does not take into account other factors such as the presence of 
blood in the joint, biomechanical and inflammatory changes after injury or signaling 
from other joint tissues. The isolation of articular cartilage from its anatomical and 
functional environment and its exposure to artificial cultural conditions, limits the use of 
this in vitro model to that of a screening system, which however, requires validation in 
vivo.  Given these limitations, the activation of candidate pathways and the expression 
pattern of the differentially regulated molecules needed in vivo validation. The in vivo 
setting was also required to investigate the function of such molecular phenomena.  
In the next chapter, I will describe how I addressed these issues by generating and 
validating a novel joint surface injury and regeneration model in adult mice. The mouse 
 110 
species was chosen because it is widely validated as a pre-clinical model and especially 
because it is amenable to genetic manipulation and therefore allows functional molecular 
studies. 
Conclusions 
 Morphogenetic signaling pathways such as those involving BMPs and Wnts are 
modulated in adult articular cartilage in response to mechanical injury. 
  Articular cartilage itself is a target for such signaling. 
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CHAPTER 5: RESULTS 
Optimization and Validation of an in Vivo murine 
model of joint surface injury 
 112 
In order to confirm in vivo the molecular events described in the previous chapter and to 
test molecular functions in the context of repair, we needed a suitable in vivo model of 
acute mechanical joint surface injury/repair. Ideally, such model should be: (1) 
consistent and reproducible, (2) amenable for biological and biochemical quantification, 
(3) amenable for molecular analysis, (4) offer the opportunity for genetic modification.  
The short reproductive cycle of the mouse, ease of handling, the similarity in 
development and pathophysiology to humans and most importantly the ability to 
generate genetically modified animals made the mouse the species of choice for the in 
vivo model.   
5.1. Generation and optimization of joint surface injury in mice 
We decided to induce the defect in the patellar groove because the articular cartilage in 
this area is well exposed after patellar dislocation and thus easily accessible. In addition, 
it is clinically relevant as the patellar articular surface was one of the most common 
locations for joint surface lesions in humans (43.3%) (132;133), and the most 
challenging to repair with conventional methods (171). To generate a full thickness joint 
surface defect (JSD) in mouse patellar groove, we generated a simple device formed of a 
26G needle with a glass bead placed approximately 200μm from the tip of the needle 
which helps in running the device longitudinally in a straight line within the patellar 
groove as indicated in figure 3.1D.  
To optimize the surgical procedure and to validate the consistency and the 
reproducibility of the defects, a preliminary set of experiments were performed on 
mouse cadavers. Following the generation of the defects, the knee joints were 
decalcified, embedded in paraffin and coronally sectioned (Figure 5.1A) to measure and 
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compare cartilage and defect histomorphometric parameters in terms of cartilage 
thickness, depth, cross-sectional width (CSW) and cross-sectional area (CSA) of the JSD 
(Figure 5.1) 
Using this approach, we identified an interval (between plane A and C) in which the 
articular cartilage was of uniform thickness and the defect was consistent, reproducible 
and full thickness (figure 5.1B-E). Within this interval, the growth plate intercepted the 
plane of cutting in four points providing a useful landmark for section level (plane A and 
C) where A is 100μm proximal to the inter-condylar notch, plane B is 100μm proximal 
to plane A and plane C is 100μm proximal to plane B (figure 5.1A). Outside this 
interval, the articular cartilage thickness varied as it gradually decreased towards the 
diaphysis of the femur resulting in different types of injury (Figure 5.1B-E). Therefore, 
all further analysis was done using sections from within the A-C interval. 
 114 
 
Figure 5.1: Optimization of joint surface injury in mice (A) Schematic representation of a 
mouse knee joint (articular cartilage in yellow and the growth plate in blue). All the sections 
comprised between A and C intersects the growth plate in 4 points (section A-C on the left). This 
landmark is absent in sections outside this interval (Section on the right). B-D 
Histomorphometric measurements of cartilage thickness, depth and cross sectional width of the 
defect (B), cross sectional area (C) and the percentage of defect depth to cartilage thickness (D) 
below level A, within A-C interval and above level C of injured knee joints obtained from 
mouse cadavers (n=3). All the values are expressed as mean ± standard error of the mean (SEM). 
E is Safranin O/light green staining of representative sections from the three different levels of 
injured mouse knee joint. 
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5.2. Reproducibility and consistency of JSD in different strains of mice 
A second set of experiments was done in vivo using different strains of mice to 
histologically evaluate the nature, the extent of the injury and to assess the 
reproducibility and the consistency of the experimental JSD. The same 
histomorphometric parameters of cartilage thickness and injury size were then measured 
and compared limiting the analysis to A-C intervals within the patellar groove of each 
mouse (Table 5.1).  The thickness of the articular cartilage within the analyzed interval 
was comparable in C57BL/6 and DBA/1 mice but significantly higher in MRL/Mpj 
mice (figure 5.2.A). Depth, CSW, and CSA of the defects were very consistent and 
highly reproducible within the same joint, and across different mice with no statistically 
significant difference between all the strains analysed (Figure 5.2.A and B). Importantly, 
in all operated C57BL/6 and DBA/1 mice, the defects were consistently full thickness 
within the analysed interval. However, the joint surface injury induced in MRL/Mpj was 
partial thickness due to the relatively higher thickness of the articular cartilage (Figure 
5.2.C &D) and therefore, they were excluded from any further analysis. 
The variability within A-C interval in C57BL/6 and DBA/1 mice was further evaluated 
calculating the coefficient of variation (in percent) for each histomorphometric 
parameters and confirming the consistency of JSD (Table 5.1). In addition, only within 
this interval, sections intercepted the epiphyseal growth plate in 4 points (Fig 5.1A), 
thereby providing a landmark recognizable on histological sections further confirming 
the accuracy of the stringent sampling protocol which allowed a remarkable level of 
consistency. 
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Figure 5.2: Consistency and reproducibility of surgically induced full thickness defect. 
Histomorphometric measurements of cartilage thickness, depth and cross sectional width of the 
defect (A), cross sectional area (B) and the percentage of defect depth to cartilage thickness (C) 
within A-C interval in C57BL/6 (n=9), MRL/MPJ (n=5) and DBA/1 mice (n=5). D, Toluodine 
Blue staining of section MRL/Mpj knee joints after injury. All the values are expressed as mean 
± standard error of the mean (SEM). 
 
Table 5.1: The mean and the standard error of the mean (SEM) of histomorphometric 
measurements 
 
 
Depth 
Cross Sectional         
Width 
Cross Sectional 
Area 
% of defect depth 
to cartilage 
thickness 
C57BL/6 
69.78 ± 4.33μm   149.55 ± 26.29μm    7302.4 ± 1258.05μm2    106.37% ± 4.28 
       CV=6.4%             CV=19%                  CV=18.9% 
DBA/1        70.36 ± 3.84μm   141.31 ± 29.37μm    6988.2 ± 1541.56μm2    104.64 %± 2.58 
                           CV=5.3%             CV=22.3%               CV=23.3% 
CV= coefficient of variation 
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5.3. Structural outcome of joint surface injury in different mouse 
strains 
Having optimized an injury model which is reproducible in two different mouse strains, 
this allowed a comparison of the outcome between these strains. The scope of this 
experiment was to investigate whether there is a genetic component in the capacity to 
repair joint surface defect and to identify a strain that has good repair capacity. This 
would therefore enable the use of the model to study the role of specific genes in joint 
surface repair and their influence in outcome determination. The outcome of joint 
surface injury was then compared in C57BL/6 and DBA/1 strains, because of their well 
known differences in skeletal biology (250) and in their susceptibility to OA in 
surgically induced joint instability model (DMM) (26).  
The histological time course analysis showed no difference between the two adult strains 
one day after injury as evaluated by histomorphometry (Figure 5.2) and histology 
(Figure 5.3A). At 1 week time point, undifferentiated spindle shaped cells partially filled 
the defects in DBA/1 mice. By 4 weeks, the tissue filling the defects in DBA/1 mice 
consisted of chondrocytes surrounded by Safranin O stained matrix. However, this repair 
tissue lacked the typical architecture of normal articular cartilage as the superficial, 
intermediate, and deep layers were not morphologically distinguishable and the bone 
front had not reached the level of the osteochondral boundary as in the surrounding 
cartilage. After 8 weeks, there was a complete filling of the defects with well organized 
Safranin O positive hyaline-like cartilage (Figure 5.3A). Polarized light microscopy 
showed continuity of the collagen network between repair tissue and original cartilage, 
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thereby indicating integration; however, superficial irregularities and fibrillar 
discontinuity were sometimes observed (Figure 5.3B).  
In contrast, the lesions induced in C57BL/6 mice healed poorly as undifferentiated 
fibroblast-like cells invaded only the bottom of the defects four weeks after injury. At 
later time points, defects were partially filled with thin cancellous bone covered by a 
superficial layer of fibrous tissue (Figure 5.3A). In addition C57BL/6 mice displayed 
progressive features of OA in the articular cartilage of the patellar groove as early as 1 
week after injury. Initially, these features included small hypo- or a-cellular areas, 
surface fibrillation and faint Safranin O staining adjacent to the experimental defect.  
Subsequent progression included cluster formation, clefts, focal lesions and loss of 
Safranin-O metachromasia. Later on, these features extended to cartilage areas far from 
the experimental injury (Figure 5.3C).  
At all time points analyzed, no histological differences in the articular cartilage of the 
patellar groove were detected within the interval analyzed between the sham operated 
and non-operated controls from both strains as evaluated by H&E and SO staining 
(Figure 5.3). 
The number of mice analyzed at different time points is shown in table 5.2 
 
.  
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Figure 5.3: Time course histological analysis after joint surface injury. A, H&E (left) and 
Safranin O (right) staining of sections from sham operated and injured joints of 8 weeks old 
C57BL/6  and DBA/1 mice at the indicated time points. B, Polarized light microscopy of 
sections from sham operated, injured C57BL/6 and DBA/1 mice 8 weeks after surgery. C, 
Higher magnification of H&E stained sections from injured C57BL/6 showing areas away from 
the experimental lesion with various degrees of OA. 
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Table 5.2: The number of mice killed per time point 
Strain Age  No. of animals Time point 
DBA/1 8 weeks 15 8 weeks 
C57Bl/6 8 weeks 15 8 weeks 
DBA/1 8 weeks 5 1 day  
C57Bl/6 8 weeks 5 1 day 
DBA/1 8 weeks 5 1 week 
C57Bl/6 8 weeks 5 1 week 
DBA/1 8 weeks 5 4 weeks 
C57Bl/6 8 weeks 5 4 weeks 
 
 
 5.4. Quantitative assessment of cartilage injury outcome 
The main aim of generating a mouse model of joint surface injury was the use of the 
model in investigating the function of individual molecules using mouse genetics. 
Therefore, quantitative outcome measures are needed to easily compare mutant strains 
and wild type littermates. Two well validated histological scoring systems (188;238;239) 
were applied in the mouse model to assess the quality of cartilage repair tissue and the 
degree of osteoarthritis in DBA/1 and C57BL/6 mice at four and eight weeks time points 
as previously described in Materials and Methods chapter. The repair scores in DBA/1 
mice were statistically significantly lower (indicating better repair) than C57BL/6 at 4 
and 8 weeks after injury (Figure 5.4A). The modified Mankin score confirmed the 
absence of OA features in DBA/1, similar to uninjured and sham controls, whereas 
C57BL/6 developed OA already at 4 weeks after injury (Figure 5.4B). 
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Figure 5.4: Quantitative assessment of cartilage injury outcome. Repair score (A) and modified 
Mankin score (B) at 4 (n=5) and 8 (n=15) weeks time points. Low score in (A) indicated better 
repair and high score in B indicated more severe OA. All the values are expressed as mean ± 
standard error of the mean (SEM). * = P<0.05. 
 
 
5.5. The outcome of joint surface injury in aged mice 
Age is a factor influencing the outcome of JSD in humans (143;251) and animal models 
(148) with older individuals being less likely to have spontaneous healing. To 
investigate the effect of ageing, we challenged 8-month old C57BL/6 and DBA/1 mice 
in this model. Aged animals from both strains reproducibly failed to repair the defect. 
However, whereas C57BL/6 mice developed severe diffuse knee OA, DBA/1 mice did 
not show any sign of OA at any time points analyzed (Figure 5.5) suggesting that the 
failure of repair alone might not be the main cause for OA development and that the two 
processes might be uncoupled.  
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Figure 5.5: Structural outcome in aged mice.  A, H&E (left) and Safranin O (right) staining of 
sections from injured joints of 8 month old C57BL/6 and DBA/1 mice 8 weeks after surgery. 
The lower panel shows higher magnification of the areas squared in the upper panel. B, modified 
Mankin score at 8 weeks time points (n=15).All the values are expressed as mean ± standard 
error of the mean (SEM).  
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Discussion 
In this chapter, we have developed and validated a murine model of cartilage 
regeneration in which the outcome of joint surface injury is strain and age dependent. 
Since the repair of JSD depends largely on their size and depth (143;149;251), the 
reproducibility of the injury in our model was an important concern that was 
successfully addressed with a rigorous sampling technique. A high reproducibility and 
consistency of the injury was achieved by combining a well controlled sampling 
technique within a selected anatomical area and the design of a simple and reliable 
device to induce the injury. Importantly, all the defects were full thickness in all C57B/6 
and DBA/1 mice and slightly deeper than 100% of the cartilage thickness. Such 
consistency was largely ensured by the resistance offered by the subchondral bone, the 
resilience of the 26 gauge needle used to make the device, and the presence of the glass 
bead which by adapting to the concavity of the patellar groove, allowed the tip of the 
needle to run reproducibly in the centre of the patellar groove. 
In this model, the full thickness injury in adult DBA/1 mice resulted in consistent 
regeneration of articular cartilage as early as four weeks after creation of the defect with 
further maturation of the repair tissue at the 8 weeks time points. However, long term 
studies are still needed to evaluate the durability of this repair tissue. In contrast, age 
matched C57BL/6 mice displayed poor repair response and developed features of 
PTOA. This observed difference in the healing capacity between the two strains of mice 
mirrors the different repair capacity of human individuals and suggests that joint surface 
defects may trigger a cascade of events that will ultimately results in either joint repair 
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or failure. These events could be probably initiated and controlled by genetically 
determined programs. 
The time course histological analysis showed that non differentiated spindle-like cells 
filled the lesions in DBA/1 mice at 1 week whereas in C57BL/6, morphologically 
similar cells appeared in the defects after 4 weeks when chondrogenesis had already 
occurred in DBA/1 mice. This delay in populating the wound could be due to differences 
reported in proliferation rate, cell surface epitopes and differentiation potential between 
bone marrow mesenchymal stem cells (MSCs) isolated from C57BL/6 and DBA/1 with 
higher chondrogenic potential of DBA/1 MSCs (252). Additional potential mechanism 
could be a delayed activation/migration of mesenchymal progenitors in response to 
cartilage signals released by injured cartilage. In the previous chapter (Chapter 4), we 
have demonstrated that genes encoding morphogens and other signaling molecules are 
activated in human adult articular cartilage after mechanical injury.  Failure of either the 
cartilage to deploy such response to injury or the mesenchymal progenitor/stem cells to 
respond to such signaling molecules may contribute to the delay of C57BL/6 
mesenchymal cells in filling the defect and thus to the poor repair outcome.  
In addition to the poor repair observed in C57BL/ mice after joint surface injury, they 
also displayed progressive degradation of the surrounding articular cartilage. No signs of 
OA were seen in any of the control or sham-operated joints and thus it is unlikely that 
these OA features developed spontaneously or as a result of joint instability induced 
temporarily during surgery. The secondary OA development after cartilage injury in 
C57BL/6 mice might be one of the reasons for repair failure. It is unclear whether the 
two processes are causally related or they represent two distinct processes.  The outcome 
of joint surface injury in old DBA/1 mice where neither repair nor OA were observed 
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suggests that these two processes might be, at least in part, uncoupled as the repair 
failure in these mice did not lead to secondary OA development and the absence of OA 
did not promote the regenerative process. In humans, 30% of JSD that have been 
detected in healthy asymptomatic individuals remained stable during the 2 year 
follow-up study without any further worsening or evidence of repair (143). These data in 
humans and animals suggest that the mechanisms responsible for the restoration of joint 
homeostasis and prevention of PTOA development after injury might be different from 
those initiating and promoting endogenous repair. However, the relationship and the 
importance of these processes for one another are not clearly defined.  
It is well established that with age, the regenerative potential of most tissues deteriorate 
due to a combination of age-dependent changes in the tissue itself, in the local 
progenitor cells and in the environmental cues that participate in tissue homeostasis and 
repair. In our study, aged mice from both strains completely failed to repair the defect 
even with a scar tissue. Aging is known to induce structural, molecular, cellular and 
mechanical changes in articular cartilage that involve age related decline in the 
proliferative and anabolic response of chondrocytes to growth factor stimulation as well 
as reduction in the levels of growth factors (11). These changes may adversely affect the 
attempt to repair the articular cartilage and contribute to the risk of its degeneration by 
decreasing the ability of the cells to maintain and repair the tissue.  However, it is still 
necessary to investigate the earlier events that were associated with this repair failure in 
aged animals and to better understand how the age related changes can influence the 
ability of the tissue to preserve and restore itself.   
The different repair outcome seen in DBA/1 and C57BL/6 mice after the induction of 
joint surface injury has provided the opportunity to investigate and compare the events 
 126 
that might take place differently in the two strains and thus help in identifying factors 
that may participate in outcome determination. The next chapter describes a systematic 
time point analysis of the events associated with joint surface damage and subsequent 
repair / OA development.  
Conclusions 
  We have generated and validated a consistent and reproducible in vivo murine 
model of joint surface injury and repair with strain and age dependent outcome. 
 The model is amenable to outcome quantification, and genetic manipulation. This 
will give the opportunity to study the function of individual molecules/genes in the 
context of adult joint surface healing/degeneration. 
 
 
 
 
 
 
 
 
 
 127 
 
 
 
 
 
CHAPTER 6: RESULTS 
Characterization of the injury response in young  
C57Bl/6 and DAB/1 mice 
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In the previous chapter we have described the generation and validation of a novel in 
vivo murine model in which the outcome of joint surface injury is strain dependent. 
Chondrocyte apoptosis, proliferation and ECM remodelling have been described in 
previous literature to be associated with JSI in humans and animal models (223;253). To 
investigate and better understand the reasons for the different healing outcome in DBA/1 
and C57BL/6 mice, we have monitored and compared aspects of these features in vivo in 
a time course analysis. 
6.1. Apoptosis 
Apoptosis has been associated with acute cartilage injury (220;223) and with OA (254). 
Hence Apoptosis has been often proposed as a pathogenic mechanism of cartilage 
breakdown in OA (255). In the injured joints, apoptotic cells were identified in the 
proximity of the injury and at the edge of articular cartilage at day one in young mice of 
both strains (Figure 6.1.A). In consecutive H&E stained section, pyknotic nuclei were 
present in the same areas (Figure 6.1.C). In subsequent time points, chondrocyte 
apoptosis in DBA/1 mice progressively decreased and nearly disappeared at 4 and 8 
week time points (Figure 6.1A&B), whereas in C57BL/6 mice, after an initial decrease, 
apoptosis persisted, mainly around areas of cartilage degeneration, with statistically 
significant difference to DBA/1 mice (Figure 6.1.A-C).  In the articular cartilage of the 
sham and non-operated knee joints, we did not detect any TUNEL-positive cells at any 
time points analyzed (Figure 6.1A).  
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Figure 6.1: Cell death. A, TUNEL assay in sham-operated and injured joints of young mice at 1 
day and 8 weeks after injury as well as the positive and negative controls. Red arrows indicate 
apoptotic nuclei (green). Nuclei are counterstained with DAPI (blue). The asterisk indicates the 
injury site. B, Numbers of apoptotic cells at different time points comparing both strains. The 
values are expressed as mean and standard deviation of 3 different operated mice using 3 
sections from each joint.*=P<0.05. C, higher magnification of the areas squared in (A) at 1 day 
and 8 weeks time points respectively, and H&E staining of a consecutive section. Pyknotic 
nuclei are indicated with black arrowheads. 
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6.2. Proliferation: 
To investigate whether mechanical cartilage injury can induce cellular proliferation 
within the joint, an antibody against phosphorylated Histone H3 (PHH3) was used to 
detect cells in the mitotic (M) phase of the cell cycle (256). Although chondrocyte 
proliferation has been reported to take place following injury (223;257), we only 
detected scattered proliferating cells within the repair tissue at 1 and 4 weeks following 
injury in DBA/1 mice but not in the articular cartilage adjacent to the injury in either of 
the two strains (Figure 6.2A&B). The synovial membrane of both strains also exhibited 
cells undergoing proliferation only at the one week time point with no statistically 
significant difference between the 2 strains (Figure 6.2C&D). No proliferating cells were 
identified either in the articular cartilage or in the synovial membrane of sham operated 
or non-operated controls. 
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Figure 6.2: Cell proliferation. Phosphohistone H3 immunoflurescence and H&E staining of a 
consecutive section at 1 and 4 weeks time points (A). White arrows indicate Proliferating cells 
(red). Nuclei are counterstained with DAPI (blue). The numbers of proliferating cells counted in 
the articular cartilage of 3 mice using 3 sections from each joint are shown as mean and standard 
deviation (B). PHH3 immunoflurescence (C) and the count of the positive cells in the synovial 
membrane (D) at one week time point. As positive control we chose bone marrow areas in which 
there were several proliferating cells and negative control (E) was section treated with isotype 
matched non immune antibodies the primary antibody. BM=Bone marrow and AC= Articular 
cartilage. 
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6.3. Synovitis 
Synovitis is not only a feature of inflammatory arthritis, but also takes place in OA and 
following trauma (258). Persistent high grade synovitis is a main feature of destructive 
arthritis in which synovial inflammation causes joint surface damage (94). On the other 
hand, synovium-residing progenitor cells have been postulated to take part in the repair 
of JSD (259). It is well known that persistent local inflammation inhibits repair in 
several systems (260;261), and therefore, a different degree of synovitis or its 
persistence might have been a determinant factor in the outcome of joint surface injury. 
Synovitis was quantified by histomorphometric analysis measuring the area of the 
synovial membrane in control, sham operated and injured joints in the two strains. All 
operated joints (sham and injured) from both strains exhibited transient synovial 
hyperplasia that was observed at the one week time point and resolved by the 4 weeks 
time point (Figure 6.3A&B). Although this analysis is incomplete, still it provides an 
idea of the inflammatory component of the injury reaction. The synovial thickening was 
not limited to the injured knees but was also present in the sham operated joints and 
therefore it is not specific to cartilage injury. No difference was observed between sham 
operated and injured knee joints from the two strains. Hence, based on this simple 
analysis, the amount of synovitis at this specific time point could not explain the 
different outcome but it is still possible that a different inflammatory response may play 
a role in repair outcome. 
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Figure 6.3: Inflammatory response to arthrotomy: A, Quantitative histomorphometric 
assessment of synovial thickening 1 and 4 weeks after surgery in C57BL/6 and DBA/1mice. B, 
Representative H&E stained sections from control, Sham operated and injured knee joints at the 
one week time point.  
 134 
6.4. Matrix remodelling 
Remodelling of the cartilage ECM has been the focus of extensive research in cartilage 
biology and its importance has been confirmed in outcome determination in a murine 
model of osteoarthritis (32). For the critical homeostatic role played by the matrix 
component of the cartilage, it is possible that ECM remodelling may also affect the 
repair process following cartilage injury and hence the final outcome of cartilage injury 
could be determined by the balance between synthetic and catabolic activities. 
Therefore, the remodelling of the two major components of cartilage matrix (type II 
collagen and aggrecan) was compared after injury in the two strains of mice. 
6.4.1. Type II collagen Neo-synthesis 
Type II Collagen is composed of three subunit polypeptide chains intertwined in triple 
helical configuration. During biosynthesis, each polypeptide chain is synthesized with 
extra registration peptides (telopeptide) on both the amino- and carboxyl terminal ends 
to prevent premature intra-cellular precipitation and assembly of the procollagen 
molecule. After its extracellular transport, the N and C- telopeptides are released by 
procollagen peptidase enzyme allowing tropocollagen to assemble into polymeric 
collagen fibrils (15). Therefore, to monitor type II collagen neo-synthesis, we immuno-
stained the C-terminal telopeptide cleaved from type II procollagen molecules using anti 
CPII antibody (262). In the control and sham-operated joints, the collagen C-telopeptide 
was detected in the mineralized deep layer of the articular cartilage (Figure 6.4A). 
Following injury, pericellular CPII staining was observed in the superficial and 
intermediate zones. In these areas, collagen type II neo-synthesis peaked one week after 
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injury in both strains, but subsequently declined in C57BL/6, while it persisted in 
DBA/1 mice for at least 8 weeks and became confined to the newly formed cartilage 
(Figure 6.4A, B). The number of CPII-positive chondrocytes was statistically 
significantly higher in DBA/1 mice at 4 and 8 weeks time points (Figure 6.4B). The 
positive and negative controls are shown in Figure 6.4C.  
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Figure 6.4:  Collagen synthesis: A, Immunoflurescence staining for type II collagen C 
telopeptide (A) in eight week old C57BL/6 (left) and DBA/1 (right). Type II collagen C-
telopeptide is shown in red and nuclei are counterstained with DAPI (blue). B, The number of C- 
telopeptide positive chondrocytes within the superficial and intermediate layer. The values from 
3 different mice from each strains at the indicated time point are expressed as mean and standard 
deviation * P<0.05.  C, Positive (left) and negative (middle and right) controls for CPII 
immunostaining. As a positive control, I used growth plate cartilage in which the antigen had 
been already reported to be present. Negative control was sections in which isotype matched non 
immune antibodies were used instead of the primary antibodies. GB=Growth plate and AC= 
Articular cartilage. 
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6.4.2. Type II collagen degradation  
Type II collagen degradation was then compared in both strains utilizing anti C1,2C 
(Col2-3/4Cshort) antibody that recognizes the carboxy-terminal end of the 
collagenase-generated fragment of type II collagen. Intact uninjured articular cartilage 
from sham and non-operated joints showed weak pericellular C1,2C staining in both 
C57BL/6 and DBA/1 young mice (Figure 6.5A).  As early as 1 week and for at least 8 
weeks following injury, immunostaining increased in both strains. The repair tissue in 
DBA/1 mice, however, displayed a weaker staining than the adjacent cartilage (Figure 
6.5A). The positive and negative controls are shown in Figure 6.5B. 
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Figure 6.5: Collagen degradation. A, immunostaining of C1,2C neoepitope in sham and injured 
C57BL/6 (left) and DBA/1 (right) at the indicated time points. Negligible staining is seen in the 
repair tissue in DBA/1 mice. B, Positive (left) and negative (middle and right) controls for 
C1,2C immunostaining. GB=Growth plate and AC= Articular cartilage. 
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6.4.3. Aggrecanase and MMPs mediated aggrecan cleavage 
Proteoglycan turnover is central to cartilage homeostasis and proteoglycan cleavage has 
been shown to be a crucial event in OA development (32). Proteoglycan remodeling has 
also been argued as an important element for cartilage repair. Therefore, we have 
compared in the two mouse strains the modalities of proteoglycan degradation utilizing 
two antibodies that recognize neoepitopes generated by aggrecan (the major 
proteoglycan in cartilage) when cleaved  by aggrecanases and metalloproteinases MMPs 
(TEGE
373 
and VDIPEN) respectively. In sham and non-operated control joints, both 
strains exhibited similar staining patterns (Figure 6A&7A). As early as one day after 
injury and thereafter, C57BL/6 mice displayed increased TEGE
373
 staining and low 
levels of VDIPEN. An opposite expression pattern was detected in DBA/1 mice with 
weak TEGE
373
 and intense VDIPEN staining (Figure 6A&7A). These findings indicate 
that aggrecan is prevalently degraded by aggrecanases in the C57BL/6 and by 
metalloproteinases in DBA/1 strain thereby confirming the critical role of aggrecanases 
in cartilage destruction and suggest that a controlled level of MMP-mediated 
aggrecanolysis may be needed for cartilage homeostasis, and possibly repair.  
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Figure 6.6: Aggrecanase mediated aggrecan degradation. A, Immunostaining of aggrecanase 
(TEGE
373
) generated neoepitope (brown) in the articular cartilage of eight week old C57BL/6 
and DBA/1. Nuclei are counterstained with Hematoxylin (blue). B, Positive (left) and negative 
(middle and right) controls for TEGE
373 
immunostaining. GB=Growth plate and AC= Articular 
cartilage. 
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Figure 6.7: MMPs mediated aggrecan degradation. A, Immunostaining of MMPs (VDIPEN) 
generated neoepitope (brown) in the articular cartilage of eight week old C57BL/6 and DBA/1. 
Nuclei are counterstained with Hematoxylin (blue). B, Positive (left) and negative (middle and 
right) controls for VDIPEN immunostaining. GB=Growth plate and AC= Articular cartilage. 
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Discussion 
We have demonstrated in this chapter that joint surface damage can trigger a series of 
cellular and extra-cellular events including apoptosis, proliferation and matrix changes. 
These events were regulated differently in DBA/1 and C57BL/6 mice resulting in the 
different outcome observed in both strains.  
Chondrocyte apoptosis progressively resolved in DBA/1 mice and persisted in C57BL/6 
for at least 8 weeks. Chondrocyte death following mechanical injury and its potential 
role in the pathogenesis of osteoarthritis have been described in several studies 
(220;223;254;263). However, apoptotic cells may play a positive role in the repair 
responses by releasing chemo-attractants for stem/progenitor cells such as HMGB1 
(264). Therefore, it is possible that controlled chondrocyte apoptosis, in the initial phases 
of repair, may play a similar function after cartilage injury; however, it could be 
detrimental if not tightly regulated and inappropriately prolonged. Our experimental 
setup does not allow us to discriminate whether the prolonged apoptosis in C57BL/6 is 
determining or a consequence of repair failure. 
Proliferation in the cartilage surrounding the injury site has been reported following 
mechanical trauma (223;257). We did not detect chondrocyte proliferation in the 
articular cartilage surrounding the injury. However, proliferating cells were identified 
within the repair tissue in DBA/1 mice at 1 and 4 weeks post-surgery. This discrepancy 
with previous literature could be due to differences in the experimental conditions, the 
time points analyzed and the detection systems used. In this study, we examined the 
phosphorylation of Histone H3 which is tightly correlated with the chromosome 
condensation phase during mitosis, thereby representing a snapshot of cells in M phase 
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of cell cycle (256). Conversely, incorporation of labeled nucleosides marks all the cells 
undergoing DNA duplication during the labeling period. Furthermore, cell proliferation 
in adult tissues occurs at a very low rate, and may take place in a short time-span after 
injury, thus our time points might have missed proliferation within the cartilage 
surrounding the injury. It is also possible that cells might first migrate from the 
surrounding cartilage and then divide within the repair tissue.  Surrounding tissues such 
as bone marrow and synovium have been proposed to contribute cells to the reparative 
process in different in vivo injury models (153;259). Indeed, proliferating cells were 
seen in the synovial membrane of both strains one week following injury suggesting a 
possible role for the synovial membrane in the repair process. Additionally, PHH3 
positive cells were also identified in the bone marrow of injured and sham operated 
joints. The fact that bone marrow contains continuously proliferating hematopoietic stem 
cells may explain our findings however, it can not be excluded that bone marrow MSCs 
may be contributing to the process of cartilage regeneration. The origin of the cells 
populating the defects and ultimately forming the repair cartilage in DBA/1 mice 
remains to be clarified.  
It is well known that the inflammatory response to trauma is an essential phase for 
repairing the damaged tissue however, if prolonged; it can impair the healing process 
and results in local destruction (261). Synovial inflammation, involving lymphocytic 
infiltration and overexpression of pro-inflammatory mediators, is a common feature in 
OA and a factor that likely causes an imbalance between the catabolic and anabolic 
activities of the chondrocytes (265). Mild transient synovial thickening was observed in 
all joints following arthrotomy suggesting that it is a surgery related reaction rather than 
a response to cartilage injury. Synovitis peaked one week after surgery and completely 
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resolved at the 4 week time points in both strains and is therefore unlikely to account for 
their different outcome. However, we can not exclude the possibility that differences in 
the composition of the inflammatory infiltrate, different cytokine profiles and dynamics 
of resolution might all be factors influencing the regeneration outcome and therefore 
more studies are still needed to further characterize and compare these factors in both 
strains.  
This study shows a prompt activation of matrix remodeling after injury within the repair 
tissue in DBA/1 mice and in the remaining cartilage in both strains. Matrix remodeling 
has been described in response to injury (223;266), during OA (20;267) and in human 
repair cartilage tissue obtained from autologous chondrocyte implantation (21). 
Interestingly, in this study, DBA/1 mice maintained a high level of Collagen type II neo-
synthesis and a low collagen catabolic activity for 8 weeks after injury. However, 
C57BL/6 mice exhibited a reverse pattern with progressive decrease in the number of 
CP II positive cells and intense Col2-3/4Cshort staining. Aggrecan degradation was 
predominantly driven by aggrecanases in C5BL/6 mice and by metalloproteinases in 
DBA/1 mice.   
Recently, ADAMTS-5 has been identified as the main aggrecanase in mouse cartilage 
and its ablation protected the mice from OA induced by DMM (32). Similarly, mutants 
harboring a genetic allele of the aggrecan gene that blocks aggrecanase-mediated 
cleavage were also protected when challenged in DMM model, but, interestingly, mice 
harboring an aggrecan mutant allele that is resistant to MMP-mediated cleavage 
developed more severe OA than their wild-type littermates (16). Moreover, 
MMP9-deficient mice were more susceptible to OA than their wild-type littermates in 
the same model (26). Taken together, these data and our results confirm the critical role 
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of aggrecanases in cartilage destruction and suggest that a controlled level of MMP- 
mediated aggrecanolysis may be needed for cartilage repair, as MMPs proteolysis can 
facilitate cell migration, regulate tissue architecture, release and activate ECM bound 
growth factors and signaling molecules (23). A caveat, in the interpretation of our data, 
is that aggrecan cleaved by aggrecanases may be internalized (268) and thereby no 
longer available for MMP cleavage even in the presence of active MMPs. This may 
explain why, in C57BL/6, although several MMPs can cleave collagen and aggrecan, we 
only detected cleaved type II collagen.  Another explanation for this discrepancy is that 
different MMPs may be responsible for aggrecan and collagen type II cleavage. 
The above mentioned cellular responses to cartilage injury are thought to be part of a 
more complex signaling triggered by joint surface damage, possibly activating and 
regulating the reparative process or contributing to PTOA development. In chapter 4, we 
have characterized the molecular response of human articular cartilage to injury in vitro 
and showed modulation of genes encoding signaling molecules and morphogens.  In the 
next chapter, we will use the mouse model of joint surface injury/repair to validate these 
findings in vivo. 
 146 
Conclusions 
 The different repair outcome in C57BL/6 and DBA/1 mice was associated with 
different regulation of apoptosis, proliferation and matrix remodelling  
 Specific measurable parameters of anabolism and catabolism may be used as 
biomarkers to predict the ability of cartilage to heal and the likelihood of 
post-traumatic OA development  
 These assays may be used to identify mechanisms by which a specific gene can 
influence the regenerative process.  
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CHAPTER 7: RESULTS 
In vivo validation of the molecular response of articular 
cartilage to injury 
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Acute mechanical injury to adult human articular cartilage results in an early molecular 
response with activation of several signalling morphogenetic pathways. Although the in 
vitro model of cartilage injury used in this study is a well validated system, it has several 
drawbacks and limitations. For instance, the cartilage tissue has already been injured 
upon dissection and isolated from its anatomical and functional environment and instead 
exposed to artificial cultural conditions. The in vivo model of joint surface injury and 
repair offers the opportunity to validate in vivo the differential expression of genes 
reported to be modulated upon cartilage injury in vitro by microarray screening. In 
particular, we focused on pathways known to play a role in embryonic skeletogenesis 
and joint morphogenesis such as BMP and Wnt pathways. 
7.1. Modulation of BMP pathway in vivo following joint surface injury 
In our in vitro experiments, BMP2 mRNA was upregulated in the injured human 
cartilage explants with phosphorylation of SMAD-1/-5/-8 indicating activation of BMP 
pathway. To investigate whether the regulation of the BMP pathway demonstrated in 
vitro also took place following injury in vivo, we utilized our new in vivo murine injury 
model. Immunohistochemical staining for BMP-2 was done on sections from mouse 
knee joints comparing the sham versus the injured at different time points following 
injury. BMP-2 was intensely detected in the extracellular matrix of the injured articular 
cartilage in both strains as early as one day and at least for 8 weeks post-surgery. At later 
time points, however, the staining became less diffuse especially in C57BL/6 mice. The 
articular cartilage of the sham operated knees showed faint pericellular staining (Figure 
7.1A). The ECM-associated staining pattern was not unexpected as BMP2 is known to 
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bind strongly to Heparan sulfate proteoglycans (HSPGs) through the heparin binding 
domain at its N-terminus (269).  
 
Figure 7.1: BMP2 activation after mechanical cartilage injury in the murine in vivo model: A, 
immunostaining for BMP-2 in the sham and injured C57BL/6 and DBA/1 mice at the indicated 
time points. The positive and negative controls for BMP-2 in the growth plate cartilage are 
shown in B. The negative control sections were treated with an isotype matched non- immune 
primary antibody.  
 150 
As activation of BMP signaling activates the phosphorylation of the intracellular 
signaling mediators SMAD-1/-5/-8, we performed immuno-staining using an antibody 
that detects the phosphorylated form of SMAD-1/-5/-8.  In the injured joints, phospho-
SMAD-1/-5/-8 positive cells can be identified both in injured articular cartilage one day 
following the injury (Figure 7.2A). In contrast, no phosphorylated SMAD-1/-5/-8 were 
detected in the sham operated joints (Figure 7.2A) indicating that the activation of BMP 
signaling is a mechanism specific to cartilage injury. The BMP pathway is known to be 
active in cartilage of the growth plate where it plays an important role in regulating the 
process of endochondral bone formation (270). Therefore, growth plate cartilage was 
used as an internal positive control for both BMP2 (Figure 7.1B) and PSMAD (Figure 
7.2B) immunostaining. 
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Figure 7.2: PSMAD immunostaining in both stains in injured and sham operated joints. Positive 
cells were identified in injured articular cartilage one day after surgery (A). The asterisks 
indicate the site of injury.  The positive and negative controls for PSMAD in the growth plate 
cartilage are shown in the lower inset (B). The negative control sections were treated with an 
isotype matched non- immune primary antibody. 
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7.2: Modulation of Wnt signalling in the in Vivo mouse model of joint 
surface injury  
The experiments done using the in vitro model of cartilage injury showed a consistent 
injury-associated up-regulation of Wnt16 as well as activation of the canonical Wnt 
signalling pathway. To test whether the same phenomena also takes place in vivo after 
cartilage injury, modulation of Wnt signalling was studied in the murine in vivo model 
of joint surface injury.  
In keeping with the in vitro data from human cartilage explants, the secreted Wnt 
inhibitor FRZB was markedly decreased in the articular cartilage of injured knees in 
C57BL/6 and DBA/1 mice (Figure 7.3A). Wnt16 was also sharply upregulated 24h after 
cartilage injury at both protein (Figure 7.3A) and mRNA (Figure 7.3B) level. It was 
interesting to notice that Wnt16 was not detected at the sham operated joints, where 
injury to the synovial membrane and the joint capsule occur and result in synovitis 
comparable to those of injured joints. This demonstrates a high level of specificity of the 
Wnt16 response to cartilage injury but not to other joint tissues.   This data also indicate 
that Wnt16 up-regulation after cartilage injury is conserved across species.  
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Figure 7.3: Wnt16 up-regulation and FRZB downregulation are reproduced in vivo in a mouse 
model of cartilage injury: immunohistochemical staining for the Wnt antagonist FRZB and 
Wnt16 (A) and quantitative real time PCR analysis of Wnt16 (B) in the sham operated and 
injured knee joints of C57BL/6 and DBA/1 mice one day after injury. The inset in A is showing 
high magnification view and Values in B are expressed as mean and standard deviation. *p 
<0.05. 
 
To investigate whether this molecular regulation is associated with activation of the β 
catenin-dependent wnt signalling pathway as in the in vitro experiments, 
immunostaining for β catenin was performed comparing the injured versus the sham 
operated knee joints. Cytoplasmic accumulation and nuclear localization of β-catenin 
was observed in the articular cartilage of injured joints from both mouse strains whereas 
chondrocytes in sham operated joints only exhibited weak staining mostly associated 
with the cell membrane (Figure7.4A). To investigate if β-catenin accumulation after 
injury is associated with up-regulation of TCF/LEF1 target genes, gene expression 
analysis of the Wnt target genes Axin2 (271) and Osteoprotegerin (OPG) (272) was 
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performed. Axin2 mRNA was significantly up-regulated in both strains one day after 
cartilage injury (Figure 7.4B) confirming the activation of Wnt signaling through the 
canonical pathway in vivo. Our experimental conditions did not reveal significant 
differences in OPG expression at protein (Figure 7.4A) or mRNA (Figure 7.4C) level 
between injured joints and sham operated controls.  
 
Figure 7.4: Activation of the canonical Wnt pathway upon joint surface injury in vivo: A, 
Immunostaining for β-catenin (upper panel) and OPG (Lower panel). B-C, quantitative real time 
PCR analysis for Axin2 (B) and OPG (C) in sham operated controls and injured joints of 
C57BL/6 and DBA/1 one day after injury. The insets in A are showing high magnification view 
and values in B and C are expressed as mean and standard deviation. *p <0.05. 
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Wnt4 and Wnt9a are co-expressed with Wnt16 in the joint interzone during embryogenesis 
and are known to activate the canonical Wnt signalling (47). To evaluate if these genes 
might contribute to the reported activation of the canonical Wnt signalling in vivo, 
modulation of these Wnt ligands was studied after cartilage injury in vivo by gene 
expression analysis. Wnt4, but not Wnt9a, mRNA was significantly upregulated in vivo 
after joint surface injury in both strains (Figure 7.5A&B) indicating a possible role in Wnt 
activation through the canonical pathway.  
 
Figure 7.5: Injury associated modulation of Wnt ligands involved in synovial joint formation. 
Quantitative real time PCR analysis of the Wnt ligands WNT4 (A), WNT9a (B) in sham 
operated and injured joints from C57BL/6 and DBA/1 mice at day one time point. Values are 
expressed as mean and standard deviation. *p <0.05. 
To explore the dynamics of wnt16 up-regulation and activation of the β 
catenin-dependent Wnt pathway in C57BL/6 and DBA/1 mice 8 weeks after injury, 
Wnt16 and β-catenin immunostaining were performed on sections obtained from both 
strains. This experiment revealed that at this late time point wnt 16 was detectable at 
very low levels and β-catenin exhibited a cytoplasmic granular pattern of staining in 
both strains tested (Figure 7.6). 
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Figure 7.6: Regulation of Wnt16 and β catenin activation at late time points: 
Immunohistochemical staining for Wnt16 (upper panel) and β catenin (Lower panel) in sham 
operated joints (Left) and injured C57BL/6 (Middle) and DBA/1 (Right) at 8 weeks following 
cartilage injury. The insets are high magnification images showing the cellular pattern of 
staining at the indicated time points. 
7.3: Effect of activation of the canonical Wnt pathway on mouse 
articular cartilage explants   
To investigate the possible effects of canonical Wnt signalling activation in mouse 
articular cartilage, articular cartilage explants from the femoral heads were isolated, 
stimulated with recombinant Wnt3a (known agonist for the canonical pathway) for 
either 24 or 48 hours and RNA was extracted for gene expression analysis. This 
stimulation was effective as shown by the up-regulation of the target gene Axin2 (Figure 
7.7.A). Wnt3a treatment also up-regulated OPG mRNA (Figure 7.7B) and significantly 
increased Col2A (Figure 7.7C) and aggrecan (Figure 7.7E) mRNA without significant 
effect on Col10 expression (Figure 7.7D) after 24 hours. The effect of stimulation was 
lost after 48 hours (Figure 7.7) indicating that activation of the Wnt signalling pathway, 
in this system is short-lived. 
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Figure 7.7: Effect of the canonical Wnt pathway activation on mouse articular cartilage 
explants: Real time PCR analysis for axin2 (A), OPG (B), Col2A (C), Col10 (D) and aggrecan 
(E) in mouse cartilage explants following stimulation with recombinant Wnt3a or the vehicle of 
the proteins (0.1%BSA-PBS). Values are expressed as mean and standard deviation. 
Under our experimental conditions, activation of the canonical pathway in articular 
cartilage explants resulted in up-regulation of cartilage markers Col2A and aggrecan 
suggesting an anabolic effect. Similar results were observed when treating adult human 
articular cartilage explants with LiCl (an inhibitor of GSK3) indicating that this effect 
may be conserved across species (273).  Up-regulation of aggrecan and Col10 mRNA 
was also reported in articular chondrocytes isolated from β-catenin cAct mice in which 
β-catenin is constitutively activated (95). Activation of wnt signalling in our 
experimental setup was transient possibly due to subsequent repression of the pathway 
through negative feedback regulatory mechanisms (56). This transient activation might 
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not be sufficient to significantly alter the expression of certain genes such as Col10 that 
may require persistent longer activation of Wnt signalling.  
In other in vitro systems, however, the activation of Wnt pathway induced 
downregulation of cartilage marker genes aggrecan and Col2A (274) suggesting that 
different experimental in vitro conditions may result in variable responses and 
highlighting the necessity for the in vivo validation. 
7.4: Identification of the target cells of the canonical Wnt signalling in 
the adult joint environment 
To identify cells in which Wnt pathway is active following cartilage injury, we used 
BAT-gal (β-catenin activated transgene driving expression of nuclear β-galactosidase 
reporter) mouse line as a readout of β-catenin activity (275). These mice express 
β-galactosidase under the transcriptional control of TCF/LEF1 responsive elements and 
therefore cells with active wnt signalling can be demonstrated using X-Gal staining 
(275). The joint surface injury model was performed in 8 weeks old BAT-gal mice (FVB 
genetic background) and X-GAL staining was done at different time points in the injured 
and sham operated joints. Up-regulation of β-galactosidase was present in a subset of 
cells within the bone marrow spaces around the injury site only at the one day time 
point. Later on, these cells disappeared despite filling of the defects with 
undifferentiated cells after one week and repair of the wound with cartilaginous tissue 
after 8 weeks (Figure 7.8).   
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Figure 7.8: BAT-gal expression at different time points following cartilage injury. X-gal staining 
was performed and sections were counterstained with eosin. X-GAL positive cells are shown in 
blue.       
Further phenotypic and functional characterization of these cells is still needed to 
identify the nature of the cells and to investigate whether they are involved in the 
reparative response. Such investigations were outside the scope of this thesis however, 
two possibilities are worth discussing because of their possible implication in repair 
processes.  The first one is that the canonical wnt signalling plays a role in the 
maintenance of the stem cell pool and in the regulation of healing process in several 
systems (247;276;277) and therefore cellular targets of this pathway within injured joints 
(β-galactosidase positive cells) may represent joint progenitor cells contributing to joint 
surface repair. The second is that the wnt pathway also has an important role in bone 
remodelling especially through RANK-RANKL-OPG axis which blocks 
osteoclastogenesis and ultimately bone resorption (94;278). Therefore, it is also possible 
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that the β-galactosidase positive cells are pre-osteoclasts targeted by the activated Wnt 
signalling after cartilage injury.  
7.5: Suitability of BAT-GAL mice as a reporter for Wnt signalling in 
adult cartilage 
Unexpectedly, in spite of the already mentioned positivity of β catenin immunostaining 
in injured cartilage, no X-GAL positive cells were identified in the articular cartilage of 
BAT-GAL mice after injury (Figure 7.9A). To test whether β-catenin accumulated in 
BAT-GAL mice as was the case in DBA/1 and C57BL/6 strains, β-catenin 
immunostaining was performed on sections obtained from these mice. As with the other 
two strains, cytoplasmic accumulation and nuclear localization of β-catenin was 
observed in the articular cartilage of BAT-GAL mice one day after injury and in growth 
plate chondrocytes with the absence of X-GAL staining (Figure 7.9A).  
To further investigate the reliability of BAT-GAL expression to reflect the Wnt/ β-
catenin activity in cartilage tissue, BAT-GAL femoral heads were stimulated in vitro 
with Wnt3a (well characterized Wnt ligand that signals through the canonical pathway) 
for either one or two days. Again, no X-GAL staining was seen in the cartilage explants 
following stimulation (Figure 7.9B) despite the up-regulation of Axin2 (Figure 7.9C) 
that suggests the activation of the canonical Wnt pathway. These results indicate that the 
expression of nuclear β-galactosidase reporter does not mirror the activation of Wnt 
signalling in cartilaginous tissue of adult mice and thus BAT-GAL mice are not suitable 
as reporter for the canonical Wnt pathway activation in adult mouse cartilage 
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Figure 7.9: BAT- GAL mice as a reporter for WNT signaling in adult cartilage: A, X-GAL  
staining (arrow) in injured articular cartilage and in the growth plate (left) and β-catenin 
immunostaining of a consecutive section (right). B, X-GAL staining of un- stimulated (control) 
and WNT3a stimulated BAT-GAL articular cartilage dissected from femoral heads. Sections 
were counterstained with eosin. Real time PCR analysis for axin2 (C) in mouse cartilage 
explants following stimulation with recombinant WNT3a or the vehicle of the proteins 
(0.1%BSA-PBS). Values are expressed as mean and standard deviation. 
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7.6: Validation of Axin2 KI
 
mice as reporters for Wnt signalling 
Axin2 mRNA was upregulated after injury in adult human cartilage explants and in mice 
with joint surface defects. Knock-in (KI) mice in which a lacZ cassette replaces exon 2 
of the axin2 gene can be used as a reporter for axin2 and since the expression of axin2 is 
under the control of Wnt signaling and Axin2 may even be a universal Wnt 
transcriptional target, these mice may serve as a useful Wnt reporter (279). In addition, 
Axin2 is a repressor of the canonical wnt signalling and therefore these mutants are 
expected to display increased Wnt/β-catenin signalling thereby providing the 
opportunity to study the effect of excessive wnt activation on joint regeneration/OA 
development after injury.  
Axin2 KI
 
mice were subjected to either arthrotomy (sham operated) or arthrotomy and 
joint surface injury (injured) and mice were killed 1, 3 and 7 days after surgery and X-
GAL staining was performed. Β-galactosidase expression was detected in chondrocytes 
and bone marrow cells in the sham operated joints (Figure 7.10) but surprisingly 
disappeared completely one day after cartilage injury (Figure 7.10). This could be 
caused by either disruption of a regulatory element within the exon that was removed 
affecting axin-2 promoter activity and rendering these mice unsuitable as reporter for 
Wnt signalling or by suppression of the Wnt signalling in Axin2 KI mice following joint 
surface injury. To further investigate whether canonical Wnt pathway is modulated in 
Axin2 KI
 mice, β-catenin immunostaining was performed on sections obtained from 
these mice. No cytoplasmic accumulation or nuclear localization of β-catenin was 
observed in articular cartilage after injury (Figure 7.10) not only suggesting  the 
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unsuitability of these mice as Wnt reporter in adult life, but also that disruption of Axin2 
might have interfered with the activation of the canonical Wnt signalling.  
 
 
Figure 7.10: Axin2 KI mice in the joint surface injury model:  X-Gal staining (upper panel) 
and β-catenin immunostaining (lower panel) of sham operated (left) and injured (right) knee 
joints (positive X-GAL cells appear in either blue when sections counter-stained with eosin 
or green when sections immunostained for β-catenin). Asterisks point to the site of injury.   
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Discussion 
In this chapter, we have validated in vivo the molecular response of articular cartilage to 
acute mechanical injury that has been previously characterized in vitro. In agreement 
with the in vitro data from adult human articular cartilage explants, joint surface injury 
in vivo was also associated with activation of the BMP and Wnt pathways which are 
known to play a crucial role in joint development, morphogenesis and homeostasis. 
These findings not only confirm the in vitro data but also suggest that such response to 
injury is evolutionary conserved.  
BMP-2 was upregulated in articular cartilage following injury in vivo in C56BL/6 and 
DBA/1 mice concomitant with phosphorylation of SMAD-1/-5/-8 indicating modulation 
of BMP signaling. BMP-2 was detected in the injured articular cartilage in both strains 
for at least 8 weeks post-surgery suggesting that some of the molecular signals triggered 
by joint surface injury might not be transient and instead be needed for a long time to 
regulate and co-ordinate the different components of the repair process. BMPs are 
known to elicit an anabolic response in articular cartilage both in vitro (119) and in vivo 
(123;124). Therefore, it is possible that the presence of BMP-2 in C57BL/6 mice at late 
time points might represent an anabolic effort to resist structural damage to cartilage 
after injury. The persistence of BMP-2 up-regulation for long periods after injury in vivo 
might explain our previous in vitro data in which the expression level of BMP-2 mRNA 
and the number of PSMAD-1/-5/-8 positive cells in the rested explants were 
intermediate between the freshly isolated explants and the injured ones and further 
support our conclusion that the resting period was not sufficient to completely reverse 
the response due to the initial dissection of the explants. 
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In addition to the modulation of BMP signaling, our in vivo and in vitro studies showed 
up-regulation of Wnt16 ligands and associated activation of the canonical Wnt pathway. 
However, in contrast to the in vitro data in which other Wnt ligands including Wnt4 and 
Wnt9a (known to co-expressed with Wnt16 in the prospective joints during embryonic 
skeletogenesis) were not regulated upon injury, Wnt4 mRNA was upregulated in vivo 
after joint surface injury in both strains. Besides the many differences between the 2 
experimental systems, one possible explanation for this discrepancy is that if Wnt4 
up-regulation following injury persists for more than 6 days, it would not be detected in 
the microarray experiment as long lasting gene regulation induced by dissection will not 
subside within the 6 days of the resting period and therefore, after being reinjured, 
rested-control and injured samples will have similar gene expression levels. Such 
regulation would instead be revealed by comparing the injured and rested control to the 
freshly dissected explants but since both rested controls and injured explants are exposed 
to cultured conditions whereas the freshly dissected explants are not, it is not possible to 
discriminate between genes regulated by injury and genes regulated by exposure to 
culture conditions. Another discrepancy between the in vitro microarray data and the in 
vivo validation was seen in the expression of OPG following injury. OPG mRNA was 
upregulated in injured adult human articular cartilage but, under our experimental 
conditions, no significant differences were found either in mRNA or protein level 
between injured mouse joints and sham operated controls. This could be due to 
differences related to species or the time point of activation. In addition, OPG is 
constitutively expressed at high level in bone and cartilage in vivo. This might have 
masked an up-regulation following injury. 
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At later time points after in vivo joint surface injury, Wnt16 expression subsided, but β 
catenin accumulation persisted and acquired a cytoplasmic granular pattern. β catenin is 
a dual function protein that plays a crucial role in regulating both Wnt signal 
transduction and cell adhesion through binding to the cytoplasmic domain of cadherins 
and linking it to the actin cytoskeleton (242). The different regulation of β-catenin at 
early and late time points following cartilage injury could be due to activation of Wnt 
signalling probably required earlier for stem cell regulation and cell fate determination 
and the adhesive functions required later for organizing tissue architecture and 
morphogenesis. A detailed in vivo characterization of the expression pattern and 
dynamics of all Wnt ligand and other components of the pathway including target genes 
and binding partners of β-catenin following cartilage injury in both strains is still needed 
to better understand the involvement of the Wnt pathway in outcome determination after 
JSI.  
Wnt proteins are pleiotropic signalling molecules and their functions are highly context 
dependent. For instance, this study as well as others (273);(95) has demonstrated that 
activation of the canonical Wnt pathway resulted in up-regulation of cartilage marker 
genes aggrecan and Col2A mRNA suggesting an anabolic response whereas under 
different experimental conditions, it induced downregulation of aggrecan and Col2A 
(274) and stimulated the expression of catabolic genes such as MMPs and ADAMTSs 
(91). Furthermore, activation of the canonical Wnt signalling has been shown to 
suppress chondrogenesis in some systems (274;280) but promotes it under other 
experimental models (281;282). In this regard, it is also interesting that both gain and 
loss of function of β-catenin in adult articular chondrocytes resulted in an OA like 
phenotype although through different mechanisms. The most likely explanation of these 
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apparently contrasting data is that tight spatiotemporal regulation of the pathway is 
necessary for joint homeostasis.  
Wnt signalling has been implicated in the regulation of stem cell maintenance, 
proliferation, migration and fate decision (247). Thus, tracking Wnt pathway activity 
following cartilage injury in vivo (where adult articular cartilage interacts with 
neighbouring tissues within the joints) might lead to the identification of joint specific 
targets of Wnt modulation that might contribute to joint surface repair. Challenging 
BAT-GAL mice in the in vivo model of JSI however showed no lacZ expression in 
articular cartilage following injury or upon treatment with Wnt3a ligand despite the 
up-regulation of the Wnt target gene Axin2. It is unlikely that the failure to identify 
X-Gal positive cells in injured and Wnt treated articular cartilage was due to lack of 
penetration efficacy of the staining into the tissues as the same negative results were 
obtained with performing the staining either in whole mount or in individual sections 
and in addition, positive cells were identified within deeper bone marrow spaces. 
Previous studies have reported instances in which BAT-Gal reporter mice failed to label 
sites of Known Wnt/β catenin signalling in the skin and pancreas (283;284). Transgenic 
TCF reporters are designed to detect the canonical Wnt dependent transcriptional 
activation through TCF. However, β catenin can activate Wnt target genes in a 
TCF-independent manner (285) and TCF can activate transcription in the absence of 
Wnt signalling (286) generating false negative or false positive results. Furthermore, 
TCF is known to interact with co-repressors to directly inhibit transcription in the 
absence of Wnt signalling (287). Therefore it is possible that Wnt signalling events that 
direct the de-repression of TCF target genes, but not trigger activation by TCF, might 
not be detected by TCF reporters which can not sense changes in repression (288).  
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Unexpectedly, Axin2/LacZ knock-in mice failed to up-regulate β-galactosidase 
expression or to accumulate β-catenin in articular cartilage following injury. These 
results suggest that Axin2 might be required for the activation of Wnt signalling. It has 
been demonstrated that Axin2 is required for the initial signalling cascade and 
specifically in the phosphorylation of LRP6 at the cell membrane via its ability to recruit 
GSK-3 (289).  Therefore, it is possible that the disruption of the axin2 gene in this 
animal model might have compromised the activation of the pathway following injury.  
These results indicate that the BAT-GAL and Axin2/LacZ knock-in mice are unsuitable 
as Wnt reporters in adult articular cartilage. However, despite the inability to track wnt 
target cells, we have demonstrated that mechanical injury to adult articular cartilage in 
vivo results in reactivation of morphogenetic pathways. This in vivo reproducibility of 
the signalling events previously observed in human cartilage following injury provides 
an opportunity to explore the function of different molecules in joint surface 
regeneration/degeneration after injury.  In the next chapter, we have used the in vivo 
murine model of JSI to investigate whether the injury induced up-regulation of Wnt16 
was required for cartilage repair in this model. 
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Conclusions 
 Morphogenetic pathways such as BMP and Wnt are modulated following 
mechanical injury in vivo 
 BAT-GAL and Axin2/LacZ knock-in mice are not suitable as reporters for the 
canonical wnt pathway activation in adult articular cartilage. 
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CHAPTER 8: RESULTS 
Functional validation of Wnt16 in cartilage 
regeneration and development of OA in vivo  
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The experiments so far have confirmed that the gene modulations that we described 
following injury to human cartilage explants are also reproduced in vivo in the mouse 
model of acute joint surface injury/repair. Thus this model gives the opportunity to 
address the function of different molecules modulated in response to injury and hence 
we decided to use it to study the requirement of Wnt16 for cartilage repair.  
Wnt16 was the only Wnt ligand to be up-regulated in human adult articular cartilage 
following injury. This up-regulation was confirmed in vivo using the mouse model of 
joint surface injury/repair and was associated with cytoplasmic accumulation and 
nuclear localization of β-catenin and up-regulation of gens encoding Wnt target genes 
such as Axin2 in vitro and in vivo. The regulation of Wnt16 after cartilage injury may 
play a role in activating a repair response or it could be a pathogenic mechanism 
contributing to cartilage degradation and PTOA development or it could be just an 
adaptive response to injury. The aim of this chapter was to investigate the function of 
Wnt16 in the context of joint surface regeneration/degeneration. 
8.1: Requirement of Wnt16 for joint surface repair 
Wnt16 deficient mouse mutants were obtained through a collaboration with Professor 
Jing Yu and Professor Andrew McMahon (Harvard University, Boston USA) on a 
mixed background (backcrossed 5 times onto the 129SvEv strain starting from a 
129/C57BL/6 background) and appeared phenotypically normal and fertile.  
Heterozygous mice were then intercrossed to generate homozygous mutants and wild 
type littermates for comparison. There was no difference in the skeletal morphology of 
adult 10 weeks old Wnt16 null mice compared to wild type mice (Figure 8.1A-C). 
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Furthermore, the standard histological analysis of the knee joint tissue did not reveal any 
morphological difference between the KO mice and their WT controls (Figure 8.1D & 
E).   
 
Figure 8.1: Wnt16 null mice have normal skeletal and joint morphology: 3D reconstruction of 
the skeleton of adult male Wnt16
+/+
 (A) and wnt16
-/-
 (B) showing no obvious abnormalities. (C) 
The measurement of adult WT and KO mice tibial length. (D-E) are H&E staining of sections 
from WT (D) and KO (E) knee joints showing normal structures. Boxed areas of the patellar 
groove and tibio-femoral joints at left are shown in higher magnifications at right.  
 
To investigate whether Wnt16 plays a functional role in the repair process of joint 
surface defects, adult Wnt16 homozygous null mutants and wild type littermates were 
challenged in the in vivo model of joint surface injury. Eight weeks following injury, the 
animals were killed and the outcome was evaluated histologically and quantified by 
histological scoring systems (188;238;239). Unfortunately, in this background, the 
regeneration in wild type mice was poor and variable with filling of most of the defects 
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with non cartilaginous tissue that stained negative for SO staining (Figure 8.2A). On the 
other hand, most of the Wnt16 null mice failed to repair the defect with any tissue 
(Figure 8.2B). The repair scores (Figure 8.2C) were better in WT mice although not 
statistically significantly. Mild degree of post-traumatic OA was observed in both WT 
and KO mice with no statistical significant difference in Mankin scores (Fig. 8.2D) 
 
Figure 8.2: Wnt16 KO mice in joint surface injury model: (A-B), H&E (upper panel) and 
Safranin O (lower panel) staining of sections from sham and injured WT 129FvEv mice (A) and 
Wnt16 KO mice (B) 8 weeks after injury. (C-D), repair scores (C) and modified Mankin scores 
(D) of WT (n=6) and KO (n=5) at 8 weeks time points. Low score in C indicated better repair 
and high scores in D indicated more severe OA. All values are expressed as mean ± standard 
error of the mean (S.E.M).  
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These preliminary results show that this injury model is unsuitable for mice on this 
mixed 129/C57BL/6 background. Despite this and the generally poor repair in WT 
animals (poorly differentiated tissue filling most defects, Figure 8.2), the outcome was 
generally worse in mutants with no tissue filling the defect, thereby resulting in a 
difference that was approaching statistical significance. This suggests that in the 
appropriate background (pure DBA/1) we might be able to observe a clearer phenotype. 
The backcrossing of Wnt16 mice into the DBA/1 background is currently in progress in 
our laboratory.  
8.2: Wnt16 expression in murine OA 
Wnt16 was upregulated upon injury in vitro in adult human cartilage explants and in 
vivo in mice. This up-regulation was not exclusive to the acute mechanical injury model 
but was also relevant to osteoarthritis as Wnt16 was abundantly present in human 
osteoarthritic cartilage but was undetectable in preserved cartilage areas of the same 
joint.  
To test whether Wnt16 is also regulated in osteoarthritis in mice, we utilized an OA 
mouse model in which osteoarthritis is induced by surgical destabilization of the medial 
meniscus (DMM) (32). This model is relevant to human OA since meniscal instability is 
well known to lead to OA in humans (160) and it has been validated in the 129SvEv 
genetic background (158) and therefore, if the Wnt16 up-regulation was also present in 
mice, this model could be used to test its function in the context of OA development. 
Wnt16 was undetected in the sham operated control knees but upregulated in murine 
 175 
osteoarthritis as early as 2 days following the surgical destabilization of the medial 
meniscus (Figure 8.3)  
 
 
Figure 8.3: Wnt16 in instability induced OA model: S.O (upper panel) and 
immunostaining for Wnt16 (lower panel) in sections from sham operated or destabilized 
knee joints 2 days following DMM. 
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8.3: Development of OA in WT and Wnt16
-/-
 mice 
Encouraged by the confirmation of Wnt16 up-regulation in the DMM model of OA, we 
sought to investigate whether such regulation has a role in OA development by 
challenging Wnt16 null mice and wild type littermates in the surgically induced 
instability model of OA (DMM). The mice were killed 8 weeks after surgery and the 
outcome was analysed histologically and the degree of osteoarthritis was assessed with 
two well established OA scoring systems by two independent observers blinded to the 
genotype of the mice.  
Neither Wnt16 null mice nor the wild type littermates developed spontaneously any 
feature of OA (Figure 8.4). However, following destabilization of medial meniscus, 
Wnt16
-/-
 mice developed more severe OA than their wild type littermates. Fibrillations, 
moderate loss of articular cartilage and loss of proteoglycans were the main features 
observed in WT mice (Figure 8.4A) whereas, deep lesions, major loss of cartilage and 
diffuse hypocellularity were a hallmark of OA developed in Wnt16 deficient mice 
(Figure 8.4B). Both the Mankin (Figure 8.4C) and the Chambers’ (Figure 8.4D) OA 
scores were statistically significantly higher in Wnt16-/- mice compared to their wild 
type littermates in the medial compartments. As expected in this model, a mild degree of 
OA was observed in the lateral compartment without difference between WT and KO 
mice (Figure 8.4 A-D). These data shows that Wnt16 is required for cartilage 
homeostasis in challenge conditions and suggests a role in cartilage protection against 
breakdown in osteoarthritis.    
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Figure 8.4: OA development in male Wnt16 null mice and WT littermates: A-B, Representative 
H&E (upper panel) and S.O (lower panel) stained sections from control and challenged 
“operated “ wild type (A) and Wnt16-/- mice (B) 8 weeks after medial meniscus destabilization. 
C-D, Mankin (C) and Chambers’ (D) scores of challenged WT (n=4) and Wnt16-/- mice (n=4). 
Higher scores indicate more severe OA. Values are expressed as mean and standard error of the 
mean (S.E.M). *P=<0.05. MT=Medial Tibia. MF=Medial femur. LT=Lateral Tibia. LF=Lateral 
Tibia.  
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Epidemiological studies have demonstrated sex-related differences in human OA 
development with higher prevalence in men before the age of 50. However, after 
menopause the incidence and the severity of the disease increase significantly in women 
(290). This is in keeping with male mice developing more severe OA than female in 
DMM model (291), which is regularly performed in young animals.  
 
To investigate whether the more severe OA outcome of wnt16 deficient mutants was sex 
dependent, joint instability was surgically induced by DMM in female Wnt16 null mice 
and wild type littermates. Mice were then killed at 8 weeks following surgery and 
cartilage degradation was evaluated histologically and graded by the Modified Mankin 
and Chambers scoring systems.  
As expected, wild type female mice developed milder OA than males but OA was more 
severe in Wnt16
-/-
 female mice as compared to their wild type littermates. Superficial 
fibrillation and localized loss of proteoglycans were observed in WT mice (Figure 
8.5A), while extensive fibrillation and deep erosions extending to the calcified cartilage 
were seen in Wnt16 deficient mice (Figure 8.5B). OA developed almost exclusively 
within the medial compartment.  A statistical significant difference between medial 
tibial and femoral OA scores of WT and KO mice was shown by both Mankin (Figure 
8.5C) and Chamber (Figure 8.5D).  
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Figure 8.5: OA development in female Wnt16 null mice and WT littermates: A-B, 
Representative H&E (upper panel) and S.O (lower panel) stained sections from control and 
challenged “operated “ wild type (A) and Wnt16-/- mice (B) 8 weeks after medial meniscus 
destabilization. C-D, Mankin (C) and Chambers’ (D) scores of challenged WT (n=6) and Wnt16-
/-
 mice (n=6). Higher scores indicate more severe OA. Values are expressed as mean and 
standard error of the mean (S.E.M). *P=<0.05. MT=Medial Tibia. MF=Medial femur. 
LT=Lateral Tibia. LF=Lateral Tibia.  
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OA was more severe in 129SvEv wild type male mice than females after DMM. The 
summed mean scores of male mice were more than two folds higher than that of the 
female mice using both the Mankin (Fig. 8.6A) and Chambers (Fig. 8.6B) scoring 
systems at 8 weeks after surgery. Interestingly, the same ratio was observed between 
summed OA scores of males and females Wnt16
-/- 
mice (Fig. 8.6). Both male and female 
Wnt16 deficient mice developed significantly more severe OA lesions than their wild 
type littermates. The mean summed scores for Wnt16
-/- 
mice were nearly 1.5 fold higher 
than that for wild type mice in both sexes (Fig. 8.6).  
 
Figure 8.6: OA severity in male and female mice: Summed Mankin (A) and Chambers (B) 
histological scores for Wnt16
+/+ 
and Wnt16
-/- 
mice 8 weeks after DMM in males and females. 
The values are expressed as the mean of the highest 3 sections scores ± SEM. * = P<0.05.  
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Discussion 
In this chapter, we have investigated the involvement of Wnt16 in joint surface repair 
and homeostasis and showed preliminary results that suggest a chondroprotective role 
for Wnt16 in vivo. Wnt16, along with other Wnt ligands such as Wnt4 and Wnt9a, are 
expressed in the developing synovial joints where they play an essential role in joint 
specification and formation (47). In adult cartilage, however, Wnt16 is not expressed in 
normal joints but re-expressed only upon mechanical cartilage injury with activation of 
the canonical Wnt pathway. These data points to the tissue specificity of this ligand in 
the biological context of cartilage injury since neither Wnt16 nor β-catenin were 
upregulated in sham operated joints which were subjected to arthrotomy and patellar 
dislocation without cartilage injury. 
The absence of overt developmental skeletal abnormalities in Wnt16 deficient mice 
could be explained by the presence of other Wnt family members such as Wnt4, Wnt9a 
which could potentially compensate the loss of Wnt16 activity during embryonic 
development.  The targeted disruption of Wnt4 also did not show any skeletal phenotype 
(80) but deficiency of both Wnt4 and Wnt9a resulted in joint fusions and synovial 
chondroid metaplasia (292) thereby, supporting the existence of functional redundancy, 
at least during development, between these different Wnt ligands.   
The preliminary functional validation of Wnt16 following cartilage injury showed better 
histological repair response of WT mice compared to Wnt16 null mice. Although this 
difference was not statistically significant, it still suggests that Wnt16 might have a role 
in promoting/supporting the repair response. Failure to detect significant differences 
could be due to insufficient number of mice or the inability of the scoring system to 
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distinguish between inferior repair tissue (seen in WT mice) and total absence of repair 
tissue (seen in KO littermates). Further studies in DBA/1 background are still necessary 
to first confirm these preliminary results and then to elucidate the molecular and cellular 
mechanisms through which Wnt16 supports the repair process. Thereafter, the ability of 
Wnt16 to improve regeneration of chronic joint surface lesions in strains with poor 
repair should be explored. 
Wnt16 up-regulation was also relevant to osteoarthritis as it was abundantly present in 
human cartilage affected by OA and expressed after destabilization of medial meniscus 
in an instability induced model of OA. In this model, Wnt16 deficient mice developed 
more severe OA compared to wild type littermates in a sex-independent fashion 
suggesting that Wnt16 might has a chondroprotective effect that, after chronic injury, 
can not be compensated.  
Although, the skeleton of Wnt16 deficient mice was indistinguishable from that of wild 
type mice in CT scans and their joint tissue appeared normal on histological 
examination, it is still possible that subtle differences in their joint architecture might 
have rendered them more susceptible to OA after induction of joint instability.  
Therefore, more detailed quantitative comparison of the skeleton of mutants and wild 
type mice as well as investigating the ability of exogenous Wnt16 delivery to reverse the 
OA phenotype in Wnt16
-/-
 mice to levels seen in Wnt16
+/+
 mice are required to confirm 
that the more severe OA seen in Wnt16 null mice is not due to any developmental defect 
that may influence the development of OA after DMM but rather due to a critical role of 
Wnt16 in cartilage degradation/regeneration taking place during OA development. 
Wnt16 might suppress some mechanisms of cartilage breakdown and/or enhance the 
anabolic/regeneration mechanisms. The biological processes and molecular mechanisms 
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leading to more severe OA development in Wnt16 null mutants following DMM remain 
to be investigated. 
Conclusions 
 Wnt16 is expressed after DMM and plays a role in outcome determination in 
experimental osteoarthritis.  
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CHAPTER 9 
General Discussion  
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Traumatic cartilage lesions represent a common symptomatic and disabling problem
 
(130;131) that often requires surgical intervention to relieve pain and to prevent possible 
evolution towards secondary OA (293). However, the evidence that full thickness 
articular cartilage defects can sometimes heal spontaneously (141-143) (151;236) 
demonstrates that adult joints possess repair machinery that, under appropriate 
conditions, can lead to anatomical and functional restoration. The absence of relevant 
pre-clinical animal models of joint surface regeneration suitable for molecular studies 
and genetic manipulation has represented a bottleneck for the understanding of the 
molecular and cellular mechanisms regulating joint surface healing and consequently the 
development of novel therapeutics to enhance/support this repair process. In this study, 
we have developed and characterized a novel murine model in which the repair outcome 
of a well controlled, consistent and reproducible full thickness JSD is dependent on the 
strain and the age of the mice and we have used this model to study the role of wnt16 
regulation in the homeostatic response of articular cartilage to injury.  
In this in vivo model, adult DBA/1 mice reproducibly healed experimental joint surface 
lesions, whereas age-matched C57BL/6 healed poorly and instead developed features of 
secondary osteoarthritis. This strain-dependent ability to repair cartilage and prevent 
progression towards PTOA demonstrates that there are genetic factors that govern the 
response of articular cartilage to injury and hence participate in outcome determination. 
This animal model of joint surface injury/repair could therefore represent a valuable tool 
to elucidate the molecular basis for articular cartilage regeneration and to address the 
functionality and hierarchy of molecules involved in the response to injury through the 
use of suitable genetically modified mice.  
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The natural history of JSD is so far unpredictable given the high variability in the repair 
capacity and the susceptibility to cartilage degeneration among human population 
(143;251). This variability was reproduced in the inbred mouse strains and was 
associated with different regulation of measurable anabolic and catabolic parameters. 
Such parameters could thus be used as biomarkers to predict the outcome of joint 
surface injury. The ability of cartilage to heal after injury and to prevent further 
degradation in mice correlated with a decline in cell death, persistent proliferation, type 
II collagen neo-synthesis, less type II collagen degradation, less aggrecanase and more 
MMP- induced aggrecan degradation. These data point to a potential window for 
therapeutic intervention to prevent posttraumatic OA with inhibitors of apoptosis and 
inhibitors of aggrecanases and/or MMPs that are being developed and tested in 
preclinical and clinical studies (294-296). 
The relationship between susceptibility to OA and capacity for repair are not well 
understood.  It is known that C57BL/6 mice develop spontaneous OA with ageing (297) 
and they are more susceptible than DBA/1 to OA induced by medial meniscus 
destabilization (DMM) (26). However, spontaneous OA appears in C57BL/6 mice only 
after their first year of age, and no signs of OA were present in control or sham-operated 
joints in our study. It is therefore unlikely that pre-existing osteoarthritis or joint 
instability inadvertently induced during surgery were the causes for repair failure. On the 
other hand, the generation of a JSD in C57BL/6 mice precipitated the appearance of 
secondary OA features as early as 1 week after injury. At 4 weeks, when the OA 
features in C57BL/6 mice had advanced, there was also a clear difference in repair 
outcome compared to DBA/1. It is possible that the rapid development of secondary OA 
may have conditioned repair failure. Our experimental setup does not discriminate 
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whether the failure of repair and the development of OA are causally related, or if they 
represent distinct processes resulting from an inferior joint homeostatic mechanism in 
C57BL/6 than in DBA/1mice. However, the observation that aged DBA/1 mice did not 
repair and did not develop OA either, under our experimental conditions and at the time 
points examined, demonstrates that repair failure alone may not be sufficient for the 
development of secondary OA and suggests that the two processes may be, at least in 
part, uncoupled. In  this regard, it must be stressed that this model is not a model of 
primary OA, but rather a model of joint surface injury and repair that provides the 
opportunity to investigate the function of the injury- regulated genes in that acute 
context. However, the occurrence of post-traumatic OA in C57BL/6 mice suggests that 
it could be also used to study the mechanism by which repair influences progression of 
post-traumatic secondary OA and vice versa.  
One important determinant of repair outcome could be local inflammation (261). Indeed, 
DBA/1 mice are responsive to inflammatory arthritis models such as type II 
collagen-induced arthritis leading to extensive new tissue formation and joint ankylosis 
whereas C57BL/6 mice are resistant (298). A modest infiltrate was present in the 
synovial membrane of the sham and injured mice from both strains during the first week 
following surgery suggesting that it is not specific to cartilage injury but rather a 
reaction to the surgical procedure. However, it is possible that different regulation of the 
inflammatory response may play a role in repair outcomes.  
The repair of JSDs encompasses highly coordinated biological events that require a fine 
tuning of diverse processes including cellular apoptosis, proliferation and tissue 
patterning regulated in a temporal-spatial manner however, the molecular mechanisms 
regulating this process are poorly understood.  We have demonstrated that mechanical 
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injury to adult articular cartilage resulted in a robust response with reactivation of 
morphogenetic pathways such as BMP and Wnt (241). In addition, previous studies have 
demonstrated the release of fibroblast growth factor 2 (FGF-2) from injured articular 
cartilage (216) and showed a chondroprotective role of this growth factor in vivo (299). 
Taken together, these data support our hypothesis that injured articular cartilage can be a 
source of signaling molecules that might participate in determining the outcome of joint 
surface defect.   
BMPs are known to elicit an anabolic response in articular cartilage both in vitro (119) 
and in vivo (123;124), and it has been shown that it is required for joint homeostasis in 
adulthood (300). Indeed, targeted deletion of the gene encoding BMP receptor 1A in the 
articular cartilage of mice resulted in joint surface degeneration resembling OA (128) 
and polymorphism in BMP-2 gene was associated with increased susceptibility to OA 
development (122). Moreover, BMPs play a crucial role in regulating the recruitment of 
progenitor cells and promoting their differentiation into the chondrogenic lineage during 
embryonic skeletogenesis. Finally, the expression of BMP-2 mRNA was linked to the 
capacity of in vitro expanded adult human articular chondrocytes to form stable cartilage 
in vivo that is resistant to vascular invasion and endochondral bone formation  (176). 
Therefore, the recruitment of chondroprogenitors, the regulation of chondrogenesis and 
cartilage ECM synthesis as well as the preservation of the phenotypic stability of 
articular chondrocytes could all be potential roles of BMP signaling in JSD repair. 
Indeed, BMPs including BMP-2 have been tested in experimental cartilage tissue 
engineering approaches (209) and several systems for their delivery including gene 
therapy have been evaluated (301) with encouraging results. However, if over-expressed 
can cause detrimental side effects such as ectopic bone formation and osteophyte (215). 
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Therefore, their potential for clinical use strongly depends on the use of optimum safe 
levels as well as on the use of efficient and safe delivery systems. 
The function of the canonical Wnt signaling in the context of joint surface injury/repair 
is still poorly understood. Several lines of evidence in many systems have demonstrated 
that the activation of Wnt signaling enhances wound healing (302), supports repair (244-
246) and promotes limb regeneration in regenerating animals (303) through regulating 
stem cell maintenance, proliferation, migration and fate determination (247). It is 
therefore possible that the Wnt pathway might have a similar function in the repair of 
JSDs. However, other studies have suggested a role of abnormal Wnt signaling in the 
pathogenesis of osteoarthritis. For example, Allelic variants of the Wnt inhibitor FRZB 
(86), Wnt co-receptor LRP5 (89) and WISP (90) were associated with the development 
of OA in humans. Furthermore, the Wnt pathway has been involved in cartilage 
destruction by regulating matrix degradation (91), chondrocyte apoptosis and 
dedifferentiation (92). In this regard, it is interesting that both gain and loss of function 
of β-catenin in adult skeleton results in cartilage loss and OA development (95;96). 
These data imply that Wnt signaling is pivotal in regulating chondrocyte survival and 
maintenance in postnatal life and that controlled balance between positive and negative 
signals is required for joint homoeostasis and repair but such mechanisms that are set 
into action to support repair in adulthood may also play a pathogenic role when not 
appropriately regulated. 
The modulation of the Wnt pathway has been an attractive therapeutic strategy to 
modify disease progression in arthritis and to enhance repair in many tissues (304). 
Although constitutive activation of Wnt pathway can lead to abnormal cell growth and 
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cancer (305), its tightly controlled modulation might have therapeutic benefit in 
regenerative medicine (306). Given the complexity of the Wnt signaling with the 
involvement of many agonists, receptors and antagonists (63), it is important to select a 
relevant tissue specific target in order to limit the undesirable side effects. Our data 
demonstrate a high level of specificity of Wnt16 in the biological context of cartilage 
injury. Wnt16 was the only Wnt ligand to be modulated in adult human cartilage 
following injury indicating ligand specificity and was re-expressed in mice following 
cartilage injury or meniscal destabilization but not following sham operation where 
injury to joint capsule and synovial membrane occur indicating tissue specificity. 
Moreover, despite the expression of several Wnt ligands in the joint environment and 
their modulation during OA, the absence of Wnt16 was not compensated following 
DMM and resulted in more severe OA in Wnt16 null mice as compared to wild type 
littermates indicating its functional specificity. The identification of a very specific 
ligand such as Wnt16 represents an opportunity to support cartilage homeostasis and 
repair with minimum side effect/toxicity.  The presence of suitable mouse models of 
joint surface injury/repair and OA, together with the availability of Wnt16 deficient 
mutant mice will allow addressing the functionality of Wnt16 in vivo during the process 
of cartilage regeneration/degradation. Subsequently, this knowledge can be exploited for 
the development of novel molecular therapeutics to improve joint surface healing in cell-
free in situ tissue engineering approaches. 
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Appendix 
Ethylenediaminetetraacetic acid (EDTA  pH 8.0 
20g of EDTA were dissolved in 80ml H2O. NaOH was used to adjust the pH. Distilled 
water was added to the final volume of 100 ml. The solution was stored at room 
temperature and diluted to 4% to be used   
Toluidine blue 
0.1% Toluidine blue (Sigma, UK) in 0.1M acetate buffer, pH 5. To prepare acetate 
buffer, mix 14.8ml of stock A (0.6ml glacial acetic acid MW 60.05 in100cm distilled 
water) to 35.2ml of stock B (0.82g sodium acetate anhydrous MW 82 in 100cm distilled 
water) and bring it to 100ml with distilled water. 
Safranin O 
0.2% in distilled water with 0.2M glacial acetic acid = 1,2 ml glacial acetic acid + 20ml 
1% SO bring to 100ml. 
Light green 
0.5% in 500ml distilled water with 1ml glacial acetic acid.  
X-gal staining solution 
 
Final staining Reagents Stock To make 1ml 
X-Gal 1mg/ml 50mg/ml 20μl 
10X PBS  10 X 100µl 
5mM Potassium ferrocyanide 50mM (211mg/10ml) 100μl 
5mM Potassium ferricyanide 50mM 100μl 
5mM EGTA 0.5M 10μl 
2mM MgCl2 1M 2μl 
0.02% NP-40 1 20μl 
Water   648μl 
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Sodium Citrate Buffer 
Dissolve 2.94g Sodium Citrate in 1L of distilled water and adjust pH to 6. 
10x PBS 
Add 80g sodium chloride (NaCl), 2g potassium chloride (KCl), 14.4g sodium phosphate 
diphasic (Na2HPO4) and 2.4g potassium phosphate monobasic (KH2PO4) to 1L distilled 
water  and adjust pH to 7.4.  
HRP Avidin-Biotin Complex (DAKO) 
10 l of Solution 1 were added to 1 ml of TBS pH 7.6, and mixed well. Another 10 l of 
solution 2 were added and mixed well. The ABC complex was prepared at least 45’ 
before use. 
Tris Acetic acid EDTA (TAE buffer 50X)  
242 of Tris base, 57.1ml of acetic acid and 18.6g of EDTA were dissolved in 800ml of 
distilled water. Distilled water was added to the final volume of 1L and the solution was 
stored at room temperature and diluted to 1X before use. 
Radio Immuno Precipitation Assay (RIPA) buffer  
Final concentration Reagents for 200ml 
150mM NaCl 1.75g NaCl 
1% NP-40 2ml NP-40 
0.5% deoxycholc acid 1g deoxycholc acid 
0.1% SDS 1ml 20% SDS 
50mM Tris pH 8 6.67ml 1.5M Tris pH 8 
Distilled water Fill to 200ml d water 
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Tris-Glycine transfer buffer 
Tris base (12 mM) 1.45 g, Glycine (96 mM) 7.2 g and Methanol (20% final 
concentration) 200 ml were dissolved in 800ml of distilled water. Distilled water was 
added to the final volume of 1L  
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